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Abstract 
IMPLEMENTATION AND ASSESSMENT OF HYPERGLYCEMIC CONDITIONS FOR 
THE CREATION OF A DIABETIC BLOOD VESSEL MIMIC 
By Vikramaditya Mediratta 
 Introduction:  Diabetes Mellitus is a metabolic disorder that affects a person’s ability to 
either produce insulin (Type I diabetes mellitus) or properly use insulin (Type II diabetes 
mellitus) in order to maintain adequate blood glucose levels.  The most severe diabetic 
complications arise due to hyperglycemia – a state of extremely high blood glucose levels – such 
as, coronary artery disease (CAD), in which coronary stent therapy is a popular method of 
treatment.  However, research has shown a high rate of in-stent restenosis in diabetic patients 
with CAD, most likely due to activation of cellular adhesion molecules on endothelial cells 
exposed to the hyperglycemic environment.  Blood vessel mimics (BVMs) have been researched 
as viable options for in vitro studies on vascular stents; thus, it would be beneficial to create an in 
vitro diabetic BVM for stent manufactures to evaluate and determine the root cause of the high 
failure rate of stents in the diabetic population.  In addition, a diabetic BVM would help 
manufactures optimize coatings or stent configurations for diabetic patients.  Methods:  The 
purpose of this thesis was to take the initial steps towards the goal of a diabetic BVM.  The first 
aim was to establish a procedure of developing glycemic cell media solutions of various glucose 
concentrations, and to establish a feasible method of monitoring the glucose concentration of the 
solutions.   Glycemic cell media solutions were developed and their glucose concentrations were 
evaluated with a blood glucose meter (specifically, the Aviva Accu-Chek blood glucose meter) 
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or visual blood glucose test strips (Glucoflex R visual blood glucose test strips).  The second aim 
was to ensure that the developed glycemic cell media solutions could be monitored in a cell 
culture environment over time, and to determine if the hyperglycemic conditions induced any 
change to endothelial cells.  Bovine aortic endothelial cells (BAECs) and human umbilical vein 
endothelial cells (HUVECs) were used to evaluate glucose consumption and cell morphology.  
Glucose concentration of the cell media was recorded to evaluate glucose consumption, and the 
cells were evaluated under a microscope in order to determine cell morphology and an increase 
in cell death.  Results & Conclusions:  Data accumulated from the first set of experiments 
confirmed that glycemic cell media solutions can be developed by adding Sigma G6512 D-(+)-
glucose to base cell media.  Additionally, the Aviva Accu-Chek blood glucose meter recorded 
the most accurate and precise glucose concentrations of the various glycemic cell media 
solutions compared to the Glucoflex-R blood glucose visual test strips.  Lastly, the series of 
experiments with BAECs and HUVECs confirmed that the glycemic cell media solutions could 
be effectively monitored over time, and that these conditions evoked higher glucose consumption 
by the endothelial cells compared to the normal glycemic cell media solutions.  Additionally, 
neither glycemic environment evoked significant cell death.  These results met the aims of this 
thesis, and therefore provide the foundation for further development of a diabetic BVM.  
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Chapter 1: An Introduction to Diabetes Mellitus 
1.1 The History of Diabetes Mellitus 
 The name Diabetes Mellitus was coined in the 1600’s by scientists who were describing 
their observations of patients with a particular set of symptoms; “diabetes” - intense thirst, 
profuse urination, rapid waste production, intense vomiting, drowsiness eventually leading to a 
coma and then death; “mellitus” – the apparent sweetness of the patient’s urine [1].  The 
outcome of diabetes was a slow and painful death.  There was no known reason behind the cause 
of the disease and no thought of what a possible cure could be.  This is why the discovery of 
insulin in 1921 was one of the most dramatic discoveries in the history of diabetes and medicine, 
contributing to a drastic change in lifestyle for patients with the disease.   
Oxford physician Thomas Willis took the first step towards better understanding diabetes 
in the 17th century [1].  He noted the sweet taste of urine from diabetic patients along with the 
high volume they were producing.  He was also the first to distinguish the sweet taste of urine 
from patients with Diabetes Mellitus versus the non-sweet urine of patients with Diabetes 
Insipidis [1].  While others were certain that diabetes was due to renal complications, Thomas 
Willis believed that complications in blood were the main contributor to the disease.   In 1776, 
Willis’ theory was supported by scientist Matthew Dobson, of Liverpool, as Dobson discovered 
that the sweet taste of urine was caused by a high concentration of glucose.  He proved that there 
was an excess of glucose in the blood of those who produced such sweet tasting urine [2].   
 Claude Bernard, of France, was one of the greatest figures of diabetes in the first half of 
the 19th century.  Some of his greatest findings included the discovery of the liver’s ability to 
2 
 
store glycogen, as well as the liver’s ability to convert glycogen and secrete sugar into the blood.  
This led him to believe that diabetes was due to an over-secretion of sugar from the liver [1].  
Claude Bernard was such an influential figure that his view on the cause of diabetes was a staple 
in the medical society.  However, by extraordinary strokes of chance, an alternative proposition 
regarding the cause and possible control of diabetes was discovered. 
1.1.1 The Discovery of Insulin 
In 1879, Joseph Von Mering of Germany discovered that removing the pancreas caused 
diabetes.  Interested mostly in digestion, Von Mering wanted to study the digestive effects of the 
pancreas by removing it from a dog and analyzing what digestive limitations the dog exhibited.  
Von Mering’s colleague, Oscar Minkowski (Figure 1) performed the procedure and later 
discovered that the dog had urinated all over its cage even though it had been house trained.  
Much more interested in what this discovery might mean, Minkowski tested the urine and found 
high levels of glucose; thus, implying that the pancreas contained the anti-diabetic agent that 
controlled glucose level and could possibly cure diabetes [1]. Unfortunately, the extraction of 
this anti-diabetic substance was extremely difficult.  It was widely held that the substance was in 
the pancreatic islets, but it was believed that digestive enzymes produced by the pancreas were 
interfering with the extraction.  While some scientists were able to develop an unstable extract 
that was lowering the blood glucose levels of dogs, none were successful in purifying the 
substance for human testing [2].  Though discouraging, there was no lack of appreciation of how 
much potential the purification of the anti-diabetic substance could have on the advancement of 
diabetes treatment. 
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Figure 1 - Oscar Minkowski surgically removed the pancreas of a dog which he later realized 
induced diabetes mellitus.  (Permission to reprint from Fischer I: Biographisches Lexikon der 
hervorragenden Arzte der letzten funfzig Jahre. T. 1. Monachium-Berlin: Urban & 
Schwarzenberg, 1933). 
Finally in 1921, one of the greatest medical discoveries occurred at the University of 
Toronto, Canada.  Dr. Fredrick Banting (Figure 2), an unsuccessful orthopedic surgeon, was 
reading on the association of pancreatic dysfunction with diabetes and became convinced that he 
could produce the anti-diabetic substance [3].  Ironically, his greatest strength was his ignorance 
towards how difficult the procedure was since he was unaware that so many other scientists had 
attempted to find it in the forty years since Minkowski’s discovery.  Nonetheless, Banting 
approached Dr. John James Richard Macleod (Figure 3), Professor of Physiology at the 
University of Toronto, and requested the funds and facilities to perform the experiment.  
Knowing the difficulties behind the procedure, Macleod assigned medical student Charles Best 
to aid Banting in the assembly of the experiment.  Banting originally believed that the external 
secretion of the pancreas was destroying the “insulin;” thus, he tied off the pancreatic duct and 
allowed for pancreas atrophy [3].  Unfortunately, there was difficulty in stabilizing the pancreatic 
secretion, so Macleod assigned James Bertram Collip (Figure 4), biochemist at the University of 
Toronto, to perform standard chemical purification in order to stabilize the substance for human 
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testing.  Within six weeks, Collip felt comfortable enough with the insulin he had isolated to try 
it on a human for the first time [3].   
 
Figure 2 - Dr. Frederick Banting (shown), and medical student Charles Best, were able to extract 
the first pure insulin substance (Permission to reprint from Nobel Lectures, Physiology or 
Medicine 1922-1941, Elsevier Publishing Company, Amsterdam, 1965). 
 
Figure 3 – Dr. John James Macleod, Professor of Physiology at the University of Toronto, 
funded the experimentation for the first stable extraction of insulin (Permission to reprint from 
Nobel Lectures, Physiology or Medicine 1922-1941, Elsevier Publishing Company, Amsterdam, 
1965). 
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Figure 4 – James Bertram Collip, biochemist from the University of Toronto, was able to purify 
and stabilize the insulin extraction for human testing (Permission to reprint from the Library of 
the University of Toronto, Canada). 
The first human trial was performed on a young 14 year-old boy dying of diabetes.  To 
everyone’s astonishment, the insulin injection lowered the boy’s blood sugar, rid the glucose in 
the urine, and eventually helped him regain his body weight and strength [3].  It was a 
miraculous transformation; a universally fatal disease had been cured – or if not cured, at least 
controlled.  Banting and Best published their first paper in 1922, and in 1923 Banting and 
Macleod were awarded the Nobel Prize in Medicine for their remarkable discovery [3].      
1.1.2 Impact of the Discovery of Insulin  
 Before the discovery of insulin, diabetes was a slow and heartbreaking death.  Mostly 
diagnosed in young children, the only method of treatment was a strict diet that eventually 
equaled starvation.  It was an unfortunate situation for early “diabetologists,” especially Dr. 
Frederick Allen, of New York, who had nothing else to offer other than starvation [1].  If the 
patient got an infection and the diabetes got worse, the answer was even stricter starvation – a 
miserable situation for the young patients, as well as the parents.  However, the arrival of insulin 
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brought a revival to the field that was best expressed by a nurse at Dr. Allen’s psychiatric 
hospital in New York.  She wrote [3]: 
“…the mere illusion of new hope cajoled patient after patient into new life.  Diabetics who had not been 
out of bed for weeks began to trail weekly about, clinging to walls and furniture.  Big stomachs, skin-and-bone 
necks, skull-like faces, feeble movements, all ages, both sexes – they looked like an old Flemish painter’s depiction 
of a resurrection after famine.  It was a resurrection, a crawling stirring, as of some vague springtime.” 
The patients heard that Dr. Allen had come back from Toronto: 
“Bed immediately after dinner was the rule of our patients.  But not that evening.  My office opened on the 
big center hallways.  I could see them drifting in, silent as the bloated ghosts they looked like.  Even to look at one 
another would have painfully betrayed some of the intolerable hope that had brought them.  So they just sat and 
waited, eyes on the ground. 
It was growing dark outside.  Nobody had yet seen Doctor Allen.  His first appearance would be at his 
dinner, which followed the patients’ dinner hour.  We all heard his step coming along the covered walk, past the 
entrance to the main hallways.  His wife was with him, her quick tapping pace making a queer rhythm with his.  The 
patients’ silence concentrated on that sound.  When he appeared through the open doorway, he caught a full 
beseeching of a hundred pair of eyes.  It stopped him dead.  Even now I am sure it was minutes before he spoke to 
them, his voice curiously mingling concern for his patients with an excitement that he tried his best not to betray.  ‘I 
think,’ he said, ‘I think we have something for you’ ”.  
 The discovery of insulin changed the lives of doctors and patients.  Those who were 
headed to certain death in the coming years lived on for another fifty.  The first insulin treatment 
was quick acting insulin that required two injections a day – long lasting insulin was still to come 
[4].  What was significant about this discovery was that it contradicted Claude Bernard’s work.  
It was not an over-secretion of glucose from the liver that was causing diabetes, but rather an 
autoimmune-induced deficiency of islet β-cells in the pancreas – cells that produced and secreted 
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insulin [1].  This new understanding of diabetes brought about the distinction of two different 
types of the disease – insulin dependent and non-insulin dependent diabetes mellitus.  In 1936, 
Harold Himsworth demonstrated the important biochemical differences in the two types by 
identifying insulin sensitivity in type I and insulin resistance in type II diabetes [2].  This brought 
about a new perspective in the search for the cure of diabetes – there was no longer one single 
cure for the disease. 
1.2 Overview of Diabetes Mellitus 
 Diabetes Mellitus is a disease that causes the body to insufficiently produce or 
improperly use insulin.  Insulin is a pancreatic hormone, secreted from β-cells in the pancreatic 
islets, that breaks down sugars, starch, etc. into energy for the body.  Diabetes Mellitus comes in 
two common forms – insulin deficient, or type I diabetes, and insulin resistant, or type II 
diabetes.  Type I diabetes, also known as juvenile diabetes, is most common in children, while 
type II diabetes is diagnosed mostly in adults.  Diabetes Mellitus is also one of the most 
prevalent diseases diagnosed in America today.  According the American Diabetes Association, 
about 23.6 million children and adults in the United States of America have diabetes mellitus 
(about 7.8% of the population), of which only 17.9 million are diagnosed.  This means that 
nearly a quarter of the 23.6 million children and adults do not know that they have diabetes.  Out 
of the 23.6 million with diabetes, about 10% have type I, leaving the other 90% diagnosed with 
type II diabetes.  This section will discuss the key similarities and differences between the two 
types of the disease. 
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1.2.1 Type I (Insulin Deficient) Diabetes Mellitus 
1.2.1.1 Causes/Pathology 
 Insulin deficient ( also known as insulin dependent) diabetes mellitus (IDDM), or type I 
diabetes mellitus, is a T-cell mediated autoimmune disease resulting in the selective destruction 
of insulin-secreting pancreatic β-cells through the detrimental immunoregulation of 
inflammatory cytokines and auto-aggressive T lymphocytes [5,6].  While the etiology of β-cell 
destruction is unknown, researchers are proposing that genetically susceptible persons, who are 
exposed to certain environmental agents, trigger the inflammatory autoimmune response [7].  
Various environmental agents have been proposed to contribute to the pre-clinical onset of the 
disease, as outlined in Table 1, but no specific environmental factors have been identified with 
certainty [8].   
Table 1 - Most significant environmental factors that contribute to the increased incidence of 
Type 1 diabetes [9, 10]. 
Environmental Factors Hypothesis 
Viral infections Viral hypothesis 
Exposure to certain food constituents Dietary hypothesis 
Increased hygiene; lack of childhood 
infections Hygiene hypothesis 
Rapid growth in early childhood Accelerator hypothesis 
As discussed before, type I diabetes is most common in children and young adults.  
Unfortunately, the incidence of type I diabetes seems to be increasing 3-5% per year [11].   
 There are five stages in the development of type I diabetes (Figure 5) [6, 7].   
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1. Genetic susceptibility; 
2. Pre-clinical β-cell autoimmunity with gradual dysfunction of insulin secretion; 
3. Onset of clinical diabetes; 
4. Transient clinical remission; and 
5.  Established diabetes associated with acute and chronic complications and 
premature death. 
 
Figure 5 - Development of type I diabetes (Permission to reprint from [7]). 
Environmental agents trigger the autoimmune attack against the pancreatic β-cells due to 
the presence of certain antibodies.  These antibodies include islet cell antibodies (ICA) against 
islet-related antigens, anti-insulin auto-antibodes (IAA), anti-64 kDa protein antibodies, anti-
ICA69, and anti-ICA512 [12, 13, 14, and 15].  These antibodies are now used for the detection of 
patients high at risk for the development of type I diabetes. Studies have found that the presence 
of two or more of the mentioned antibodies is highly predictive for the development of type I 
diabetes [16].     
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The first thing to happen during the pre-clinical onset of type I diabetes is the loss of 
first-phase insulin secretion.  This is due to the gradual degeneration of pancreatic β-cells; 
however, the patient maintains a stable glycemic state [6].  The presence of these autoantibodies, 
with β-cell antigens, also leads the onset of hyperglycemia due to the loss of first-phase insulin 
secretion, and eventually results in the clinical onset of diabetes [7].  A significant effort is being 
made to develop antigen- and antibody-based immunotherapies that effectively prevent and/or 
treat type I diabetes [17].  While transient remission follows the clinical onset of the disease, the 
disease continues to develop resulting in further complications that greatly degenerate the rest of 
the body [18].  These complications will be discussed further in a subsequent section. Type I 
diabetic patients manage their hyperglycemia with daily injections of insulin via insulin pens or 
by subcutaneous insulin infusion therapy with an insulin pump.  While effective, insulin therapy 
is by no means a cure. 
1.2.2 Type 2 (Insulin Resistant) Diabetes Mellitus  
1.2.2.1 Causes/Pathology 
 Insulin resistant (also known as insulin independent) diabetes mellitus, or type II diabetes 
mellitus, is the most common form of diabetes.  Type II diabetes is characterized by the body’s 
resistance to the metabolic effects of insulin – especially its suppressive effects on the body’s 
blood glucose levels.  Many clinical disorders, such as hypertension, dyslipidemia, and 
atherosclerosis, are related to the development of insulin resistance and are linked to the high 
glucose levels of type II diabetes.  Several factors contribute to the impaired function of insulin 
in type II diabetes – genes, environmental factors, and obesity (Figure 6).     
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Figure 6 – The main contributors to the pathogenesis of type II diabetes insulin resistance are 
genetics, environmental factors, and the adverse effects of obesity (Permission to reprint from 
[19]). 
 
1.2.2.2 Genetics 
 Type II diabetics may exhibit defects in insulin action, as well as insulin secretion; both 
believed to be genetically predetermined [19].  Several rare mutations in genes associated with 
insulin resistance have been linked to extreme insulin resistance, including mutations of insulin 
receptors or polymorphisms of specific proteins (i.e. G972R polymorphism of insulin receptor 
substrate-1).  Genes associated with the development of type II diabetes include Transcription 
factor 7-like 2 (TCFL2), KCNJ11, just to name a few [20].  TCFL2 is a protein that acts as a 
transcription factor, and variance in this gene has been linked to the development of type II 
diabetes.  KCNJ11 is a gene that encodes the Kir6.2 major subunit of the ATP-sensitive K+ 
channel.  Mutations to this gene are linked to development of congenital hyperinsulinism, which 
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can lead to insulin resistance due to its over activity.  There is an extremely strong inheritance 
pattern for type II diabetes.  
1.2.2.3 Environment 
Environmental factors that lead to insulin resistance include different medical conditions, 
homeostatic imbalance within the body, and life style choices (exercise and diet).  For example, 
different factors of renal failure, such as accumulation of uremic toxins, increased levels of 
growth hormone (described below), abnormal filtration of glucose, metabolic acidosis, and 
dyslipidemia are proposed mechanisms of increased insulin resistance [21].  Insulin resistance 
has also been identified as a result to different types of cancers, particularly pancreatic cancer 
[22].  Factors involving homeostatic imbalance, include abnormal hormone levels, especially 
excess hormone levels such as hyperinsulinism – an abnormally high level of insulin secretion – 
a classic indicator of insulin resistance [23].   
Growth hormone also acts in many levels to block insulin activity, including inhibiting 
the phosphorylation of the insulin receptor and its principal signaling molecule, IRS-1, in 
response to insulin administration [20].  This results in a reduced sensitivity of insulin in both 
glucose uptake and suppressing glucose production.  In addition, insulin resistance induced by 
abnormal nutrient intake, such as a high glucose diet causing hyperglycemica (glucose toxicity) 
or increased levels of circulating free fatty acids, is a common feature of insulin resistance and 
type II diabetes [24].  Poor diet paired with poor levels of exercise have linked the onset of type 
II diabetes with obesity – a significant factor common among type II diabetics, especially when 
the disease’s strong inheritance pattern was discussed. 
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1.2.2.4 Obesity 
Obesity is an important factor in the pathogenesis of insulin resistance and the increased 
risk of type II diabetes [20].  In most patients, obesity is associated with inflammation of white 
adipose tissue resulting from chronic activation of the innate immune system, which can lead to 
insulin resistance, impaired glucose tolerance and type II diabetes [25].  Although BMI accounts 
for only a part of the variance in insulin sensitivity, obesity and insulin resistance are related; 
however, insulin resistance generally is directly proportional to body-mass [26].   
Adipose tissue influences insulin action in the whole body through the release of free 
fatty acids and adipose-derived proteins (proinflammatory peptides that cause inflammation of 
adipose tissue, such as adiponectin, leptin, and resistin), and has dramatic effects on glucose 
metabolism and insulin effectiveness [27, 28, 29].  These proinflammatory molecules induce 
insulin resistance and can contribute to complications in obese diabetic patients, including 
atherosclerosis [30].   It is still argued whether insulin resistance is the primary defect that 
precedes β-cell failure in the development of hyperglycemia and type II diabetes, or vice versa.   
However, in the end, there is a linear decrease in first-phase insulin release and insulin sensitivity 
in patients who are excessively in a hyperglycemic state [31].  Along with obesity, abnormal fat 
distribution and physical inactivity suffer the consequences of insulin resistance that include 
hyperglycemia, high triglycerides, hypertension, atherosclerosis (just to name a few) – all having 
shown to be predictors of type II diabetes [31].   
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1.2.3 Phases of Insulin Secretion 
 In non-diabetics, about 50% of the total daily insulin is secreted during basal periods 
(periods in between meals) to suppress lipids, proteins, and glucose.  The remainder of insulin is 
rapidly secreted postprandial in response to a meal.  This rapid release, or bolus, of insulin from 
the pancreatic β-cells is called the “first phase” of insulin secretion.  The first phase promotes 
utilization of the prandial nutrients, suppresses liver glycogen-to-glucose production, and limits 
the elevation of blood glucose levels.  First-phase insulin secretion occurs within two minutes of 
food ingestion and continues for approximately ten minutes.  The second phase of insulin 
secretion follows and is sustained until normal blood glucose levels are restored.  The effects of 
hyperglycemia on insulin secretion will be discussed further in the following chapter. 
1.2.4 β-cell Dysfunction of Diabetes Mellitus 
Pancreatic β –cell dysfunction is an early and extremely significant step in the 
progression of the pathophysiology of type II diabetes [32]; opposed to full degeneration of β -
cells in type I diabetes.  Functioning pancreatic β –cells accomplish proper regulation and 
storage of glucose through a negative feedback loop where elevated glycemic concentrations up-
regulate insulin secretion from the pancreatic β –cells, which in turn lowers glycemic 
concentrations by inhibiting hepatic glucose production and increasing glucose uptake by cells 
on target organs [33].  Assessments have shown that β-cell dysfunction affects both the first-
phase and second-phase insulin response to elevated blood glucose.  Thus, the decline in β-cell 
function precedes the development of hyperglycemia and continues after the clinical diagnosis of 
type II diabetes [34].   This characteristic of type II diabetes – the loss of first-phase insulin 
response to a meal – is the main cause of postprandial hyperglycemia seen in diabetics [33].  The 
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defects of insulin resulting from type II diabetes are likely due to both the cellular dysfunction 
and reduction of the β-cell mass [34].  The mechanism and etiology of β-cell dysfunction is still 
being studied, but proposed hypotheses include glucose toxicity: chronic hyperglycemia causing 
hyperstimulation and overwork of the β-cells; and β-cell exhaustion: hyperstimulation of insulin 
secretion due to chronic hyperglycemia.  The dramatic involvement of β-cell function in the 
development of type II diabetes will result in pancreatic β-cell-directed therapies for the 
treatment of the disease. 
1.2.5 Major Complications of Diabetes Mellitus 
 There are numerous major complications that result from diabetes mellitus.  As discussed 
earlier, type I diabetes is characterized by complete β-cell degeneration, and type II diabetes is 
characterized by insulin resistance and β-cell dysfunction.  This eventually leads to chronic 
hyperglycemia, and a constant exposure to high blood glucose levels leads to significant 
complications.  Of the extensive list of complications, the most significant resulting from 
hyperglycemia includes hypertension, ketoacidosis, nephropathy, neuropathy, and most notably 
heart disease. 
1.2.5.1 Hypertension 
 Hypertension is a very common condition in diabetics, and especially common in patients 
with type II diabetes. Normal blood pressure is commonly defined as 120/80 mmHg for people 
without diabetes, and 130/80 mmHg for people with diabetes; however, stage one hypertension 
begins with a consistent blood pressure reading of 140-160/90-100 mmHg.  Hypertension 
increases the risk of macrovascular and microvascualr complications, specifically cardiovascular 
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diseases including stroke, coronary artery disease, peripheral vascular disease, retinopathy, 
nephropathy, and even neuropathy [35].  In fact, when hypertension coexists with diabetes, the 
risk of stroke or cardiovascular disease is doubled, and the risk of developing renal disease 
increases five to six times compared to hypertensive patients without diabetes [36].  In type I 
diabetics, hypertension is usually a mark of diabetic nephropathy, and these two disorders 
aggravate each other.  In type II diabetics, hypertension is associated with complications such as 
microalbuminuria, obesity, insulin resistance, dyslipidemia, hypercoagulation, and 
hyperuricemia [36].  Basic treatment of hypertension involves dietary and lifestyle modifications 
such as weight loss, exercise, reduced sodium intake, and an improved balanced diet.  
Pharmacologic therapy is another method with the use of drugs, such as ACE-inhibitors, 
diuretics, and β-blockers [37].   
1.2.5.2 Ketoacidosis 
 Diabetic ketoacidosis is the most common hyperglycemic complication in patients with 
diabetes mellitus [38].  It occurs when there are dangerously high levels of ketone acids in the 
blood. The combination of uncontrolled hyperglycemia, metabolic acidosis, and increased body 
ketone concentration characterize diabetic ketoacidosis.  This is a serious condition more 
commonly found in type I diabetics than type II, and can lead to a diabetic coma or even death if 
not treated properly.  Diabetic ketoacidosis occurs when glucose is not available as a fuel source 
for the body; thus, fat is used instead.  The byproducts of fat breakdown are ketones and acid, 
dropping the blood pH and making it more acidic than usual.  The basic mechanism behind 
ketoacidosis is mostly insulin deficiency along with elevated levels of counter-regulatory 
hormones, such as glucagon, cortisol, and growth hormone [39].  The treatment of diabetic 
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ketoacidosis involves correcting the fluid and electrolyte imbalances with saline, water, and 
potassium, normalizing the blood glucose levels with insulin, and correcting the acid-base 
disturbances using insulin or bicarbonate [40].  
1.2.5.3 Nephropathy 
Renal dysfunction in diabetes, known as diabetic nephropathy, is a progressive disease 
that occurs as a result of both direct and indirect effects of hyperglycemia and hypertension [41].  
It is a multifactorial disorder that results from the interaction of both environmental and genetic 
factors [42]. The risk of developing diabetic nephropathy is only partially determined by 
glycemic control and is highly influenced by genetic susceptibility [43].  It is a progressive renal 
disease caused by angiopathy of capillaries in the kidney glomeruli, resulting in the leakage of 
albumin protein into the urine.  It remains the leading cause of end-stage renal disease and 
develops in 20-25% of type I diabetic patients [44].  Although the risk of diabetic nephropathy in 
type I diabetes is similar to that of type II diabetes, it is most commonly associated with type II 
diabetics [45] due to the low level of glycemic control and the high level of hypertension 
associated with type II diabetes.  Diabetic nephropathy occurs first with glomerular 
hyperflitration (due to the thickening of the glomerular basement membrane) followed by 
increased urinary albumin excretion known as microalbuminuria - the leakage of albumin 
proteins into the urine [46].  Once HA1C values pass the threshold value of 8.0%, there is a 
significant increase in the chance of microalbuminuria [47].  Treatment of diabetic nephropathy 
involves control of blood glucose levels to prevent chronic hyperglycemia, plus the management 
of hypertension that is known to aggravate the disorder even further.  Pharmacological therapy, 
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with the use of ACE-inhibitors, is another option to reduce the hypertension and also reduce 
microalbuminuria to control proteinuria in both type I and type II diabetics.  
1.2.5.4 Neuropathy 
A common complication of diabetes, diabetic neuropathy occurs due to damaged nerves 
as a result of hyperglycemia.  Diabetic neuropathy affects both type I and type II diabetics, but 
progresses more rapidly and has more severe consequences in type I diabetics [48].   There are 
two common types of nerve damage; the first is peripheral diabetic neuropathy (PDN) that has 
devastating complications to the cranial nerves and spinal nerves causing tingling, pain, 
numbness, or weakness to the hands and feet and is the leading cause of foot amputations.  PDN 
occurs due to complex interactions among multiple hyperglycemia-initiated mechanisms, 
impaired insulin signaling, inflammation, and disturbances of fatty acid and lipid metabolism 
[49].  The second common type of nerve damage is called autonomic neuropathy that 
significantly influences the nerves that regulate heart, gastrointestinal, and genitourinary system. 
It also affects the regulatory function of microcirculation that may lead to different late diabetic 
complications such as gastroparesis, bladder dysfunction, erectile dysfunction, and retinopathy 
[48].  Parasympathetic nerve fibers are affected first, leading to a relative increase in sympathetic 
tone resulting in the increase in resting tachycardia.  This decrease in parasympathetic tone may 
also be responsible for worsening ischemia in diabetics due to the exaggerated coronary 
vasoconstriction [50]. Despite numerous drug trials and studies, other than strict glycemic 
control, there are no other methods of treatment to slow the progression of diabetic neuropathy 
[51].  
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1.2.5.5 Cardiovascular Disease 
Diabetes is the seventh leading cause of death in the United States, and much of that is a 
result of cardiovascular disease. Type I and type II diabetes are independent risk factors for 
atherosclerotic diseases, stroke, and peripheral arterial disease (PAD) [52].  These macrovascular 
complications are coupled with microvascular complications such as retinopathy, neuropathy, 
and nephropathy making diabetes mellitus, according to the American Heart Association, a 
cardiovascular disease on its own.  Chronic high blood pressure (hypertension) and abnormalities 
in glucose metabolism are the mechanisms by which diabetes contributes to adverse heart 
dysfunction and failure [53].  There is evidence that adequate glycemic control may improve 
cardiac metabolism and myocardial function in diabetics with a high risk of heart disease; 
therefore, there is a direct relationship between hyperglycemia and cardiovascular disease in type 
I and type II diabetic patients [54].       
1.2.5.6 Coronary Artery Disease 
Out of all cardiovascular diseases, diabetes mellitus is a major contributor to the 
development and the manifestations of coronary artery disease (CAD).  Patients with CAD and 
diabetes mellitus represent a particularly high-risk population because of the specific 
characteristics associated with the atherosclerotic disease [55].  CAD occurs late in the third or 
fourth decade of a diabetic’s life, regardless of whether diabetes developed early in childhood or 
during late adolescence.  While men are generally more susceptible to CAD than women, studies 
have shown that women with diabetes are at especially high risk for CAD, relatively more so 
than men with diabetes [56].  The disease results in the narrowing of coronary arteries due to 
atherosclerosis – the build-up of atheromatous plaques (Figure 7).  
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Figure 7 - Coronary artery disease results when a normal healthy coronary vessel, (a) narrows 
due to atherosclerosis and plaque build-up, and (b) leads to inadequate blood flow through the 
vessel (Permission granted from the National Heart, Lung, and Blood Institue as a part of the 
National institute f Health and the US Department of Health and Human Services). 
Risk factors that emerge as predictors for coronary artery disease in type I diabetics 
include nephropathy and autonomic neuropathy [57].  Nephropathy has always emerged as a 
major predictor [58], but coronary artery disease is still a risk even if the patient does not have 
nephropathy. Diabetic nephropathy is associated with an atherogenic lipoprotein profile that 
includes elevated levels of low-density lipoprotein (LDL) and very-low-density lipoprotein 
(VLDL), and decreased levels of high-density lipoprotein (HDL) [59].  Several mechanisms 
contribute to the atherosclerotic process, including hypertension, lipid abnormalities, fibrinolysis, 
and coagulation alterations [60]. As discussed before, hypertension is frequently present in 
patients with nephropathy and can intensify coronary artery disease in patients with type 1 
diabetes.  As for patients with type II diabetes, hypertension, hyperglycemia and increased 
concentrations of LDL along with decreased concentrations of HDL are independent risk factors 
that contribute to the development of coronary artery disease [61].   
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Medical therapies for treating coronary artery disease in patients with diabetes include 
insulin therapy, aspirins, β-blockers and ACE inhibitors.  Lifestyle modifications should be taken 
as well by reducing cholesterol levels, treating chronic hypertension, and controlling glycemic 
concentrations.  With the increase of endothelial dysfunction in the coronary blood vessels due to 
hyperglycemic conditions, diabetics are more susceptible to CAD, which commonly manifests 
itself into unstable angina or worse – myocardial infarction.  CAD is a significant complication 
related to diabetes and is the leading cause of death in the world.  Due to the significant and 
dominance of the heart disease, this thesis will focus on the involvement of CAD with diabetes 
mellitus. 
1.3 Treatments for Diabetics with Coronary Artery Disease 
Regardless of whether a patient has diabetes or not, revascularization is a common 
treatment for patients with coronary artery disease.  Treatment procedures include coronary 
angioplasty, coronary bypass surgery, and coronary stent placement. Numerous studies show that 
patients with diabetes experience a greater need for repeat revascularization (angioplasty, bypass, 
or stent replacement), a higher rate of cardiac events, and lower overall survival following the 
coronary therapy procedures compared to their non-diabetic counterparts [62].  Diabetic patients 
commonly have more pretentious coronary artery involvement than non-diabetics, which 
probably contributes to their less favorable outcome following revascularization [62].   Each of 
these treatments will be summarized below, along with a description of the additional impact of 
diabetes on the treatment’s success. 
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1.3.1 Angioplasty 
Coronary angioplasty (Figure 8) is a medical procedure where a balloon catheter is 
deployed to open a coronary artery that has been narrowed by plaque build-up from 
atherosclerosis.  Angioplasty provides effective relief of angina – chest pain that occurs when a 
part of the heart is not receiving enough oxygenated blood – and is usually successful in patients 
with or without diabetes mellitus.  However, the great long-term effects of angioplasty are 
greatly limited by the increased rates of restenosis in patients with diabetes (Figure 9) [63].  New 
angioplasty devices have been used (laser angioplasty and directional coronary atherectomy), but 
have failed to show any major improvement on the high rate of restenosis among patients with 
diabetes.   
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Figure 8 – With the build-up of plaque in a coronary artery, coronary angioplasty is a medical 
procedure where, (a) a balloon catheter is inserted to the site of plaque buildup, (b) the balloon is 
inflated and pushes the plaque against the blood vessel wall, and (c) proper blood flow is 
restored to the artery (Permission granted from the National Heart, Lung, and Blood Institue as 
a part of the National institute f Health and the US Department of Health and Human Services). 
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Figure 9 – The graph above displays that angiographic restenosis (50% diameter stenosis) was 
significantly greater in diabetic patients than non-diabetic patients (Permission to reprint by 
[63]). 
Diabetics may exhibit an accelerated form of intimal hyperplasia and atherosclerosis in 
response to the vascular injury caused by balloon deployment.  A study using intravascular 
ultrasound found exaggerated intimal proliferation in patients with diabetes at the site of arterial 
injury caused by angioplasty, and this response was striking in restenosis lesions [64].  
Hyperinsulinemia, common in type II diabetics with insulin resistance, may contribute to the 
atherogenic process since insulin may directly promote smooth muscle cell proliferation, and the 
procoagulant state in diabetics may contribute directly to the progression of restenosis [65].   In 
summary, while there are some similarities in the angiographic outcomes after successful 
angioplasty in diabetics and non-diabetics, the vascular injury caused by treatment of balloon 
angioplasty contributes to the increased risk of restenosis in the treated blood vessel.  
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1.3.2 Coronary Artery Bypass Surgery  
Coronary artery bypass surgery involves rerouting blood around a clogged artery to 
reinstate proper blood flow to the heart.  This is an extremely invasive procedure where surgeons 
take a segment of a healthy blood vessel (preferably a portion of the great saphenous vein) and 
make a new path around the blocked region on the coronary artery for blood to flow freely to the 
heart muscle.  Coronary artery bypass surgery is effective in relieving angina symptoms in 
patients with and without diabetes, but with respect to vein grafts, several reports have noted 
decreased survival of vein grafts in patients with diabetes [66].  Intimal proliferation, that causes 
luminal loss in the first years following bypass surgery with venous vessels, may be accelerated 
in patients with diabetes mellitus [67].  Studies have shown that restenosis after coronary artery 
bypass grafting is more common among diabetics versus non-diabetics at 1-year angiography 
mainly because of more graft failures in diabetics [68].  It is believed that the decreased success 
of coronary artery bypass grafts in diabetics and the increased short-term mortality in diabetics is 
due to metabolic abnormalities, such as hyperglycemia, and cardiac complications (especially in 
type II diabetics), which include hypertension and a possible history of peripheral vascular 
disease or stroke [74].  Thus, with reduced availability of healthy vein graft replacements within 
diabetic patients, coronary artery bypass surgery is becoming a less common method of 
treatment for CAD patients with diabetes mellitus. 
1.3.3 Coronary Stent Placement 
Coronary stent placement involves the placement of a man-made wire mesh tube during 
angioplasty that expands and props open the coronary artery that is narrowed or blocked by 
atherosclerotic plaque build-up.  During the percutaneous coronary intervention, the same steps 
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as other angioplasty procedures are performed as the stent expands and locks into place when the 
balloon inflates.  Although bare metal stents have improved outcomes among patients 
undergoing percutaneous coronary interventions, their efficacy has been limited by the 
development of in-stent restenosis [69] (Figure 10).  Studies have shown that the rate of 
restenosis increases in patients with both type I and especially type II diabetes, and specific 
angiographic characteristics, such as vessel size and stent type (bare metal vs. drug-eluting), are 
predictive of a higher rate of restenosis and a need for repeated revascularization procedures after 
the initial stent implantation [70].  Although vessel recoil may also contribute to decrease of 
lumen size, the increased restenosis rate in patients with diabetes, following stent placement, is 
due primarily to the enhanced proliferation of smooth muscle cells, because coronary artery 
“stenting” decreases the elastic recoil and vascular spasm at the treated site [63].  
Restenosis is the healing response of the arterial wall to mechanical injury (stent 
implantation in this case) and is composed of two main processes – neointimal hyperplasia (i.e., 
smooth muscle migration/proliferation, extra cellular deposition) and vessel remodeling [71].  
From a few animal study observations, neointimal hyperplasia is a general wound-healing 
response – platelet aggregation, inflammatory cell infiltration, release of growth factors, medial 
smooth muscle cell modulation and proliferation, proteoglycan deposition, and extracellular 
matrix remodeling as major milestones in the temporal sequence of the response [72].  Further 
research added that thrombosis often occurred as a cause of smooth muscle cell proliferation 
[73].  The adhesion of circulating leukocytes to endothelial cells plays an important role in the 
initiation of CAD and certainly in the occurrences of restenosis in stent-implanted diabetic CAD 
patients [74].  Levels of cellular adhesion molecules, particularly intracellular adhesion molecule 
(ICAM)-1 and vascular cellular adhesion molecule (VCAM)-1, have been found at increased 
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levels in diabetic patients [75, 76].  Notably, hyperglycemia was shown to condition the 
concentration of these cellular adhesion molecules acutely [77, 78].  In support of this, recent 
studies have shown that levels of VCAM-1 and ICAM-1 increase in high glucose environments; 
thus, the hyperglycemic environment in diabetics is a significant contributing factor to the high 
rate of in-stent restenosis [77, 79]. 
 
Figure 10 – The diagram shows the progression of in-stent restenosis as a vessel injury response 
resulting in the proliferation of smooth muscle cells, the expression of vessel adhesion 
molecules, and the adhesion of leukocytes (Permission to reprint from [71]). 
The development and use of drug-eluting stents reduced the risk of restenosis, target 
lesion revascularization, and myocardial infarction as compared to bare-metal stents; however, 
the risk of very late thrombosis is higher with drug-eluting stents than with bare metal stents 
[80].  There are two primary types of drug-eluting stents used in the market – sirolimus-eluting 
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stents and paclitaxel-eluting stents.  Recent studies have compared the use of sirolimus-eluting 
stents and paclitaxel-eluting stents in diabetics and suggest that the sirolimus-eluting stent is 
associated with a decrease in late lumen loss and a reduced risk of restenosis [81].  Implantation 
of drug-eluting stents has emerged as the predominant revascularization strategy in diabetic 
patients, especially with the improved reduction of in-stent restenosis [82].   
1.4 Coronary Stent Treatment in the Diabetic Population 
1.4.1 Restenosis in In Vivo Diabetic Studies 
 The increased atherothrombotic risk in patients with diabetes is related to their pro-
inflammatory and pro-thrombotic status [162].  Coronary artery plaques of diabetic patients with 
acute myocardial infarction had significantly higher necrotic core percentages and lower fibro-
fatty tissue percentages than non-diabetics [163, 164].  In addition, diabetic patients with stable 
angina and significantly larger dense calcium in culprit lesions [164, 165].  The pathogenic 
mechanism of restenosis after drug-eluting stent implantation under hyperglycemia is still not 
completely understood, and most reports have been conducted in a clinical setting, with little 
research done on animals.  However, a recent rat study conducted showed increased thrombus, 
inflammatory cell infiltration, and neointimal hyperplasia (NIH) without change of smooth 
muscle cell number after drug-eluting stent implantation in diabetic rats (493.3 ± 85.8 mg/dL) vs. 
non-diabetic rats (140.0 ± 8.5 mg/dL) (Figure 11) [162].  This discovery supported that the main 
mechanism of restenosis after drug-eluting stent implantation under hyperglycemic conditions 
was initial thrombus and inflammatory cell accumulation – causing a delay of 
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reendothelialization – with changes of extracellular matrix rather than smooth muscle cell 
proliferation [162].   
 
Figure 11 - Increased thrombus was located in the surrounding region of the stent strut (green 
arrows) of rats with diabetes vs. rats without diabetes (Permission to reprint from [162]). 
  In another recent diabetic rat model study showed the development of in-stent restenosis 
enhanced by long-term type I diabetes in BBDP rats [166].  Quantitative analysis supported that 
long-term diabetes resulted in a 32% increase in surface neointima compared to non-diabetic rats 
BBDP rats (Figure 12) [166].  Though the underlying mechanism(s) were not studied, this study, 
however, suggested that long-term diabetes increases the proliferative and migratory capacity of 
medial and neointimal smooth muscle cells [166]. 
 Future studies aimed at identification of cellular and molecular mechanisms involved 
with increased restenosis in diabetic animal models are warranted to improve therapeutic 
interventions. 
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Figure 12 - Long-term type I diabetes in BBDP rats is associated with enhanced in-stent 
restenosis four weeks after stenting the abdominal aorta (Permission to reprint by [166]). 
1.4.2 Clinical Results of Diabetic Coronary Stent Implantation 
1.4.2.1 Type I Diabetics vs. Type 2 Diabetics 
 In-stent restenosis is common occurrence in CAD patients, and is even greater in CAD 
patients with diabetes.  However, is there a difference in the rate of restenosis between type I and 
type II diabetics?  After reviewing the literature, no significant data has been reported showing 
any difference between the rates of in-stent restenosis between type I and type II diabetics.  
Studies do report that a chronic hyperglycemic state in the coronary vessels of diabetics 
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contributes to greater progression of CAD and an increased rate of restenosis, and since type I 
diabetics have much more control over their levels of hyperglycemia compared to type II 
diabetics, it would make sense that the occurrence of in-stent restenosis is greater in type II 
diabetics than in type I diabetics.  This also supports the fact that type II diabetics are much more 
susceptible to cardiovascular complications – thus, needing more revascularization treatments – 
which would produce higher cases of restenosis in that population compared to the other. 
1.4.2.2 Bare Metal Stents vs. Drug-Eluting Stents in the Diabetic Population 
The next studied comparison involved researching whether or not any significant 
difference existed in the rate of restenosis between diabetics with implanted bare metal stents and 
diabetics with implanted drug-eluting stents.  Recent studies compared and reported the reduced 
rate of in-stent restenosis for both types of drug-eluting stents (sirolimus and paclitaxel) 
compared to bare metal stents.  The results of a follow-up study concurred with the previous 
results in that drug-eluting stents lowered the restenosis rate by 50% in diabetic patients with one 
implanted drug-eluting stent, compared to diabetic patients with one implanted bare metal stent 
[83].  Although, on average, sirolimus-eluting stents and paclitaxel-eluting stents are associated 
with a significant reduction in target lesion revascularization compared to bare metal stents, the 
overall mortality and cardiac mortality of all three stents are quite similar [84].  However, as 
mentioned before in 1.3.3, when comparing paclitaxel-eluting against sirolimus-eluting stents in 
patients with diabetes mellitus, the use of sirolimus-eluting stents is associated with a decrease in 
late luminal loss and a reduced rate of restenosis compared to the use of paclitaxel-eluting stent 
[85, 86].   
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1.4.3 Summary of Clinical Results 
To summarize, diabetic patients (mostly type II diabetics) with coronary artery disease 
are highly susceptible to in-stent restenosis after stent implantation, due to the vascular 
aggravation induced by the chronic hyperglycemic environment.  There is an effort to improve 
stent revascularization therapy for the diabetic population, but there is limited information from 
clinical trials to guide manufacturers in the right direction for better treatment.  Thus, the 
following section will reveal the purpose and goal of this thesis, and also touch upon the overall 
perspective on how this study supports the development of improved in vitro testing of coronary 
stent treatments. 
1.5 Summary and Aims of the Thesis 
 Diabetes mellitus is an amazing disease to study – from its severe, deadly nature before 
the dramatic discovery of insulin, to its variability as distinct types, it is a disease that seems to 
produce new obstacles in treatment.  However, its treatment coincides with the treatments of so 
many other severe complications. The chronic hyperglycemic state exhibited by type II diabetics 
is the root cause of the numerous complications associated with the disease – the most severe 
complication being coronary artery disease; the leading cause of death in the world.  The vessel 
damage caused by hyperglycemia can lead to atherosclerotic plaque build-up in the coronary 
vessels of the heart, and stent implantation is the most popular treatment to eliminate the 
blockage. However, patients with diabetes experience a high rate of in-stent restenosis – the 
reformation of the atherosclerotic blockage – due to the vascular injury caused by the 
deployment of the stent.   
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Stent designs are constantly modified and improved to meet the demands of 
cardiovascular treatment, and it is important for stent producers to be able to evaluate the 
practicality and mechanics of the designs in a time and cost efficient manner.  While in vivo 
animal models and clinical testing are vital for product evaluation, these are extremely expensive 
and time consuming; thus, it would be beneficial to be able to test and evaluate stents beforehand 
in a controlled in vitro setting that accurately replicates the environment of a coronary blood 
vessel.  A blood vessel model that accurately replicates the anatomy and physiology of a native 
blood vessel – a blood vessel mimic (BVM) – could meet this need 
 The primary purpose of BVM research has been to evaluate the endothelialization of bare 
metal and coated stents [87].  In the case of diabetes mellitus, an in vitro model of a diabetic 
coronary blood vessel would be extremely useful to evaluate the failure behind the implantation 
of bare metal and drug-eluting stents in the diabetic population with coronary artery disease, and 
aid the improvement of the vascular treatment for the ailing population. 
 The goals of this thesis focused on the feasibility of creating and monitoring a 
hyperglycemic environment that would help develop a diabetic/hyperglycemic BVM.  
Hyperglycemia is the most significant root cause of the major complications in diabetics; thus, it 
is no surprise that it was determined to be the basis of a diabetic BVM.  However, before diving 
into the creation of a diabetic BVM, it was necessary to test whether or not an induced 
hyperglycemic environment could be created and monitored in vitro, and what the effects on 
cells in culture would be.   
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Therefore, this thesis was driven by the hypothesis that a high concentration of glucose 
can be created and monitored in vitro to replicate the chronic state of hyperglycemia in a diabetic 
environment.  In order to test this hypothesis, the thesis was broken down into three major aims: 
1. Establish a protocol to create high glucose solutions in standard cell culture media 
2. Establish a protocol to accurately monitor the concentrations of the high glucose 
solutions 
3. Test this monitoring protocol in cell culture over time and determine how the high 
glucose solutions affect endothelial cells 
These aims served the purpose of determining whether or not a feasible hyperglycemic 
environment can be induced into an in vitro BVM; thus, ultimately allowing the creation of a 
diabetic blood vessel environment.  The potential success of this study would progress towards 
an improved evaluation of bare metal and drug-eluting stents that currently experience a high 
rate of in-stent restenosis in diabetic patients with coronary artery disease.   
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Chapter 2: Establishment & Evaluation of High 
Glucose Solutions in Order to Create Hyperglycemic 
Environments  
2.1 Introduction 
As discussed in Chapter 1, diabetes mellitus is one of the most common and deadliest 
diseases among Americans.  According to the American Diabetes Association, about 23.6 
million adults and children in the United States are diagnosed with diabetes – which is 7.8% of 
the population [88].  Diabetes is most commonly seen in two forms, type I and type II.  Type I 
diabetes, also known as insulin deficient (or dependent) diabetes, is an autoimmune disease that 
degrades pancreatic ß-cells; thus, preventing the secretion of insulin.  Patients suffering from this 
type of diabetes are usually treated with subcutaneous insulin injections.  Type II diabetes, also 
known as insulin resistant (or independent) diabetes, occurs due to genetics, poor diet, and poor 
health.  The result is complete dysfunction of pancreatic ß-cells; thus, the body no longer 
responds to the physiological effects of insulin and results in a chronic hyperglycemic state.  
Patients suffering from type II diabetes may be treated with insulin along with oral medication; 
however, significant lifestyle changes involving improved diet and increased exercise are 
necessary.  Out of the 7.8% of Americans diagnosed with diabetes, about 95% have type II 
diabetes making it the more significant and deadly form of the disease [88]. 
The high death rate associated with diabetes mellitus is due primarily to the 
complications caused by hyperglycemia - high blood glucose concentration – in the body.  The 
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body’s inability to adequately control its blood glucose levels induces this hyperglycemic 
environment and can lead to the severe complications that were discussed in section 1.2.5.  Due 
to its severity and significance, replicating a hyperglycemic environment is the desired approach 
to accurately replicating a diabetic environment for a blood vessel mimic (BVM).   The focus of 
this chapter will revolve around studying the glucose concentrations of a hyperglycemic 
environment, and the most practical method of replicating this environment for incorporation 
with a BVM. 
2.1.1 Significance of Hyperglycemia & Common Complications in Diabetic 
Patients 
As described in detail in Chapter 1, hyperglycemia is a condition seen in type I and type 
II diabetics.  If not treated properly, the condition can result in a range of complications.  The 
condition usually occurs in type I diabetics if an insufficient amount of insulin has been 
delivered, but is more prevalent in type II diabetics since the metabolic effect of insulin is 
ineffective.  Miscalculations in carbohydrate counting when adjusting insulin dosages, or daily 
stresses from life can worsen the hyperglycemic condition.  For patients, it is important to 
constantly monitor their own glucose concentrations and avoid drastic hyperglycemic episodes.  
It is also important for diabetic patients (especially type I diabetics) to avoid hypoglycemic 
episodes – a state of extremely low blood sugar – as it can lead to a diabetic coma and even 
death.  Since this study focuses on the effects of hyperglycemia in CAD patients with diabetes, 
the state of hypoglycemia will not be discussed.   
It is extremely important for diabetic patients to treat a severe case of hyperglycemia as 
soon as it is detected.  Failing to do so can first lead to a complication called ketoacidosis, which 
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can also lead to a diabetic coma.  The human body usually relies on glucose as its natural fuel.  
Without insulin working effectively, the body is unable to breakdown glucose properly and is 
required to break down fats as an energy source instead.  Once the body breaks down fats, waste 
products called ketones are produced that the body cannot tolerate at high levels.  This results in 
the body’s attempt to rid of the ketones through urine but is usually unable to; thus, leaving an 
excess that eventually ends up in the bloodstream causing ketoacidosis [89].  This condition is 
life threatening and requires immediate attention (usual symptoms are shortness of breath, 
nausea, vomiting, dry mouth, and even a fruity smelling breath) [89]. 
While lower states of hyperglycemia do not cause severe complications rapidly, a 
prolonged hyperglycemic condition usually leads to more long-term complications including 
hypertension, neuropathy, nephropathy, eye complications (retinopathy, cataracts, glaucoma), 
and most significantly heart disease – notably, coronary artery disease (CAD) [88].  Table 2 lists 
the most significant complications of hyperglycemia and provides brief descriptions. 
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Table 2 - Common complications associated with diabetes mellitus resulting from hyperglycemia 
Complication  Description 
Ketoacidosis 
 
 
 
Diabetic coma; increased blood ketone 
concentration & metabolic acidosis 
Hypertension 
 
 
 
Increased blood pressure 
Neuropathy 
 
 
 
Impaired nervous system signaling 
Nephropathy 
 
 
 
Kidney disease leading to protein leakage 
into urine 
Retinopathy 
 
 
 
Decreased vision or blindness due to 
damages to retinal vasculature 
Glaucoma 
 
 
 
Disease affecting optic nerve and loss of 
retinal ganglion cells 
Heart Disease/Coronary Artery Disease  
Disease of the coronary artery involving 
accumulation of atherosclerotic plaques 
within blood vessel walls 
2.1.2 Vascular Damage Induced by Hyperglycemia 
As noted before, microvascular diseases are extremely prevalent in diabetic patients [91], 
and these alterations to the vasculature are the most common causes of mortality in diabetics 
[90].  Hyperglycemia is associated with endothelial cell dysfunction and reduced 
neovascularization – essential steps for wound healing and prevention of cardiovascular ischemia 
[92].  Studies have demonstrated that in patients with cardiovascular risk factors, such as the 
complications associated with diabetes, the number of endothelial progenitor cells is reduced and 
their functions are impaired [93].  For example, several animal models of diabetes showed 
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increased vascular permeability [94], alterations in erythrocyte velocity [95], entrapment of 
leukocytes in microcirculation [96, 97], and morphological alterations, such as changes in 
vascular density [95].  All these alterations are mainly described as a result of hyperglycemia 
[98, 99].  One study has illustrated that in type I diabetes, endothelial progenitor cell numbers are 
inversely correlated with HbA1C levels, demonstrating that a high degree of blood glucose 
concentration directly affects endothelial cell proliferation and differentiation [100].  
Further studies with diabetic mice showed a decrease in vascular density; however, there 
was also an increase in vessel diameter (Figure 13) [90].  The increase in vessel diameter 
resulted in the combination of an unchanged blood flow rate and a lower vascular density, 
therefore, leading to decreased tissue perfusion in subcutaneous tissue and an impaired supply of 
oxygen and nutrients [90].  This explains the impaired wound healing seen in diabetics as 
mentioned previously.  The increase in vessel diameter and the reduction in vessel density 
correlated with the levels of hyperglycemia represented by the blood glucose levels and body 
weight of the diabetic mice.  Additionally, these correlations support the hypothesis that 
impaired glycemic control progressively leads to functional and morphologic alteration in the 
vasculature of early-stage diabetes [90].   
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Figure 13 - A study by Algenstaedt et al. showed that diabetic mice experienced a decrease in 
vascular density, but an increase is vascular diameter with an increase in glycemic concentration 
(Permission to reprint from [90]).  
Despite the drastic impact of hyperglycemia on endothelial dysfunction and 
microcirculatory properties, more needs to be understood about the alterations of endothelial 
cells during the development of diabetes.  Recall, diabetics with CAD have a high rate of in-stent 
restenosis after implantation.  With all of the supporting information, it is reasonable to propose 
that the high rate of restenosis in diabetics is the result of the chronic hyperglycemic 
environment of their blood vessels. 
2.1.2.1 Molecular Mechanisms of Glucose-Mediated Vascular Damage 
 Four main mechanisms have been hypothesized on how hyperglycemia causes diabetic 
complications.  These four mechanisms are: increased polyol pathway flux; increased advanced 
glycation end-product (AGE) formation; activation of protein kinase C (PKC); and increased 
hexosamine pathway flux (Figure 14) [167]. 
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Figure 14 - Potential mechanisms by which hyperglycemia-induced mitochondrial superoxide 
overproduction activates four pathways of hyperglycemic damage (Permission to reprint by 
[167]). 
 For the polyol pathway, aldose reductase is the first enzyme that is responsible for 
catalyzing glucose.  In normal glucose concentrations, a very small percentage of glucose is 
metabolized via this pathway; however, in a hyperglycemic environment, the increased 
intracellular glucose concentration results in the conversion of glucose to the polyalcohol sorbitol 
and a coinciding decrease in NADPH [167].  Mechanisms have been proposed as the root cause 
of the negative effects induced by a hyperglycemic environment.  These mechanisms include 
osmotic stress induced by elevated sorbitol concentrations; decreased (Na+ + K+) ATPase 
activity; and an increase in cytosolic NADH/NAD+ and a decrease in cytosolic NADPH [167].  
The reduction of glucose to sorbitol by NADPH consumes NADPH, which is required for 
regenerating reduced glutathione (GSH).  Decreased levels of GSH have been found in 
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transgenic mice that overexpress aldose reductase; thus, is most likely the mechanisms that 
results in detrimental consequences via the increased flux through the polyol pathway [168].  
However, in vivo studies of inhibition of the polyol pathway have yielded inconsistent results – a 
five-year study in dogs showed a prevention of diabetic neuropathy but failure to prevent 
retinopathy or thickening of capillary basement membrane in the retina and kidney, with the 
inhibition of aldose reductase [169]. 
 Advanced glycation end-products (AGEs) have been found at excessive concentrations in 
diabetic retinal vessels [170] and renal glomeruli [171].  Additionally, it now seems likely that 
intracellular hyperglycemia initiates the formation of intracellular and extracellular AGEs [172].  
Intracellular auto-oxidation of glucose to glyoxal [173], decomposition of glucose-derived 1-
amino-1-deoxyfructose lysine adducts to 3-deoxyglucosone, and fragmentation of 
glyceraldehyde -3-phosphate and dihydroxyacetone phosphate to methylglyoxal [174] can cause 
an acrease in AGEs.  The production of intracellular AGE precursors damage target cells by 
three general mechanisms.  First, intracellular proteins modified by AGEs have altered function; 
second, extracellular matrix components modified by AGE precursors interact abnormally with 
other matrix components and receptors for matrix proteins on cells; and third, plasma proteins 
modified by AGE precursors bind to AGE receptors on endothelial cells, mesangial cells and 
macrophages, inducing receptor-mediated production of reactive oxygen species [167].  For 
endothelial cells specifically, fibroblast growth factor is one of the main AGE-modified proteins 
[175].  Additionally, AGE formation alters the functional properties of several matrix molecules 
– intermolecular AGE crosslinking induces an expansion of the molecular packing on type I 
collagen [176], which has been shown to decrease elasticity in large vessels from diabetic rats 
[177].  Lastly, AGE formation on extracellular matrix also interferes with matrix-cell interaction 
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[167].  For example, type IV collagen’s cell-binding domains are modified by AGE causing a 
decrease in endothelial cell adhesion [178].  
 Increased protein kinase C (PKC) activity is induced by hyperglycemia since 
hyperglycemia increased diacylglyceral (DAG) concentration; DAG is responsible for the 
activation of protein kinase C.  Activation of PKC has numerous detrimental consequences.  
Early studies have shown that the activation of the β PKC isoform mediated blood flow 
abnormalities by depressing nitric oxide production and/or increasing endothelin-1 activity 
[167].  Activation of PKC also causes an increased expression of VEGF, which enhances 
vascular permeability of smooth muscle cells and also induces angiogenesis [167].  Additionally, 
PKC activity contributes to increased microvascular matrix protein accumulation by inducing the 
expression of TGF- β1, fibronectin, the fibrinolytic inhibitor PAI-1, and type IV collagen, which 
contributes to capillary and overall vascular occlusion [179, 180]. 
 Lastly, excessive intracellular glucose into the hexosamine pathway may also induce 
several diabetic complications [181].  In this pathway, when glucose is converted to glucose-6-
phosphate and then converted to fructose-6-phosphate, instead of entering glycolysis, fructose-6-
phosphate is used to provide substrates for reactions that require UDP-N- acetylglucosamine, 
such as proteoglycan synthesis and the formation of O-linked glycoproteins [167].  Conversion 
of fructose-6-phosphate to glucosamine with the rate-limiting enzyme GFAT increases 
hyperglycemia-induced increased in the transcription of TGF- β1 and PAI-1; thus, this pathway 
is also plays an important role in hyperglycemia-induced and fat-induced insulin resistance [182, 
183].  Though it is not entirely known how the mechanisms by which increased activity through 
the hexosamine pathway initiates hyperglycemic-induced increases in gene transcription, there 
has been an observation that binding sites for the transcription factor Sp1 regulate the 
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hyperglycemia-induced activation of PAI-1 promoter in vascular smooth muscle cells [184].  
This suggested that modification of Sp1 by N-acetylglucosamine (G1cNAc) might explain the 
link between the activation of the hexosamine pathway and the hyperglycemic-induced changes 
in the transcription of the gene for PAI-1 [167].  Additionally, recent studies have shown 
hyperglycemia increasing activity of the hexosamine pathway 2.4-fold in aortic endothelial cells 
[185].  In addition to transcription factors, many other nuclear and cytoplasmic proteins are 
modified by O-linked G1cNAc, such as the inhibition of eNOS activity by hyperglycemic-
induced O-acetylglucosaminylation at the Akt site of the eNOS protein [186].  Thus, activation 
of the hexosamine pathway by hyperglycemia can result in changes to gene expression and 
protein function, contributing to the pathogenesis of diabetic complications.  
Since hyperglycemia is one of the most significant factors in diabetes, high glucose 
solutions were proposed as the most feasible method of replicating a diabetic environment in a 
BVM.  However, before exploring the creation and evaluation of the hyperglycemic 
environments, it is essential to first understand the fundamental physiology of blood glucose in 
the human body, and the basics behind the metabolic dysfunction that results in hyperglycemia.   
2.1.3 Blood Glucose 
2.1.3.1 Properties of Glucose 
Glucose is an extremely important monosaccharide – a simple sugar – used as a source of 
energy and metabolic intermediate for living cells.  The name “Glucose” comes from the Greek 
word glukus, meaning “sweet.”  The suffix “-ose” denotes sugar [101].   
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The chemical formula for glucose is C6H12O6, and its structure makes it an aldohexose, 
that is, a hexose with an aldehyde at the end (Figure 15) [102].  A hexose is a monosaccharide 
with six carbon atoms and usually has the chemical formula C6H12O6 [102].  An aldehyde is an 
organic compound containing a terminal carbonyl group (Figure 16) [103].  This is a functional 
group that contains a carbon atom bonded to a hydrogen atom and double-bonded to an oxygen 
atom (chemical formula O=CH).  In solution, the glucose molecule can exist in an acyclic (open-
chain) and a cyclic (ring) form.  The cyclic form, also referred to as glucopyranose, is a result of 
the aldehyde carbon atom double-bonded to the hydroxyl group (oxygen bonded to a hydrogen) 
on the fifth carbon of the open chain – making a six-member ring (Figure 17) [102].  At a neutral 
pH of 7 and in solid form, glucose takes its cyclic form. 
 
Figure 15 - Glucose is an aldohexose; a hexose with an aldehyde attached at the end (Permission 
to reprint from [102]). 
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Figure 16 - An aldehyde is an organic compound containing a terminal carbonyl group 
(Permission to reprint by [103]). 
 
Figure 17 - The cyclic form of glucose, glucopyranose, results from the aldehyde carbon atom 
double-bonded to the hydroxyl group on the fifth carbon of the open chain (Permission to reprint 
by [102]). 
There are two stereoisomers of the aldohexose sugars referred to as glucose: L-glucose 
and D- glucose, but only D-glucose is biologically active (Figure 18) [102].  Stereoisomers are 
isomeric molecules with the same molecular formula and sequence of bonded atoms, but differ 
only in 3-D orientation.  The orientation of L-glucose (pretty much a mirror-image of D-glucose) 
disables it from being metabolized by cells via glycolysis; however, L-glucose is not entirely 
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unnecessary [102].  While it is less sweet than D-glucose and it cannot be used as a source of 
energy, L-glucose can be converted into a low-calorie sweetener.  In addition, L-glucose has 
been found to be a laxative and has been proposed as a colon-cleansing agent [104]. 
 
Figure 18 - D-glucose and L-glucose are two stereoisomers of the aldohexose sugars.  However, 
D-glucose is the biologically active form (Permission to reprint by [102]). 
2.1.3.2 Normal Blood Glucose Levels 
Most mammals normally maintain a blood glucose level within the range of 3.6 mmol/L 
and 5.8 mmol/L (about 80 mg/dL to 120 mg/dL).  The average normal blood glucose level in a 
human is 5 mmol/L (approximately 90 mg/dL).  Thus, the total amount of glucose circulating in 
blood, assuming the blood volume in an adult human is 5 L, is about 3.3 to 7.0 grams [105].  
According to the American Diabetes Association, after a person consumes an average size meal, 
the post-meal glucose levels for a non-diabetic person usually reach 140 mg/dL (7-8 mmol/L) 
[88].  Diabetics, however, have a pre-meal glucose level of 90 mg/dL-130 mg/dL and can reach a 
post-meal glucose level of 180 mg/dL [106]. 
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While this may seem like a substantial difference to some, it is actually quite surprising 
that such a small amount of glucose is circulating in the blood.  Assuming that the average adult 
male is 165 lbs. (75 kg) and contains a blood volume of 5 L (1.3 gal), a normal blood glucose 
level of 100 mg/dL (5.5 mmol/L) is equivalent to only 5 g of glucose in the entire volume of 
blood, and about 45 g in the total volume of body water [105]!  To visualize this, 5 grams of 
sugar is about the mass of a small packet of Splenda sugar.  It is astonishing that such an 
insignificant amount of glucose can differentiate a healthy patient from a diabetic patient.  
Knowing the various blood sugar ranges is useful when diagnosing diabetes mellitus.  A 
type I diabetic will usually have very low plasma insulin levels during fasting and after a meal.  
This is contrary to type II diabetics who have abnormally high levels of plasma insulin during 
fasting and after a meal.  This level increases even more after ingesting a “load” of glucose 
during a glucose tolerance test [107].  A glucose tolerance test helps establish the diagnosis of 
diabetes and also the type.  As seen in the “glucose tolerance curve” (Figure 19), when a normal 
fasting person ingests 1 gram of glucose per kilogram of body weight, the blood glucose level 
increases from about 90-100 mg/dL to about 120-140 mg/dL, and falls back to its normal values 
after 2 hours [107].  Recall that in a person with diabetes, the starting fasting blood glucose level 
is usually around 120-130 mg/dL (it can even be above 140 mg/dL depending on the severity).  
After ingesting 1 gram of glucose, these patients exhibit a much greater rise in blood glucose 
concentration and take about 4-6 hours to return to normal levels, sometimes not even reaching 
normal levels and never dipping below it [107].  The slow fall of the curve and the failure to fall 
below healthy glucose levels demonstrates that either normal insulin secretion after glucose 
ingestion does not occur, or there is a decreased sensitivity to insulin.  Distinguishing between 
type I and type II diabetes in these patients comes down to analyzing the plasma insulin levels – 
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again, with plasma insulin being low or undetectable in type I diabetics, and high in type II 
diabetics.  
 
Figure 19 – A glucose tolerance test illustrates that a normal patient who has consumed glucose 
will return to homeostasis after about 2 hours.  A diabetic patient, however, will take 4-6 hours 
and sometimes not even reach normal glycemic levels.  Distinguishing between type I and type II 
diabetes comes down to analyzing the plasma insulin levels – low levels in type I diabetics, and 
high levels in type II diabetics (Permission to reprint by [107]). 
2.1.3.3 Metabolism & Regulation of Glucose 
Most of the mechanics and characteristics of the human body’s physiologic functions are 
based on one common goal – achieving and maintaining homeostasis.  Homeostasis is a property 
of an open or closed system, in this case the human body, which regulates its internal 
environment and tries to maintain a stable, constant condition.  Vitals such as blood pressure, 
heart rate, calcium-release, hormonal secretions, and especially blood glucose levels try to 
achieve and maintain a homeostatic state.  When it comes to maintaining a stable blood glucose 
level, carbohydrate metabolism with the help of insulin plays a key role.  The final products of 
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carbohydrate digestion are usually glucose, fructose, and galactose – glucose usually 
representing about 80% of the end products [108].  After absorption through the intestinal tract, 
most of the fructose and almost all of the galactose is converted to glucose in the liver; thus, 
leaving little fructose and galactose circulating in the blood [108].  Therefore, more than 95% of 
all monosaccharides circulating in the blood is glucose, and when carbohydrates transport 
through cell membranes, it is common for carbohydrates to convert into glucose first [109].     
The maximum molecular weight for a particle to diffuse readily through a cell membrane 
is usually 100 atomic mass units (amu).  Although glucose has a molecular weight of 180 amu, it 
still passes into the interior of cells with a reasonable degree of freedom via facilitated diffusion 
[109, 110].  Facilitated diffusion is the transport of a particle, in this case glucose, with the help 
of a carrier enzyme.  Penetrating through the lipid matrix of the cell membrane are large numbers 
of protein carrier molecules that bind with glucose, cause glucose to undergo a conformational 
change, and easily transport the newly structured glucose to the other side of the cell membrane.  
This process is usually initiated by an existing concentration gradient that promotes more 
glucose to follow into the cell [110]. 
Insulin drastically increases the rate of glucose transport – nearly ten times more than the 
rate of transport when insulin is not present.  To initiate the process of glucose consumption on a 
target cell, insulin first binds to the α-subunits of its cell membrane receptor protein outside of 
the cell, which causes the autophosphorylization of the receptor’s β-subunits inside the cell; thus, 
making the insulin receptor protein an enzyme-linked receptor[107] (Figure 20).  Enzyme-linked 
receptors are proteins that pass through the cell membrane only once and have a hormone 
binding site on the outside of cell and the enzyme-binding site inside the cell [110].  Once 
activated by the hormone binding to the receptor, the enzyme inside the cell is immediately 
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activated.  The autophosphorylization of the β-subunits activates tyrosine kinase, which causes 
the phosphorylation of insulin-receptor substrates (IRS) [107].  IRS control glucose metabolism 
cause glucose transporters to be moved to the cell membrane in order to facilitate glucose entry 
into the cell [107]. 
 
Figure 20 - The binding of insulin to its cell membrane receptor induces a series of subsequent 
events, which cause the facilitated diffusion of glucose into the cell (Permission to reprint from 
[107]). 
Insulin secretion is associated with energy abundance, that is, when there is a great 
abundance of energy-giving foods in a person’s diet (high carbohydrate diet), large quantities of 
insulin are secreted due to the high concentration of blood glucose [111].  Therefore, 
carbohydrate metabolism is a significant factor for diabetes.  Insulin also plays a key role in 
storing excess energy in liver cells in the form of glycogen – a large polymer of glucose – 
through the process of glycogenesis.  Between meals, when food is not available and blood 
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glucose concentration begins to fall, insulin secretion decreases rapidly and the glycogen in the 
liver is converted back into glucose and secreted back into the blood to maintain homeostasis.  
As blood glucose concentrations rise above 100mg/dL, the rate of insulin secretion increases 
rapidly [107] (Figure 21).   
 
Figure 21 - As blood glucose concentration rises, the rate of insulin secretion rises at a rapid rate.  
This increase in insulin secretion is non-existent in type I diabetics, and ineffective in type II 
diabetics – thus, resulting in hyperglycemia (Permission to reprint by [107]).  
The rate of insulin secretion can reach nearly 20-25 times the basal level at extremely 
high blood glucose concentrations.  The cessation of insulin secretion is almost equally as rapid, 
occurring within 3-5 minutes after blood glucose levels return back to the normal fasting level 
[107].  This association is an important feedback mechanism for regulating blood glucose 
concentration; however, in type I diabetics, this feedback mechanism is non-existent [112].  
While this mechanism is present in type II diabetics, a dysfunction in the insulin-signaling 
cascade results in insulin resistance. 
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2.1.3.4 Dysfunction of Glucose Metabolism & Insulin Signaling 
The dysfunction in the mechanism of insulin secretion in diabetic patients starts with the 
destruction of pancreatic ß-cells.  The ß-cells have a large number of glucose transporters, 
GLUT-2 and GLUT-4 for example, that permit a rate of glucose influx that is correlated to the 
blood glucose concentration [113].  Glucose is then phosphorylated inside the ß-cells into 
glucose-6-phosphate by an enzyme called glucokinase.  This step senses and adjusts the amount 
of insulin that will be secreted.  Glucose-6-phosphate is oxidized to form adenosine triphosphate 
(ATP), which inhibits ATP-sensitive potassium channels.  This inhibition of potassium entering 
the cell causes drastic depolarization, which in turn, activates voltage-gated calcium channels.  
The entrance of calcium stimulates vesicles, containing insulin, to fuse with the cell membrane, 
and secrete insulin into the blood via exocytosis [114] (Figure 22).   
 
Figure 22 - The influx of glucose into the pancreatic ß-cells is controlled by glucose transporters 
(GLUT-2 and GLUT-4) depending on the blood glucose concentration (Permission to reprint 
from [107].   
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With the destruction of ß-cells in type I diabetics, there is a lack of glucose transporters 
and glucokinase to phosphorylate the glucose into glucose-6-phosphate; thus, resulting in a lack 
of insulin secretion to compensate for the increase in blood glucose concentration. 
Insulin resistance in type II diabetes is caused by abnormalities of the signaling pathway 
that link the activation of the cell membrane insulin receptor with the multiple subsequent 
cellular mechanisms that result in glucose uptake [115].  Although many of the proximal steps in 
insulin signaling have been identified [116], the downstream pathways that are important for 
insulin to maintain glucose homeostasis are less well defined [117].  Different IRSs are 
expressed in different tissues, but produce the desired effects on insulin signaling [107, 115].  
Some animal studies associated insulin resistance with the defects and inactivity of 
phosphoinositide 3-kinase – an enzyme responsible for intracellular trafficking – resulting in 
decreased activation of glucose transport proteins [117, 118].  Other animal studies claim that the 
defect in signaling occurs between the insulin receptors and the phosphorylation of IRS and other 
enzymes within the cell [119].  The exact dysfunction in the signaling cascade is still under 
investigation, but proposed mechanisms, if correct, offer new therapeutic targets for insulin-
sensitizing agents, especially for type II diabetics. 
2.1.3.5 Summary 
Hyperglycemia is the major consequence of diabetes since it is the root cause of so many 
complications in diabetic patients.  Hyperglycemia is characterized as high concentration of 
blood glucose.  The aim of this thesis is to create a diabetic BVM, and from the research that was 
conducted, the most practical method of inducing a diabetic environment was to induce a state of 
hyperglycemia.  Therefore, the first set of experiments conducted and explained in this chapter 
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involved the creation of a hyperglycemic environment, which was hypothesized as a high 
glucose cell media solution.   In addition, an established method of monitoring the glycemic cell 
media solutions was necessary.  Thus, the goals of the studies in this chapter were: 
1. To explore and identify practical methods of measuring levels of glucose in different 
glycemic cell media solutions;  
2. To develop and establish a procedure to create hyperglycemic cell media solutions 
with the addition of glucose into base cell media; and  
3. To use the hyperglycemic cell media solutions in order to evaluate the different 
methods of monitoring glucose concentrations and determine the most feasible method. 
The following section begins by describing various methods available for measuring 
blood glucose concentrations, followed by methods of creating different hyperglycemic solutions 
to test the reliability of various glucose monitoring methods.     
2.2 Methods 
There are a variety of methods to measure blood glucose concentrations, ranging from 
bio-implants and continuous monitoring systems, to blood glucose meters and visual blood 
glucose test strips.  Since the glycemic solutions in these experiments would be produced using 
cell culture media instead of blood, it was essential to assess not only the feasibility of each 
method, but also the method that would provide the most accurate and precise results in cell 
culture solutions.  A range of methods was first reviewed, as will be summarized below, and then 
the top two methods were selected for experimental testing. 
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2.2.1 Methods of Measuring and Monitoring Blood Glucose 
In this section, three methods for measuring blood glucose are described: blood glucose 
meters, continuous glucose monitoring systems, and visual blood glucose strips.  In addition to 
these methods, a look into future methods of monitoring, such as glucose sensing bio-implants, 
and other non-invasive technologies, are briefly discussed. 
2.2.1.1 Blood Glucose Meter 
A blood glucose meter is a medical device used to measure blood glucose concentrations.  
The meter requires only a small drop of blood (3 µL – 10 µL) that is obtained by pricking the tip 
of a finger with a small lancet, and a disposable test strip consumes the drop of blood, via 
capillary action and measures the blood glucose level in units of mg/dL or mmol/L.  This device 
is a key addition to “home blood glucose monitoring” and helps patients avoid 
hyperglycemic/hypoglycemic episodes by testing several times a day. 
The blood glucose meter functions via the oxidation of glucose to gluconolactone that is 
catalyzed by glucose oxidase (GOD), or some meters use a similar reaction catalyzed by glucose 
dehydrogenase (GDH) instead [120].  Most meters use an electrochemical method with the 
mentioned reagents.  The disposable test strips contain a capillary that sucks up the drop of blood 
and the glucose within the blood reacts with an enzyme electrode containing either GOD or 
GDH [121].  The enzyme is reoxidized with an excess of ferricyanide ion, a mediator reagent, 
and this mediator in turn is reoxidized by the reaction at the electrode that generates an electric 
current.  The total charge that passes through the electrode is proportional to glucose 
concentration in the drop of blood that reacted with the electrode [122].  This method is an 
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example of the coulometric method – very much equivalent to determining how hard a ball was 
thrown by measuring the distance it traveled in a certain amount of time.   
  The first two models of the blood glucose meters to dominate North America were the 
Glucometer (owned by Bayer) and the Accu-Chek (by Roche, previously known as Boehirnger 
Mannheim) (Figure 23) [123].  Compared to visual glucose test strips, which were more popular 
before the arrival of the blood glucose meter, blood glucose meters are preferred by patients 
mostly for the ease of use.  However, the accuracy of glucose meters is a common clinical 
concern [123, 124]. 
 
Figure 23 - The Aviva Accu-Chek blood glucose meter is the most popular meter used among 
diabetics to test blood sugar levels (Permission to reprint by Accu-Chek Blood Glucose 
Monitoring Systems). 
Most blood glucose meters have the same level of accuracy (+/- 10%-15%); however, 
factors such as calibration of the meter, ambient temperature, size and quality of the blood 
sample, contamination of the meter, humidity, and aging of the associated test strips can affect 
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the accuracy of each test [125].  To limit the inaccuracy of test results, the Clarke Error Grid 
Analysis (EGA) (Figure 24) was a common way of analyzing and displaying accuracy of 
readings [126].  The EGA was developed in 1987 to quantify the clinical accuracy of a patient’s 
estimate of their blood glucose levels compared to the value obtained on the meter [127].  The 
EGA became accepted as the key reference for determining the accuracy of blood glucose 
meters.  The grid was broken down as a scatter plot comparing a reference glucose meter and an 
evaluated glucose meter into five regions: 
 Region A – values within 20% of the reference glucose meter 
 Region B – values outside of 20% but do not lead to inappropriate treatment 
 Region C – values leading to unnecessary treatment 
Region D – values indicating potentially dangerous failure to detect glycemic imbalance 
Region E – values that confuse treatment of hypoglycemia or hyperglycemia 
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Figure 24 - The Clarke Error Grid Analysis (EGA) was developed to quantify the clinical 
accuracy of a patient’s estimate of their blood glucose compared to the value obtained on the 
meter.  Patients could estimate their blood glucose levels by another blood glucose meter or 
visual test strips (Permission to reprint by [127]). 
The analysis takes into account the value of the evaluated blood glucose meter, the value 
of the reference blood glucose meter, the relative difference between the two values, and the 
clinical significance of the difference [127].  Although there is a level of inaccuracy in blood 
glucose meters, animal and clinical studies monitoring diabetic patients use multiple blood 
glucose meters to ensure that an accurate blood glucose level is being measured [128]. 
2.2.1.2 Continuous Glucose Monitoring 
A continuous glucose monitoring system (CGMS) is a device that monitors and records 
blood glucose concentrations twenty-four hours a day (Figure 25).  The idea behind this device is 
to measure blood sugars continuously for 3-5 days while the diabetic patient conducts daily 
routines and activities. The “sensor” of the CGMS is inserted subcutaneously just under the skin 
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of the abdomen where it measures glucose levels in the tissue every 10 seconds.  Information is 
transmitted from the sensor to the associated insulin pump that reads and plots the changes in 
glucose concentration.  The entire system usually records an average glucose value every 5 
minutes and plots it on a curve for the patient to see.  While standard blood glucose meter 
measurements are still taken and entered into the insulin pump for calibration, the CGMS 
continuously measures the glucose concentrations during those critical times, such as before and 
after a meal, during and after exercise, and during the night when the patient is asleep.  After the 
3-5 day period, the sensor is removed and stored information in the insulin pump is downloaded 
to a computer where the plots of recorded glucose concentrations are printed in order to evaluate 
fluctuations and patterns.   
 
Figure 25 - The MiniMed Paradigm REAL-Time System uses a glucose sensor attached to a 
wireless transmitter that records blood glucose levels and graphs it on the incorporated insulin 
pump (Permission to reprint by Medtronic Diabetes). 
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This system is not intended for long-term self-care or as a replacement for the blood 
glucose meter; the CGMS is mostly used to study patterns of a patient’s glucose levels, 
especially at those critical times mentioned above.  For example, a pattern or trend can indicate 
that a patient’s blood glucose level is dangerously low during the night and is at risk of a 
hypoglycemic episode while fast asleep.  Or, a pattern revealing an elevated blood glucose level 
during the afternoon can expose a patient’s tendency to eat a high carbohydrate lunch at work.  
Though studies have shown that with the information given from the CGMS, patient HA1c 
levels have decreased with adjustments to their therapies, the CGMS still cannot replace frequent 
testing with blood glucose meters [129].  Animal tests are continuously conducted to ensure 
CGMS are accurately monitoring glucose concentration.  Testing on diabetic cats showed that 
there was a good correlation between the CGMS values and blood glucose concentration 
measured using a blood glucose meter [130].  Numerous clinical studies have shown that using 
CGMS provides adequate information, and treatment changes would not have been made on the 
basis of glucose meter data alone.  The improvement of a patient’s health, however, is only 
achieved if the information supplied by the system is used properly and effectively towards 
improved insulin therapy [131, 132]. 
There are three main CGMS manufacturers – Medtronic, DexCom (Animus/J&J), and 
Abbott.  Medtronic currently has two FDA-approved CGM systems in the market – the Guardian 
REAL-Time CGMS, and the MiniMed Paradigm REAL-Time System.  DexCom has the 
DexCom Seven, and Abbott has the FreeStyle Navigator.  Though these systems are produced by 
different manufactures, the overall concepts among the products are very similar with no 
significant advantage of one over another. 
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2.2.1.3 Visual Blood Glucose Test Strips 
Visual blood glucose test strips are a convenient and simple alternative for diabetic 
patients who occasionally monitor blood glucose levels (usually type II diabetic patients) and 
patients who cannot afford the disposable test strips used for blood glucose meters.  Visual blood 
glucose test strips that change color (not to be confused with disposable test strips that are 
associated with the blood glucose meter) were widely used in the 1980s and had a slight 
advantage over the blood glucose meter since they could be cut longitudinally to save money.  
However, once the accuracy and insurance coverage improved for the blood glucose meter, 
visual blood glucose test strips lost popularity [124].   
There are various types of visual blood glucose strips, usually taking measurements using 
blood or urine.  Blood glucose dipsticks react with blood glucose and display a color that 
correlates with a specific glucose concentration.  Unfortunately, urine glucose dipsticks cannot 
reflect simultaneous blood glucose concentrations but do have incredible reproducibility and can 
answer the question of whether or not a stable glucose concentration is being tested. 
The type of visual blood glucose strip this chapter will focus on is the Betacheck 
Glucoflex-R that uses a color comparison for accurate and clear readings with only a drop of 
blood (10-20 µL) from the fingertip placed on the droplet zone of the test strip.  The test zone of 
the Glucoflex-R consists of two test pads that undergo a reaction with glucose via the glucose 
oxidase/peroxidase reaction.  This reaction causes a color change in direct proportion to the 
amount of glucose in the blood.  Typically, visual blood glucose test strips (including the 
Glucoflex-R) will have approximately ten color assortments that correlate with glucose levels 
from 20 mg/dL all the way to 800 mg/dL.   
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One advantage of visual blood glucose strips over blood glucose meters is accuracy.  
Glucose meters have to go through constant maintenance and calibration to ensure accurate 
readings.  The accuracy of chemical visual test strips (+/-5%) outdoes the accuracy of blood 
glucose meters (+/- 10%-15%).  The quality check for Glucoflex-R visual strips, however, only 
involves comparing a new test strip against the “0” color reference on the container.   
The most obvious limitation of these test strips, however, is the limited quantitative result 
that is given along with the potential variance of the results.  While blood glucose meters are able 
to give an exact measurement, visual glucose strips can either give a range of values or an 
estimation of a close value.  In a comparative study, for blood glucose values less than or equal 
to 180 mg/dL, blood glucose meters had the best correlation.  For glucose values of 181-400 
mg/dL, visual strips were just as accurate as meters, but not as precise [133].   
2.2.1.4 Glucose sensing bio-implants 
To ease the burden of continuous blood glucose monitoring on patients, the development 
of long-lasting glucose sensing bio-implants is under development. 
One particular product under development is the SMSI Glucose Sensor.  The sensor is 
implanted under the skin in a short outpatient procedure and is designed to automatically 
measure interstitial glucose every few minutes.  With a small external reader, the sensor will 
communicate wirelessly allowing the user to monitor levels on demand [134].  The implanted 
sensor’s targeted operational life is 6-12 months, after which it would be replaced [135].   
Currently, this product is in the process of completing animal studies; however, results and 
conclusions are not yet available for public viewing. 
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2.2.1.5 Non-Invasive Technologies 
One major burden diabetics continuously complain about is the constant finger pricking 
that is necessary for blood glucose testing.  Manufacturers of diabetic devices are researching 
and developing new technologies that will not require direct contact with blood to measure 
glucose levels.  These new non-invasive technologies range from near IR detection, to 
ultrasound, to dielectric spectroscopy [136, 137].   
Although a thorough review of these emerging technologies is beyond the scope of this 
thesis, one intriguing product under development is the Sensy Glucose Tracking System.  Sensy 
Medical is developing the new method of glucose monitoring using near-infrared (NIR) diffuse 
reflectance spectroscopy (DRS) to measure glucose levels in a non-invasive manner [138].  NIR 
light ranges from 750-2500nm and interacts differently with various molecules (fat, glucose, 
protein, water, etc.) by absorbing different amounts of NIR light.  The amount of light absorbed 
is proportional to the concentration of the particular molecule [138].  Thus, the blood glucose 
concentration will be measured in light absorbance units that can be converted to the usual blood 
glucose units of mg/dL. 
2.2.1.6 Summary 
After researching and discussing the different practical methods available to measure 
blood glucose concentrations, the next step was to determine the most feasible method(s) for the 
laboratory and apply that method of measurement to the measurements of various glycemic 
solutions.  Based on the information from the above section, the most feasible methods to 
monitor the glycemic solutions were the blood glucose meter and visual blood glucose test strips, 
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mostly due to their quick return of results, availability, and affordability.  Thus, the next step in 
the study was to develop the procedure to create cell media solutions of various glucose 
concentrations, in hopes that a solution with elevated glucose concentrations properly replicates 
a hyperglycemic environment, and can be accurately measured by either the blood glucose meter 
or the visual blood glucose test strips. 
The following section discusses the experimentation conducted to develop and establish 
various cell media solutions of specific glucose concentrations, and whether the tested methods 
of measuring these glycemic solutions – the blood glucose meter and visual blood glucose test 
strips – accurately and precisely measured the expected glucose concentrations. 
2.2.2 Methods of Producing and Monitoring Different Glycemic Solutions 
2.2.2.1 Levels of Glycemia 
The first step taken when developing the proper procedure for creating glycemic cell 
media solutions was to determine what glucose concentrations to achieve.  Based on the 
discussion regarding the different levels of hyperglycemia seen in diabetics, three different 
glucose concentrations were specified, created, and monitored over time.  The different glucose 
concentrations were organized as follows: 
Normal glycemic level: 100 mg/dL 
 Hyperglycemic level: 250 mg/dL 
 Extreme Hyperglycemic level: 400 mg/dL 
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Four levels of hyperglycemia were initially attempted, but after preliminary testing, it 
was difficult to maintain a degree of separation among the three glycemic levels without crossing 
over into another level of hyperglycemia (see Appendix A for summary of preliminary testing).  
Recall that only 5 grams of glucose are within the entire volume of blood in an average human 
male (5 L); thus, there is an extremely small margin of error when adding glucose to small 
volumes of cell culture media. 
2.2.2.2 Cell Media with D-(+)-Glucose 
To create the different glycemic cell media solutions, Sigma G6152 D-(+)-glucose 
(Figure 26) was added to Gibco Medium 199 (+: Earle’s salts, L-Glutamine, 2.2 g/L Sodium 
bicarbonate) (Figure 27) by Invitrogen.  An important note to consider is that cell media does not 
contain the same properties as blood.  Blood contains many constituents (plasma, albumin, 
hemoglobin, uric acid, etc.); thus, the viscosity of blood is much greater than the viscosity of just 
cell media with added glucose.  In addition, blood contains functioning and circulating cells that 
are not present in cell media; however, for the purposes of creating an in vitro environment, the 
use of cell culture media was appropriate. 
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Figure 26 - Sigma G6512 D-(+)-Glucose was added to Gibco Medium 199 in the attempt to 
create glycemic cell media solutions.   
 
Figure 27 - Gibco Medium 199 by Invitrogen was used as the base cell media for the 
experimentation of different glycemic cell media solutions.  This media was also used for later 
experimentation when developing glycemic cell media solutions for use with human umbilical 
vein endothelial cells (HUVECs). 
Three separate solutions were created for each level of glycemia.  In order to produce the 
different solutions, the following recipes were used: 
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• For the 100 mg/dL normal glycemic solution: 
0.100 g of Sigma G6152 D-(+)-Glucose was weighed and added to 100 
mL of Gibco Medium 199 in a 150 mL beaker 
• For a 250 mg/dL hyperglycemic solution: 
0.250 g of Sigma G6152 D-(+)-Glucose was weighed and added to 100 
mL of Gibco Medium 199 in a 150 mL beaker 
• For a 400 mg/dL extremely hyperglycemic solution: 
0.400 g of G6152 D-(+)-Glucose was weighed and added to 100 mL of 
Gibco Medium 199 in a 150 mL beaker 
After the glucose was weighed and added to the cell media, each solution was placed on a 
stir plate with a magnetic stir bar, and stirred for 30 minutes at 25ºC to promote uniform mixing.   
2.2.2.3 Monitoring Hyperglycemic Levels 
The blood glucose meter and the visual blood glucose test strips were the selected 
methods of measurement to be tested.   For this experiment, the glucose concentration of the 
developed glycemic cell media solutions were then taken at t = 1, 2, 3, 4, 5, 6, 12, 24, 36, and 48 
hours after mixing began.   
Two blood glucose meters were used to monitor glucose concentration – the Aviva Accu-
Chek blood glucose meter, and the Bayer Contour blood glucose meter.  These meters were 
chosen because the meters and the associated test strips were easily obtainable.  Also, from 
personal experience as a Medical Assistant in an Endocrinology office, these meters were the 
favorite among doctors and patients due to their accuracy and reliability.     
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The type of visual blood glucose strips used was the Glucoflex-R Blood Glucose Strips 
(Figure 28).  These strips were purchased from Ambe Medical Group in England and were at 
$16.11 (9.99 GBP) for a set of 50 strips. 
 
Figure 28 - Glucoflex-R Blood Glucose Strips by Ambe Medical Group in England (Permission 
to reprint by Ambe Medical Group). 
 Before taking measurements for each solution at the specific time point, both meters and 
the visual test strips were “calibrated” using Hyclone Dulbecco’s Modified Eagle Medium 
(DMEM) / High Glucose (+: 4.00 mM L-Glutamine, 4500 mg/L Glucose, Sodium pyruvate) 
4500 mg/L high glucose cell media.  This was manufactured high-glucose cell media that was 
already calibrated to accurately resemble a glucose concentration of 450 mg/dL; thus, it was used 
to ensure each monitoring device was functioning properly.   
The intention of using multiple blood glucose meters was to accumulate more data in 
hopes of obtaining normalized data, while also assessing which method was most consistent and 
appropriate for this application.  The intention of the visual blood glucose strips was to ensure 
that the tested cell media was at least within the correct glucose range, and also confirm an 
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accurate and stable glucose environment.  Considering the levels of inaccuracy for both glucose 
meters and visual blood glucose strips, it was necessary to use both methods in order to identify 
any variance in the results.  Plus, it would also expose whether or not one of the methods was 
significantly different from another.   
After the glucose concentrations were recorded for the three solutions of each glycemic 
level, an average was taken along with the standard deviation, and a percent error was calculated 
based off of the targeted glucose level.  Lastly, a series of two-tailed T-tests were conducted 
between each solution based on method of measurement, and an ANOVA test was conducted on 
all three solutions to ensure there was no statistical significant difference among the solutions 
within the same method of measurement.  The following section discusses the accumulated 
results and analysis. 
2.3 Results 
2.3.1 Results of Preliminary Testing 
Preliminary testing was conducted in order to establish the proper procedure of creating 
the different glycemic solutions.  Once established, the glycemic cell media solutions were tested 
over a period of 48 hours in order to see which method of measurement was best for the 
glycemic solution study.  The Bayer Contour meter and its test strips were unable to give 
consistent readings as an “error message” would continuously appear on the meter at random 
time intervals.  Therefore, only the results from the Accu-Chek blood glucose meter and the 
Glucoflex-R visual blood glucose strips were used to draw conclusions.  The following sections 
analyze and discuss the results accumulated for each method of measurement for each developed 
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glycemic cell media solutions.  However, one note must be mentioned before discussing the 
results, as it plays a significant role in the analysis of the results. 
2.3.1.1 Glycemic Level of Gibco Medium 199 
 After testing, a significant attribution was discovered regarding the composition of the 
Gibco Medium 199.  The recorded glucose concentrations were higher than the expected; thus, 
the chemical composition of the cell media was researched on the Invitrogen website.  What was 
discovered was that the Gibco Medium 199 was a “low glucose” cell media that already 
contained of 1000 mg/L (100 mg/dL) of D-glucose (Figure 29).   
 
Figure 29 - The Invitrogen website confirmed that the composition of the Gibco Medium 199 
contained 1000 mg/L (100 mg/dL) of D-glucose. 
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To confirm, measurements were taken via the Accu-Chek blood glucose meter as well as 
the Glucoflex-R visual blood glucose strips, and both confirmed a glucose concentration of 100 
mg/dL.  Therefore, to compensate for the additional 100 mg/dL already within the cell media, the 
expected glucose concentrations for each solution were adjusted to the following levels: 
Adjusted Normal glycemic level: 200 mg/dL 
 Adjusted Hyperglycemic level: 350 mg/dL 
 Adjusted Extreme Hyperglycemic level: 500 mg/dL 
Using the adjusted glucose concentrations, the accumulated data was analyzed. 
2.3.1.1 Normal Glycemic Solutions (200 mg/dL) 
  A glycemic cell media solution of 200 mg/dL was developed to replicate a normal 
glycemic environment.  Recall, three solutions composed of 0.100 g of Sigma G6152 D-(+)-
Glucose and 100 mL of Gibco Medium 199 were created.  Three solutions gave an adequate data 
sample size for practical and repeatable data analysis.  Table 3 displays the exact amounts of 
glucose added to each volume of cell media.   
Table 3 - Amount of Sigma G6152 D-(+)-Glucose added to 100 mL of Gibco Medium 199 for 
200 mg/dL Normal Glycemic Solutions 
Solution Sample Amount of Glucose Added (g)  Volume of Cell Media (mL) 
1 0.1009  100 
2 0.1003  100 
3 0.1004  100 
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The purpose of the additional glucose was to compensate for any glucose lost during the 
transfer from the weigh boat to the beaker containing the cell media.  After taking glucose 
concentrations at the specific time intervals for 48 hours, the accumulated results matched the 
expected glucose concentration of 200 mg/dL. 
Figure 30 is a plot showing the recorded glucose concentrations using the Aviva Accu-
Chek blood glucose meter.  This plot shows that the blood glucose meter recorded values very 
close to the expected concentration, and took approximately until t = 2 hours to reach the 
expected glucose concentration of 200 mg/dL.   
 
Figure 30 – The plot shows that the accumulated glucose concentrations by the Aviva Accu-
Chek blood glucose meter matched the expected glucose concentration of 200 mg/dL for each 
solution.  The glucose concentration rose rapidly, but plateaued at the expected value after 
roughly 2 hours of mixing. 
As for the accumulated results by the Glucoflex-R visual blood glucose test strips, Figure 
31 shows that, it too, was able to consistently measure a glucose concentration throughout the 
entire test, and the results were approximately equivalent to the expected 200 mg/dL.  However, 
the recorded measurements were not nearly as precise as those of the Aviva Accu-Chek blood 
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glucose meter, as outliers within the Glucoflex-R measurements are obviously apparent.  The 
Glucoflex-R visual strips also took until approximately t = 2 hours to record a consistent 
measurement of roughly 200 mg/dL.    
 
Figure 31 - The recorded glucose levels, using the Glucoflex-R visual test strips, were within the 
expected range of 200 mg/dL.  However, the variance of the recorded results was quite high, and 
is not an ideal characteristic for a sensitive hyperglycemic environment. 
Error! Reference source not found.Table 4 shows the average glucose concentrations 
of each solution using the Aviva Accu-Chek blood glucose meter and the Glucoflex-R visual test 
strips, as well as the percent error in relation to the expected 200 mg/dL glucose concentration.  
Both methods of measurement had average glucose concentration close to the expected value 
(except for solution 3, which consisted of the outlier), considering they had low percent errors.  
However, the key factor to take into consideration is the low variance for the Aviva Accu-Chek 
blood glucose meter compared to the high variance for the Glucoflex-R visual test strips.  It can 
be seen on Figure 30 and Figure 31 that the variance is much greater for the Glucoflex-R visual 
test strips compared to the Aviva Accu-Chek meter.  This level of variance is not ideal for 
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obtaining an accurate and precise glucose concentration, especially given the sensitivity of any 
hyperglycemic environment.  
Table 4 - Average Glucose Concentrations Recorded with Accu-Chek Blood Glucose Meter & 
Glucoflex-R Visual Blood Glucose Strips for 200 mg/dL Glycemic Solutions 
Aviva Accu-Chek Blood Glucose Meter 
 
 
Solution 1 Solution 2 Solution 3 Hyclone High Glucose 450 mg/dL Calibration 
Average 
Glucose 
Concentration 
(mg/dL) 
204.70 198.50 195.30 446.56 
Standard 
Deviation 6.55 7.54 12.89 11.383 
% Error 
 
2.35 % 
 
-0.75 % -2.35 % -0.765 % 
Glucoflex-R Visual Blood Glucose Strips 
 Solution 1 Solution 2 Solution 3 Hyclone High Glucose 450 mg/dL Calibration 
Average 
Glucose 
Concentration 
(mg/dL) 
205.00 194.00 312.00 N/A 
Standard 
Deviation 53.59 109.16 199.38 N/A 
% Error 
 
2.50% 
 
-3.00 % 56.00 % N/A 
Lastly, a two-tailed T-test was conducted to compare the mean glucose concentrations of 
each solution based on the method of measurement.  The null hypothesis was that the mean 
glucose concentration accumulated by the Aviva Accu-Chek blood glucose meter was equal to 
the mean glucose concentration accumulated by the Glucoflex-R visual test strips (Ho: χAccu-chek = 
χGlucoflex-R).  Thus, the alternative hypothesis was that these two means were not equal (Ha: χAccu-
Chek ≠ χGlucoflex-R).  With a 95% confidence interval (α = 0.05), all p-values were greater than 0.05; 
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thus, not rejecting the null hypothesis, and confirming that there was no statistical significant 
difference.   
In addition, an ANOVA test was conducted to compare the mean glucose concentrations 
of all three solutions within each method of measurement.  The null hypotheses were that the 
mean glucose concentration of each solution measured by the Aviva Accu-Chek blood glucose 
meter were equal (Ho: χSolution1 = χSolution2 = χSolution3), and that the mean glucose concentration of 
each solution measured by the Glucoflex-R visual test strips were equal as well (Ho: χSolution1 = 
χSolution2 =  χSolution3).  Once again, a 95% confidence interval was used (α = 0.05), and the 
resulting p-values were greater than 0.05; thus, confirming no statistical significant difference 
among the average glucose concentrations of each solution within the specific method of 
measurement.  Both the two-tailed T-tests and ANOVA tests indicated that the accumulated 
glucose concentrations were statistically similar, and recording a concentration consistently close 
to the expected concentration of 200 mg/dl.  However, the high variance of the Glucoflex-R 
visual strips was not an ideal attribute for the purposes of further experimentation.  
2.3.1.2 Hyperglycemic Solution (350 mg/dL) 
 A hyperglycemic solution of 350 mg/dL was created to replicate a hyperglycemic 
environment.  The established protocol called for 0.250 g of glucose to be weighed and added to 
100 mL of media for each solution.  Table 5 displays the exact amount of glucose added to each 
volume of cell media. 
Table 5 - Amount of Sigma G6152 D-(+)-Glucose added to 100 mL of Gibco Medium 199 for 
the 350 mg/dL hyperglycemic solutions 
Solution Sample Amount of Glucose Added  Volume of Cell Media (mL) 
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(g) 
1 0.2506  100 
2 0.2501  100 
3 0.2508  100 
As with the 200 mg/dL solutions, after recording glucose concentrations for t = 48 hours, 
the accumulated results matched closely with the expected concentration of 350 mg/dL.   
Figure 32 shows that the recorded glucose concentrations for each solution, using the 
Aviva Accu-Chek blood glucose meter, were very close to expected concentration of 350 mg/dL.  
While it took approximately two hours for the 200 mg/dL solutions to settle at a consistent 
concentration, the concentrations of the 350 mg/dL solutions gradually increased for the first few 
hours and finally settled after approximately four hours of mixing.   
 
Figure 32 – The plot shows that the glucose concentrations recorded by the Aviva Accu-Chek 
blood glucose meter were similar to the expected glucose concentration of 350 mg/dL for each 
solution.  The glucose concentration rose rapidly, but settled after approximately four hours of 
mixing. 
As for the Glucoflex-R visual test strips, Figure 33 shows results similar to that of the 
200 mg/dL solutions.  The visual test strips were able to consistently record a glucose 
78 
 
concentration, throughout the 72 hour experimentation time, that was within range of the 
expected 350 mg/dL concentration.  However, the reoccurrence of high variance of the recorded 
glucose measurements continued to question the precision of the visual test strips.  Recall, a high 
variance is not an ideal characteristic for a method of measurement glucose concentrations 
considering the sensitivity of any glucose environments. 
 
Figure 33 – The recorded glucose concentrations, using the Glucoflex-R visual test strips, for the 
350 mg/dL solutions, were within range of the expected glucose concentration.  However, the 
extremely high variance further proved the lack of precision of the visual test strips.  
 Table 6 shows the average glucose concentrations for each solution recorded by the 
Aviva Accu-Chek blood glucose meter and the Glucoflex-R visual test strips, along with the 
standard deviation and percent error from the expected glucose concentration of 350 mg/dL.  
Since it took approximately four hours for the solutions to mix uniformly, the average glucose 
concentration for each solution was calculated from t = 4 hours to t = 48 hours.  This limited the 
amount of variance in the data since the glucose concentrations recorded from t = 1 to t = 3 hours 
did not properly represent the actual glucose concentration of each solution.  Looking at Error! 
Reference source not found.Table 6, the Aviva Accu-Chek blood glucose meter recorded 
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concentrations close to the expected concentration of 350 mg/dL with limited variance.  The 
glucose concentrations recorded by the Glucoflex-R visual test strips, however, once again had 
extremely high variance and were not as precise as the Aviva Accu-Chek blood glucose meter.  
Table 6 - Average Glucose Concentrations Recorded with Accu-Chek Blood Glucose Meter & 
Glucoflex-R Visual Blood Glucose Strips for 350 mg/dL Hyperglycemic Solutions 
Aviva Accu-Chek Blood Glucose Meter 
 
 
Solution 1 Solution 2 Solution 3 Hyclone High Glucose 450 mg/dL Calibration 
Average 
Glucose 
Concentration 
(mg/dL) 
(t = 4) 
356.71 354.00 357.57 449.00 
Standard 
Deviation 
(from t = 4) 
23.91 11.54 9.91 13.06 
% Error 
 
1.92 % 
 
1.14 % 2.16 % -0.222% 
Glucoflex-R Visual Blood Glucose Strips 
 Solution 1 Solution 2 Solution 3 Hyclone High Glucose 450 mg/dL Calibration 
Average 
Glucose 
Concentration 
(mg/dL) 
(t = 4) 
364.29 321.43 292.86 N/A 
Standard 
Deviation 
(t = 4) 
201.48 128.64 18.90 N/A 
 
% Error 
 
 
4.08 % 
 
-8.16% -16.33 % N/A 
 Again, to finalize the analysis, a two-tailed T-test was conducted to compare the 
mean glucose concentrations of each solution based on the method of measurement.  The null 
hypothesis was that the mean glucose concentration accumulated by the Aviva Accu-Chek blood 
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glucose meter was equal to the mean glucose concentration accumulated by the Glucoflex-R 
visual test strips (Ho = χAccu-Chek = χGlucoflex-R).  Thus, the alternative hypothesis was that these two 
means were not equal (Ha = χAccu-Chek ≠ χGlucoflex-R).  With a 95% confidence interval (α = 0.05), 
all p-values were greater than 0.05, therefore, not rejecting the null hypothesis and confirming 
that there was no statistical significant difference between the means of the Aviva Accu-Chek 
blood glucose meter and the Glucoflex-R visual test strips.   
Lastly, an ANOVA test was conducted to compare the mean glucose concentrations of 
each solution within each method of measurement.  The null hypotheses were that the mean 
glucose concentration of each solution measured by the Aviva Accu-Chek meter were equal (Ho 
= χSolution1 = χSolution2 = χSolution3), and that the mean glucose concentration of each solution 
measured by the Glucoflex-R visual test strips were equal as well (Ho = χSolution1 = χSolution2 =  
χSolution3).  Once again, a 95% confidence interval was used (α = 0.05), and both resulting p-
values were greater than 0.05, therefore, not rejecting the null hypothesis and confirming that 
there was no statistical significant difference between the means of each solution within the 
method of measurement. 
 Although statistical analysis confirmed that the glucose concentrations recorded by the 
Glucoflex-R visual test strips were not statistically different from the glucose concentrations 
recorded by the Aviva Accu-Chek blood glucose meter, the variance of the data accumulated 
with the Glucoflex-R visual test strips was even higher than the variance from the 200 mg/dL 
solutions.  It was possible that the accuracy of the Glucoflex-R visual test strips decreased as the 
glucose concentrations of the tested solutions increased.  
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2.3.1.3 Extreme Hyperglycemic Solution (500 mg/dL) 
A hyperglycemic solution of 500 mg/dL was created to replicate an extremely 
hyperglycemic environment.  The established protocol called for 0.400 g of glucose to be 
weighed and added to 100 mL of media for each solution.  Table 7 displays the exact amounts of 
glucose added to each volume of cell media. 
Table 7 - Amount of Sigma G6152 D-(+)-Glucose added to 100 mL of Gibco Medium 199 for 
500 mg/dL extreme hyperglycemic solutions 
Solution Sample Amount of Glucose Added 
(g) 
 Volume of Cell Media (mL) 
1 0.4006  100 
2 0.4002  100 
3 0.4003  100 
After accumulating the data, the results were very similar to those of the 200 mg/dL and 
350 mg/dL solutions.   
Figure 34 shows the plot of measured glucose concentrations for each 500 mg/dL 
solution using the Aviva Accu-Chek blood glucose meter.  The plot shows that the measured 
glucose concentrations were very close to the expected concentration of 500 mg/dL.  In addition, 
the plot shows that it took approximately five hours for the solutions to mix uniformly.  This was 
not a surprise since it took approximately four hours for the 350 mg/dL solutions to mix 
completely. 
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Figure 34 - Even though the Accu-Chek glucose meter continued to measure glucose 
concentrations higher than the expected value of 400 mg/dL, the average measurements were 
much more accurate compared to the average measurements for the other glycemic 
environments. 
 Figure 35 shows a plot of measured glucose concentrations for each 500 mg/dL solution 
using the Glucoflex-R visual test strips.   As with the results from the 200 mg/dL and 350 mg/dL 
solutions, the visual test strips were able to consistently measure a glucose concentration for each 
solution throughout the test, but the variation of the measurements was again very high relative 
to the variation of the Aviva Accu-Chek blood glucose meter.   
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Figure 35 - The Glucoflex-R strips were able to monitor the glucose concentrations of the 
extremely hyperglycemic 400 mg/dL solutions much more accurately than the other glycemic 
environments.   
Error! Reference source not found.Table 8 shows that the calculated average glucose 
concentrations obtained from the Aviva Accu-Chek blood glucose meter and the Glucoflex-R 
visual test strips.   Recall, it took approximately five hours for the solution to mix uniformly; 
thus, the averages were taken from t = 5 hours to t = 48 hours.  The calculated averages from the 
Aviva Accu-Chek blood glucose meter were extremely close to the targeted value of 500 mg/dL, 
resulting in a very low percent error for each solution.  In addition, the Aviva Accu-Chek blood 
glucose meter was able to measure glucose concentrations with limited variance (higher variance 
than 200 mg/dL and 350 mg/dL solutions, but expected with the increased amount of glucose 
added to the solutions).  While the calculated average glucose concentrations obtained from the 
Glucoflex-R visual test strips were close to the expected glucose concentration as well (solution 
1 even hit 500 mg/dL exactly), the significant factor once again was the relatively high variance 
of the Glucoflex-R data, especially in relation to the low variance seen with the data accumulated 
by the Aviva Accu-Chek blood glucose meter.  This confirms that, while the visual test strips are 
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able to consistently measure the glucose concentrations throughout the test, the precision of the 
blood glucose meter is much higher than that of the visual test strips in all three tested levels of 
glucose concentration. 
Table 8 - Average Glucose Concentrations Recorded with Accu-Chek Blood Glucose Meter & 
Glucoflex-R Visual Blood Glucose Strips for 500 mg/dL extreme hyperglycemic solutions 
Aviva Accu-Chek Blood Glucose Meter 
 Solution 1 Solution 2 Solution 3 Hyclone High Glucose 450 mg/dL Calibration 
Average 
Glucose 
Concentration 
(mg/dL) 
(t = 5) 
493.33 472.67 466.50 447.33 
Standard 
Deviation 
(from t = 5) 
27.990 10.482 11.221 6.250 
% Error -1.33 -5.48 -6.70 N/A 
Glucoflex-R Visual Blood Glucose Strips 
 Solution 1 Solution 2 Solution 3 
Hyclone High Glucose 
450 mg/dL Calibration 
Average 
Glucose 
Concentration 
(mg/dL) 
(t = 5) 
500.00 383.33 400.00 N/A 
Standard 
Deviation 
(t = 5) 
189.737 75.277 89.443 N/A 
% Error 0.00 -23.33 -20.00 N/A 
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Lastly, a two-tailed t-Test was conducted to compare the mean glucose concentrations of 
each solution based on the method of measurement.  The null hypothesis was that the mean 
glucose concentration accumulated by the Aviva Accu-Chek blood glucose meter was equal to 
the mean glucose concentration accumulated by the Glucoflex-R visual test strips (Ho = χAccu-Chek 
= χGlucoflex-R).  Thus, the alternative hypothesis was that these two means were not equal (Ha = 
χAccu-Chek ≠ χGlucoflex-R).  With a 95% confidence interval (α = 0.05), all p-values were greater than 
0.05, therefore, not rejecting the null hypothesis and confirming that there was no statistical 
significant difference between the means of the Aviva Accu-Chek blood glucose meter and the 
Glucoflex-R visual test strips.    
Lastly, an ANOVA test was conducted to compare the mean glucose concentrations of 
each solution within each method of measurement.  The null hypotheses were that the mean 
glucose concentration of each solution measured by the Aviva Accu-Chek meter were equal (Ho 
= χSolution1 = χSolution2 = χSolution3), and that the mean glucose concentration of each solution 
measured by the Glucoflex-R visual test strips were equal as well (Ho = χSolution1 = χSolution2 = 
χSolution3).  Once again, a 95% confidence interval was used (α = 0.05), and both resulting p-
values were greater than 0.05 (though, the p-value for the ANOVA test conducted on the 
Glucoflex-R solutions was very close to 0.05, further confirming the troubles of high variance), 
therefore, not rejecting the null hypothesis and confirming that there was no statistical significant 
difference between the means of each solution within the method of measurement. 
2.4 Discussion and Conclusions 
Recall, the goals of this chapter were the following: 
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1. To explore and identify practical methods of measuring levels of glucose in different 
glycemic cell media solutions;  
2. To develop and establish a procedure to create hyperglycemic cell media solutions 
with the addition of glucose into base cell media; and  
3. To use the hyperglycemic cell media solutions in order to evaluate the different 
methods of monitoring glucose concentrations and determine the most feasible method. 
Reviewing the literature confirmed that the most practical methods of monitoring glucose 
concentrations of  cell media solutions were the blood glucose meter and the visual blood 
glucose test strip.  Additionally, preliminary tests showed that the Aviva Accu-Chek glucose 
meter and Glucoflex-R visual blood glucose strips gave accurate and reliable measurements.  
Therefore, the Aviva Accu-Chek blood glucose meter and the Glucoflex-R visual blood glucose 
test strips were used to measure glucose concentrations of three glycemic cell media solutions – 
200 mg/dL, 350 mg/dL, and 500 mg/dL.  
The results from the experiments in this chapter indicated that a high glucose 
concentrated solution, with Sigma G6152 D-(+)-Glucose and Gibco Medium 199, can properly 
represent a hyperglycemic environment.  In addition, the Aviva Accu-Chek blood glucose meter, 
over a 48 hour time period, was able to accurately and precisely monitor and record glucose 
concentrations very close to the expected concentration of each glycemic cell media solution.  
Though the Glucoflex-R visual test strips were able to consistently record an average glucose 
concentration close to the expected concentration, the variability of the visual test strips was very 
high – a characteristic that would be extremely detrimental to the data acquisition of further 
experiments.  In addition, although t-tests confirmed that there was not a statistical significant 
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difference between the averages accumulated by the Aviva Accu-Chek blood glucose meter and 
averages accumulated with the Glucoflex-R visual test strips, the combination of a low percent 
error with a low standard deviation made the Aviva Accu-Chek blood glucose meter the better 
option for evaluation of glucose concentration for glycemic cell media solutions. 
One key observation was the amount of time necessary to ensure that all the added 
glucose completely mixed into the cell media.  While the 200 mg/dL media took relatively little 
time to uniformly mix, the 350 mg/dL and 500 mg/dL solutions needed approximately four to 
five hours of mixing before the solution mixed to its expected concentration.  This time was 
taken into consideration when establishing the protocol for developing glycemic cell media 
solutions (Appendix D). 
The greatest challenge of the experiments in this chapter was adding an accurate amount 
of Sigma G6152 D-(+)-Glucose to the 100 mL of cell media.  Even in a large volume of media, 
an extremely small amount of glucose can cause a great fluctuation in the glucose concentration.  
This error was limited by ensuring that a very small amount of additional glucose was weighed 
to compensate for any lost glucose during transfer from the weigh boat to the solution.  The 
calculated percent errors of the results confirmed that this test procedure was executed correctly.  
A possible way to avoid this complication, however, would be to use an even greater volume of 
cell media.  Adding glucose to 100 mL of cell media to achieve 200 mg/dL leaves an extremely 
small margin of error; thus, it would be beneficial to increase the cell media volume to 500 mL 
or even 1000 mL if necessary.   
In addition, the concentrations that were used were slightly higher than the initial target 
values, due to the existing glucose in M199.  If cell media with 1000 mg/L (100 mg/dL) of D-
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glucose is used in the future, here are the recipes that should be used for achieving 100mg/dl, 
250mg/dl, and 400mg/dl as initially intended: 
• 100 mg/dL 
o 100 mL of M199 only  
*Gibco Medium 199 already contains 1000 mg/L (100 mg/dL) of D-
glucose; thus, no additional modifications are necessary 
• 250 mg/dL 
o Add 0.15 g of Sigma G6152 D-(+)-Glucose to 100 mL of M199 
• 400 mg/dL 
o Add 0.30 g of Sigma G6152 D-(+)-Glucose to 100 mL of M199 
One last note was that the test initially called for two blood glucose meters to be used to 
measure the glucose concentrations of the glycemic cell media solutions (the Bayer Contour 
blood glucose meter along with the Aviva Accu-Chek blood glucose meter).  Unfortunately, the 
Bayer blood glucose meter was unable to give any recording at all as it consistently gave an 
“error” message.  One reason for this was probably due to the meter’s inability to analyze 
glucose when it is in its cyclic structure.  Recall, that at a neutral pH of 7.0, D-glucose is in its 
cyclic form.  The human body is not always at a pH of 7.0; thus, it is possible that glucose 
circulating in blood is not in cyclic form and glucose meters accurately measure glucose 
concentrations of blood only when it is in its straight chain form.  The Gibco Medium 199 has a 
pH of about 7.4 meaning that the tested glycemic solutions probably contained glucose in its 
cyclic form.   
The series of experiments in this chapter both established a procedure of creating 
glycemic cell media solutions with the addition of Sigma G6152 D-(+)-Glucose to Gibco 
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Medium 199, as well as a method of monitoring the glucose concentration of these solutions with 
the Aviva Accu-Chek blood glucose meter.   The next step of this thesis study involved the 
incorporation of the developed glycemic solutions with endothelial cells, in an attempt to 
determine whether or not the glycemic cell media solutions evoked a negative response by 
endothelial cells.   This work will be described in the next chapter.   
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Chapter 3: Evaluation of Endothelial Cells in High 
Glucose Solutions  
3.1 Introduction 
In Chapter 2, hyperglycemia – the major dysfunction of diabetes mellitus – was 
discussed.  It was determined that hyperglycemia was the most practical attribute to take into 
consideration when trying to replicate a diabetic environment.  Thus, in order to create and 
monitor a hyperglycemic environment, a protocol was established to develop high glucose 
concentrated solutions using Sigma G6152 D-(+)-Glucose and Gibco Medium 199, and different 
methods of measuring glucose concentrations were discussed.  After reviewing the literature, the 
Aviva Accu-Chek blood glucose meter and the Glucoflex-R visual blood glucose test strips were 
the most feasible methods of measuring the glucose concentration of various glycemic cell media 
solutions.  Three different glycemic cell media solutions were developed to resemble three 
glycemic environments: 
1. Normal glycemic level: 100 mg/dL 
2. Hyperglycemic level: 250 mg/dL 
3. Extreme Hyperglycemic level: 400 mg/dL 
It was determined that the Aviva Accu-Chek blood glucose meter was the best method to 
measure the glucose concentrations of glycemic cell media solutions because of its ability to 
record very accurate and precise result,.  In addition, it was uncovered that the Gibco Medium 
199 was a “low glucose” solution and already contained 1000 mg/L (100 mg/dL) of glucose.  
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Therefore, it was necessary to compensate and adjust the amount of glucose added to the cell 
media when creating the glycemic cell media solutions for further experiments.  
  The next step then was the incorporation of the developed glycemic cell media solutions 
with endothelial cells in the attempt to determine whether or not the hyperglycemic cell media 
solutions evoked a noticeable negative response in endothelial cells.  Specifically, bovine aortic 
endothelial cells (BAECs) and human umbilical vein endothelial cells (HUVECs) were used to 
evaluate the effect of hyperglycemic cell media recipes.  The BAECs and HUVECs in this study 
were exposed to two different glycemic environments – a normal glycemic environment of 100 
mg/dL, and a hyperglycemic environment of 400 mg/dL.  The development of these recipes will 
be discussed in the proceeding “Methods” section. 
Remember, a very small amount of glucose is circulating in the body (roughly 5 grams of 
glucose in the average human body).  Thus, the chance of error due to a minor miscalculation in 
the amount of glucose added to the cell media is relatively high.  Therefore, the hyperglycemic 
environment of 350 mg/dL, which was tested in the previous chapter, was removed from 
experiments in this chapter to avoid any overlapping.  Therefore, experimentation with BAECs 
and HUVECs focused entirely on a 100 mg/dL normal glycemic environment, and a 400 mg/dL 
hyperglycemic environment.  
3.1.1 Bovine Aortic Endothelial Cells (BAECs) 
 Bovine aortic endothelial cells are vascular cells from the aortic valve of USDA-cattle.  
These cells are usually preserved at second passage and can be cultured and passed for at least 
sixteen population doublings [139].  These cells play a critical role in cardiac homeostasis; thus, 
studies have linked changes in structure and function of these endothelial cells to vascular 
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diseases such as thrombosis, atherosclerosis, and hypertension – all significant complications of 
diabetes mellitus [139].  Therefore, these endothelial cells are a suitable and economical option 
to study endothelial function and metabolism.   
 Researchers have used BAECs to study the effects of elevated glucose levels on cultured 
endothelial cells [140].  One study showed that hyperglycemia inhibits endothelial nitric oxide 
activity in BAECs; nitric oxide synthase 3 (eNOS) plays an important role in preventing vascular 
diseases [141].  Figure 36 shows how increased glucose concentration hindered eNOS activity.  
BAECs exposed to a 5 mM glucose environment (90 mg/dL) had much higher eNOS activity 
than BAECs exposed to a 30 mM environment (540 mg/dL). 
 
Figure 36 - This study showed how exposure of BAECs to a hyperglycemic environment 
hindered nitric oxide (eNOS) activity.  BAECs exposed to a 5 mM (90 mg/dL) normal glycemic 
environment had higher eNOS activity than BAECs exposed to the 30 mM (540 mg/dL) 
hyperglycemic environment.  eNOS plays an important role in preventing many vascular 
diseases (permission to reprint from [141]). 
Another study showed that hyperglycemia increased intracellular reactive oxygen species 
(ROS) production in cultured BAECs [142].  The study showed that ROS activates mechanisms 
that link hyperglycemia to several functional pathways that are responsible for the microvascular 
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damage induced by diabetes [142].  These mechanisms include an altered cellular redox state, an 
increase in diacylglycerol (DAG), which in turn adds the subsequent activation of protein kinase 
C (PKC) isoforms [143].  Recall from the beginning of Chapter 2 that the activation of the DAG-
PKC pathway has been associated with many vascular abnormalities in the retinal, renal, neural 
and cardiovascular tissues in diabetes mellitus. The DAG-PKC pathway affects the regulation of 
endothelial cell permeability, vasoconstriction, extracellular matrix (ECM) synthesis, endothelial 
cell growth, and angiogenesis [143].  These studies are a few of the examples that support the 
use of BAECs in a hyperglycemic environment as a suitable method to study the function and 
metabolism of endothelial cells in vitro. 
3.1.2 Human Umbilical Vein Endothelial Cells (HUVECs) 
Human umbilical vein endothelial cells (HUVECs) are isolated from human umbilical 
veins.  These cells are responsive to cytokine stimulation in the expression of cell adhesion 
molecules; thus, these cells are primarily used to study physiological and pharmacological 
functions, such as macromolecule transport, blood coagulation, and fibrinolysis [144].  
A previous study had shown that incubation of HUVECs in high glucose environments 
(roughly 30 mmol/L or 540 mg/dL) for 72 hours caused a significant increase in apoptosis, 
possibly related to increased oxidative stress [145, 146].  The study showed that the 
hyperglycemic environment altered fatty-acid metabolism, which in turn hindered Akt activation 
by insulin (Akt phosphorylation usually occurs in the presence of insulin that induces optimum 
metabolism of glucose).  In addition, there was an increase in caspase-3 activity preceding 
HUVEC apoptosis in the hyperglycemic environment (Figure 37).      
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Figure 37 – TUNEL staining will typically show apoptotic configuration among the HUVECs 
with shrinkage and fragmentation of the nuclei.  This figure shows how exposure of HUVECs in 
a 30 mM hyperglycemic environment caused a significant amount of cell death after 72 hours 
compared to after only 24 hours.  Supporting pictures are also shown, which support greater 
apoptosis in the 30 mM hyperglycemic environment (permission to reprint from [145]). 
Figure 37 also shows the apoptotic effect of 5-aminoimidazole-4-carboxamide-riboside 
(AICAR) on the HUVECs exposed to the 30 mM hyperglycemic environment.  Earlier studies 
showed that HUVEC incubation with AICAR, which activates AMPK (an enzyme that promotes 
cellular uptake of glucose), enhanced fatty-acid oxidation in many of the endothelial cells and 
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inhibited apoptosis [147, 148, 149].  This indicates that exposure of HUVECs to a 
hyperglycemic environment induces a negative response by the endothelial cells, which is 
expected in the experiments of this chapter. 
In addition, an earlier study showed that a high oxidative stress level may play a 
significant role in the pathogenesis of diabetic complications via a hyperglycemic environment 
causing an increase in oxygen-derived free radicals [150].  Evidence has supported that these 
reactive molecules play a prominent role as mediators of endothelial cell dysfunction in diabetes 
[150].  Specifically, the expression of the antioxidant enzymes CuZn-superoxide dismutase, Mn-
superoxide-dismutase, catalase, and glutathione peroxidase were all evaluated after 14 days of 
culture in a high glucose environment (superoxide dismutase is a class of enzymes that catalyze 
the separation of superoxide, O2-, into oxygen and hydrogen peroxide [151]).  The study 
demonstrated that a hyperglycemic environment induced an overexpression of these antioxidant 
enzymes, suggesting that high levels of glucose produce an oxidative stress level in endothelial 
cells – specifically, HUVECs.   
The studies mentioned above are just a small sample of the number of studies researchers 
have conducted involving the culturing of HUVECs in a high glucose environment.  Thus, along 
with BAECs, researchers have shown the use of HUVECs as a suitable method to study the 
physiological effects of a hyperglycemic environment on endothelial cells. 
3.1.3 Purpose of This Study 
The purpose of this study was to evaluate BAECs and HUVECs in a normal glycemic 
(100 mg/dL) and hyperglycemic (400 mg/dL) environment.  The hypothesis of this study was 
that the 400 mg/dL hyperglycemic cell media solution would evoke a cellular response similar to 
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cells exposed to an actual hyperglycemic environment.  Therefore, the BAECs and HUVECs 
exposed to the 400 mg/dL glycemic cell media solution should exhibit greater glucose 
consumption over a 72 hour time period than the BAECs and HUVECs exposed to the 100 
mg/dL normal glycemic cell media solution.  In order to measure glucose consumption, the 
glucose concentration of the glycemic cell media solutions was taken, with an expectation of a 
decreased concentration over time.   
Recall, cells try to maintain a homeostatic balance, and a 100 mg/dL glycemic 
environment is considered state of homeostasis.  Thus, it was expected that relatively minimal 
glucose consumption would occur in the normal glycemic environment.  Additionally, a 400 
mg/dL hyperglycemic environment is a state of homeostatic imbalance.  Thus, cells should 
consume higher amounts of glucose to the state of glucose toxicity.  The following sections 
discuss the methods of creating the experiments and the analysis of the accumulated results. 
3.2 Methods 
Three experiments were conducted per cell type – three experiments using BAECs and 
three experiments using HUVECs.  Thus, a total of six experiments were conducted.  For each 
experiment, the endothelial cells were thawed and cultured into 6 wells of a six-well plate using 
standard cell culture technique, and incubated at 37˚C.  During the culture time for the 
endothelial cells, the two glycemic cell media solutions were prepared and stored at 4˚C inside 
the lab refrigerator.  Thus, before adding the glycemic media to the cells, it was necessary to 
warm the solutions in a 37˚C water bath.  Also, since the 400 mg/dL cell media solutions were 
made with the unsterile Sigma G6152 D-(+)-Glucose, it was necessary to sterilize it via syringe-
filter sterilization.  The following sections describe the development of each glycemic cell media 
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solution, the sterilization of the 400 mg/dL hyperglycemic cell media solutions, and the 
incorporation of the glycemic cell media solutions with the endothelial cells. 
3.2.1 Preparation of Glycemic Media Solutions 
The initial preparation for the study involved developing the 400 mg/dL hyperglycemic 
cell media solution.  For the experiments with BAECs, Sigma G6152 D-(+)-Glucose was added 
to Lonza Endothelial Cell Basal Media (EBM) (Figure 38).  For the HUVEC experiments, Sigma 
G6152 D-(+)-Glucose was added to Gibco Medium 199.   
 
Figure 38 - For experiments with BAECs, the glycemic cell media solutions were made using 
Lonza Endothelial Cell Basal Medium (EBM). 
Recall from Chapter 2, the Gibco Medium 199 was a “low glucose” solution; thus, it 
already contained 1000 mg/L of D-glucose (100 mg/dL).  This was also the case for the Lonza 
EBM.  Therefore, neither further modification nor sterilization was necessary for the 100 mg/dL 
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normal glycemic cell media solutions.  The following section describes the method used to 
develop the 400 mg/dL hyperglycemia cell media solutions for the BAEC and HUVEC 
experiments.    
3.2.1.1 Preparation of the 400 mg/dL Hyperglycemic Cell Media Solution 
The procedure established in Chapter 2 was used to create the 400 mg/dL hyperglycemic 
cell media solution for the BAEC and HUVEC experiments.  Recall, the method involved adding 
x g of Sigma G6152 D-(+)-Glucose to be added to y mL of cell media.  Additionally, it took 
approximately five hours for the 500 mg/dL glycemic cell media solution to uniformly mix.  
Thus, the 400 mg/dL hyperglycemic cell media solutions for these experiments were mixed for 
at least six hours on a magnetic hot plate with a magnetic stir bar at 25˚C and then stored at 
approximately 4˚C inside the laboratory refrigerator (Figure 39). 
 
Figure 39 - After adding the Sigma G6152 D-(+)-Glucose to the cell media, the solution was 
stirred with a magnetic stir plate and bar for at least six hours at 25 ºC to ensure uniform mixing. 
Error! Reference source not found.Table 9 below summarizes the recipes used to 
create the glycemic solutions for the initial four experiments.  Since a substantial volume of the 
400 mg/dL hyperglycemic cell media solution was created for the first HUVEC experiment, 
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much of it was left over and available for the second experiment with HUVECs.   The last two 
experiments will be discussed later.   
Table 9 - Recipes to Create the 400 mg/dL Hyperglycemic Cell Media Solutions for Initial 
BAEC & HUVEC Experiments 
Experiment Volume of Cell Media (mL) 
 
 
Amt Glucose  
Added (g) 
Mixing 
Parameters 
Recorded 
Glucose 
Concentration 
(mg/dL) 
BAECs 1 30  0.0906 12 hours 25˚C 432 
BAECs 2 20  0.0613 12 hours 25˚C 435 
HUVECs 1 40  0.1214 12 hours 25˚C 465 
HUVECs 2 40  0.1214 12 hours 25˚C 465 
3.2.2 Sterilization of the 400 mg/dL Hyperglycemic Cell Media Solutions 
Before adding the 400 mg/dL hyperglycemic cell media solution to the endothelial cells, 
it was necessary to sterilize it first to prevent any contamination to the sterile environment of the 
cells.  The method of sterilization used was syringe-filter sterilization with 10 mL syringes and 
0.22 µm syringe filters. 
Sterilization was conducted in an aseptic environment under a laminar flow hood.  
During sterilization, the 10 mL syringe took up 10 mL of the hyperglycemic cell media solution 
(Figure 40a).  The 0.22 µm syringe filter was placed on the end of the syringe and the 10 mL of 
cell media solution was slowly transferred through the filter and into a brand new sterile 50 mL 
conical (Figure 40b).  A brand new filter was used for every 10 mL of glycemic media solution 
being sterilized.  The solution in the new 50 mL conicals was now sterile 400 mg/dL 
100 
 
hyperglycemic cell media solution that was ready to be warmed and added to the endothelial 
cells. 
(a)   (b)  
Figure 40 – Syringe-filter sterilization was conducted to sterilize the 400 mg/dL hyperglycemic 
cell media solutions.  (a) 10 mL of the solution was taken up by a 10 mL syringe and the 0.22 
µm syringe filter was added onto the end of the syringe.  (b) The 10 mL of solution was slowly 
transferred into a sterile 50 mL conical.  This entire sterilization was conducted in a laminar flow 
hood. 
3.2.3 Applying the Glycemic Media Solutions to the Endothelial Cells 
Once sterilization of the 400 mg/dL hyperglycemic cell media solution was complete, 
both glycemic solutions were ready to be added to the endothelial cells.  The most important 
factor taken into consideration when working with the endothelial cells was sterility.  It was 
crucial to ensure that, along with the glycemic cell media solutions, the surrounding work 
environment, the tools, and the hands managing all the equipment were properly sterilized or 
made aseptic with 70% isopropyl alcohol (IPA).  Therefore, the first step of every experiment 
was to wash hands with soap and warm water, wear properly fitted latex gloves, and spray the 
gloves with the 70% IPA.  Next, it was critical to spray the entire inside of the sterile hood with 
70% IPA both before and after the experiment.   
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To introduce the glycemic cell media solutions to the cultured cells, an electronic pipette 
was used with 10 mL sterile tubes.  For each experiment, the 100 mg/dL normal glycemic cell 
media solutions were introduced to the cells in the bottom three wells, and the 400 mg/dL 
hyperglycemic cell media solutions were introduced to the cells in the top three wells (Figure 
41).  
   
Figure 41 - To introduce the glycemic cell media solutions to the endothelial cells, an electronic 
pipette was used.  The 100 mg/dL solution was added to the bottom three wells, and the 400 
mg/dL solution was added to the top three wells. 
For the first BAEC experiment, 10 mL of the 100 mg/dL and 400 mg/dL cell media 
solutions was introduced to each well (Figure 42a).  For the second BAEC experiment, and the 
two HUVEC experiments, the volume of media solution introduced to each well was reduced 
from 10mL to 3 mL (Figure 42b).  The reason for this reduction was to prevent exaggerated 
glucose toxicity for the endothelial cells and to ensure the media did not overflow from the well.  
As mentioned before, the method for the third BAEC and HUVEC experiments will be discussed 
later.   
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(a)  
First BAEC experiment 
(b)  
Second BAEC experiment & first two HUVEC experiments 
Figure 42 - (a) For the first BAEC experiment, 10 mL of the glycemic cell media solutions was 
added to each well.   The 400 mg/dL cell media was introduced to the cells in the top three wells, 
and the 100 mg/dL cell media was introduced to the cells in the bottom three wells.  (b) For the 
second BAEC experiment and the first two HUVEC experiments, the volume of media 
introduced to each well was reduced to 3 mL.  Again, the 400 mg/dL cell media was introduced 
to the cells in top three wells, and 100 mg/dL cell media was introduced to the cells in the bottom 
three wells. 
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3.2.4 Evaluation of BAECs and HUVECs 
The purpose of this study was to compare and evaluate the glucose consumption and 
cellular death of BAECs and HUVECs in the hyperglycemic environment.  In order to evaluate 
the glucose consumption, the glucose concentration of the introduced glycemic cell media 
solution was monitored over the seventy-two hour experimentation time.  The glucose 
concentration of each well was recorded at t = 0, 24, 48, and 72 hours.   
In addition to glucose consumption, it was ideal to evaluate cellular morphology, 
especially of the cells in the 400 mg/dL hyperglycemic cell media solution to determine if cell 
death was occurring.  Cells in 100mg/dL could serve as a control.  However, the cells of only the 
third and final BAEC and HUVEC experiments were evaluated and recorded under a microscope 
with pictures.  It was expected that the wells with the 400 mg/dL hyperglycemic cell media 
solutions would have much greater cell death than the wells with the 100 mg/dL normal 
glycemic cell media solution, as indicated by a rounded, ball-like morphology.   
Once the glycemic cell media solutions were properly introduced to the BAECs and 
HUVECs, the glucose concentration of each well was recorded with the Aviva Accu-Chek blood 
glucose meter (the blood glucose meter was sprayed with 70% IPA before being appended to the 
aseptic environment under the laminar flow hood).  Once the initial t = 0 evaluation was 
complete, the cells were stored in the incubator.  Again at t = 24, 48, and 72 hours, the cells of 
each well were re-evaluated.  The following section explains the recorded results for each of the 
first two BAEC and HUVEC experiments.  In addition, the following section will lead into the 
reason and results of the third and final BAEC and HUVEC experiments. 
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3.3 Results 
This section displays the accumulated data of the first two BAEC and HUVEC 
experiments and is formatted to assess the results between the cells exposed to the 100 mg/dL 
normal glycemic cell media solutions and the cells exposed to the 400 mg/dL hyperglycemic cell 
media solutions. 
3.3.1 100 mg/dL Normal Glycemic Environment 
3.3.1.1 Glucose Consumption 
Recall from Chapter 1, the average blood glucose level of a healthy individual falls 
within the 80-120 mg/dL range.  The initial expectation for the endothelial cells exposed to the 
100 mg/dL solution was for there to be minimal glucose consumption since the cells are in a 
state of homeostasis.  Therefore, the results should show minimal decrease in glucose 
concentration throughout the entire 72 hour test period.   
Figure 43 shows the average glucose concentrations of all wells exposed to the 100 
mg/dL normal glycemic cell media solution at each time of evaluation.  Additionally, Table 10 
lists the average glucose concentrations for each experiment, as well as the calculated difference 
in glucose concentration between t = 0 and t = 72 hours.  
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Figure 43 – There was minimal decrease in glucose concentration throughout the 72 hour test 
period; therefore, the glucose consumption for the BAEC and HUVEC studies was minimal. 
Table 10 - Average Glucose Concentrations of 100 mg/dL Normal Glycemic Cell Media 
Solutions Exposed to BAECs & HUVECs 
Average Glucose Concentrations of the 100 mg/dL Normal Glycemic Cell Media 
Solutions Exposed to BAECs & HUVECs 
Time 
(Hours) 
Average Glucose Concentration of Three 100 mg/dL Wells 
BAECs 1 BAECs 2 HUVECs 1 HUVECs 2 Average St. Dev. 
0 98.67 88.00 103.00 91.67 95.33 6.76 
24 100.33 89.00 94.00 81.67 91.25 6.83 
48 93 82.33 89 81 86.33 4.90 
72 95.33 71.67 90.33 77.67 83.75 9.49 
∆ (t0–t72) 3.33 16.33 12.67 14.00 11.58 5.70 
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Looking at Figure 43, the glucose consumption for the BAEC and HUVEC trials looked 
minimal; thus, showing that there was little glucose consumption by the endothelial cells 
exposed to the normal glycemic solution.  The values recorded in Table 10 were calculated by 
taking the average of the recorded glucose concentrations for all three wells containing the 100 
mg/dL normal glycemic cell media solution at each evaluation period (these values can be seen 
in Appendix B).  In addition, Table 10 gives the average of these averages, as well as the 
standard deviation, in order to illustrate the low degree of variance in the accumulated data.    
In order to analyze whether an average ∆ (t0–t72) of 11.58 mg/dL was a significant 
reduction in glucose concentration, a series of two-tailed T-tests were conducted on the recorded 
glucose concentrations of each well for each experiment between each time of evaluation.  The t-
tests were conducted assuming that the recorded data was normally distributed.  Table 11 shows 
the calculated p-values for each T-test with the null hypothesis Ho: µ1=µ2, the alternative 
hypothesis Ha: µ1≠µ2, and α=0.05. 
Table 11 - Two-Tailed T-Tests Results for BAECs & HUVECs Exposed to 100 mg/dL Normal 
Glycemic Cell Media Solutions 
Two-Tailed T-Tests Results for the BAECs & HUVECs Exposed to the 100 mg/dL 
Normal Glycemic Cell Media Solutions 
Ho: µ1=µ2; Ha: µ1≠µ2; α=0.05  
Array 1 (hours) Array 2 (hours) p-Value 
0 24 0.165750622 
0 48 0.00129592 
0 72 0.002858474 
24 48 0.080847457 
24 72 0.050738757 
48 72 0.444784919 
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Table 11 shows a statistically significant difference between the average glucose 
concentrations for t = 0 and t = 72 hours.  The question turned to how this difference compared 
with the difference seen in the 400 mg/dL hyperglycemic environment.  Therefore, it was 
essential to review the data recorded from the endothelial cells exposed to the 400 mg/dL 
hyperglycemic cell media solutions, and compare the amount of glucose consumption between 
the two environments.  
3.3.2 400 mg/dL Hyperglycemic Environment 
3.3.2.1 Glucose Consumption 
Figure 44 shows the average glucose concentrations of all wells exposed to the 400 
mg/dL hyperglycemic cell media solution at each time of evaluation.  (Note: the reason that t=0 
does not closely correspond to 400mg/dL will be discussed later.) Additionally, Table 12 lists the 
average glucose concentrations for each experiment, as well as the calculated difference in 
glucose concentration between t = 0 and t = 72 hours.   
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Figure 44 – There was a greater decrease in glucose concentration throughout the 72 hour test 
period.  The data also shows that there was a substantial decrease in glucose concentration for 
the second BAEC experiment, as well as the two HUVEC experiments starting at t = 0. 
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Table 12 - Average Glucose Concentrations of 400 mg/dL Hyperglycemic Cell Media Solutions 
Exposed to BAECs & HUVECs 
Average Glucose Concentrations of the 400 mg/dL Hyperglycemic Cell Media 
Solutions Exposed to BAECs & HUVECs 
Time 
(Hours) 
Average Glucose Concentration of Three 400 mg/dL Wells 
BAECs 1 BAECs 2 HUVECs 1 HUVECs 2 Average St. Dev. 
0 409.33 287.67 246.67 282.33 306.50 70.93 
24 347.00 277.33 224.33 270.33 279.75 50.62 
48 346.67 257.33 222.00 269.00 273.75 52.56 
72 336.67 248.33 227.00 259.00 267.75 47.83 
∆ (t0–t72) 72.67 39.33 19.67 23.33 38.75 24.17 
The initial expectation for the BAECs and HUVECs exposed to the 400 mg/dL 
hyperglycemic cell media solutions was for a high level of glucose consumption over a 72 hour 
period.  Looking at Figure 44, there was a greater decrease in glucose concentration over the 72 
hour time period.  The values in Table 12 were calculated by taking the average of the recorded 
glucose concentrations for all three wells containing the 400 mg/dL hyperglycemic cell media 
solution at each evaluation period (these values can also be seen in Appendix B).    
The average ∆ (t0–t72) of the glucose concentration in the cells was 38.75 mg/dL – a 
substantial amount of glucose consumption.  In order to analyze whether the average ∆ (t0–t72) of 
38.75 mg/dL was a significant reduction in glucose concentration, a series of two-tailed t-tests 
was conducted on the recorded glucose concentrations of each well for each experiment between 
each time of evaluation.  These tests were conducted assuming that the recorded data was 
normally distributed.  Table 13 shows the calculated p-values for each t-test with a null 
hypothesis Ho: µ1=µ2, an alternative hypothesis Ha: µ1≠µ2, and α=0.05. 
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Table 13 - Two-Tailed T-Tests Results for BAECs & HUVECs Exposed to 400 mg/dL 
Hyperglycemic Cell Media Solutions 
Two-Tailed T-Tests Results for the BAECs & HUVECs Exposed to the 400 mg/dL 
Hyperglycemic Cell Media Solutions 
Ho: µ1=µ2; Ha: µ1≠µ2; α=0.05  
Array 1 (hours) Array 2 (hours) p-Value 
0 24 0.264684404 
0 48 0.176583635 
0  72 0.102422521 
24 48 0.761585943 
24 72 0.526862047 
48 72 0.752230261 
Although the average ∆ (t0–t72) was approximately 38.75 mg/dL, the calculated p-values 
showed no statistical significant difference between any average glucose concentrations at any 
evaluation points – especially between t = 0 and t = 72 hours.   
Additionally, there was cause for concern in the results.  The expected t = 0 glucose 
concentration of approximately 400 mg/dL was recorded for the first BAEC experiment. 
However, the data shows a substantial decrease in glucose concentration at t = 0 for the second 
BAEC experiment, and the two HUVEC experiments. This observation will be discussed and 
explored in the following sub-sections. 
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3.4 Investigating the Decreased Glucose Concentration at t = 0 for 
the 400 mg/dL hyperglycemic cell media solutions 
3.4.1 Testing the Loss of Glucose during Syringe-Filter Sterilization 
Recall from Section 3.2.3, sterilization of the 400 mg/dL hyperglycemic cell media 
solutions was necessary before introducing the solutions to the endothelial cells.  The method of 
sterilization used was syringe-filter sterilization with 10 mL syringes and 0.22 µm syringe filters. 
A significant step missed in the procedure was that the glucose concentration of the solutions 
was not taken right after sterilization.  This would have been useful, since the glucose 
concentration of the solution was going to be recorded after it was added to the cells. 
A potential cause for the initial loss of glucose was thought to be the syringe-filter 
sterilization.  Remember, an extremely small amount of glucose can differentiate a 
hyperglycemic glucose concentration from a normal glycemic concentration; therefore, even a 
minuscule amount of glucose lost in the 0.22 µm filters could cause the glucose concentration of 
the 400 mg/dL hyperglycemic solutions to drop to roughly 250 mg/dL – as seen in the second 
BAEC experiment and the two HUVEC experiments.   
In order to test this hypothesis, four sets of 400 mg/dL hyperglycemic cell media 
solutions were created and sterilized into three separate 10 mL samples per solution (a total of 
twelve test samples).    From previously derived calculations, approximately 0.12 g of Sigma 
G6152 D-(+)-Glucose was added to 40 mL of Gibco Cell Medium 199.  Table 14 displays the 
exact amounts of glucose added to the volume of cell media.     
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Table 14 – Recipes to Create 400 mg/dL Hyperglycemic Solutions to Test Glucose Loss during 
Syringe-Filter Sterilization 
Solution Sample Glucose Added (g)  Volume of Cell Media (mL) 
1 0.1213  40 
2 0.1208  40 
3 0.1209  40 
4 0.1211  40 
Each solution was mixed on a magnetic hot plate with a magnetic stir bar at 25º C for at 
least six hours.  Once the solutions were uniformly mixed, the glucose concentration was taken 
with the Aviva Accu-Chek blood glucose meter.  Next, the solutions were sterilized and 
transferred into twelve different sterile 50 mL conicals.  The glucose concentration was 
measured again for each sample and the amount of glucose loss was calculated and recorded in 
Table 15.  The calculations were conducted by converting the post sterilization glucose 
concentration into grams per volume of cell media.  Additionally, the calculated glucose loss was 
based off the initial amount of glucose added to the solutions, not the initial glucose 
concentration of each solution; thus, if the calculation theoretically indicated no glucose loss, 
then it was not included in the data. 
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Table 15 - Effect of Syringe-Filter Sterilization on 400 mg/dL Hyperglycemic Cell Media 
Solutions 
Table 15 shows that all four solutions experienced a very small loss of glucose after 
syringe-filter sterilization with an average glucose loss of 0.0033 g.  Thus, the experiment 
suggested that the root cause of the low glucose concentrations recorded at t = 0 was not the 
sterilization process.  However, a third set of experiments with BAECs and HUVECs was 
conducted with an additional amount of glucose added to the initial calculated mass of glucose 
for the 400 mg/dL hyperglycemic solution recipe.  This compensation was conducted in the 
attempt to limit the degree of glucose loss in the hyperglycemic solutions.  The following section 
describes these experiments. 
Effect of Syringe-Filter Sterilization on 400 mg/dL Hyperglycemic Cell Media 
Solutions 
Solution # 
Amount of 
Glucose in 
Solution (g) 
Initial Glucose 
Concentration 
(mg/dL) 
Test 
Sample # 
Post-
Sterilization 
Glucose 
Concentration 
(mg/dL) 
Glucose 
Lost (g) 
1 0.1613 416 
1 387 0.0065 
2 412 N/A 
3 402 0.0005 
2 0.1608 411 
1 403 N/A 
2 392 0.004 
3 406 N/A 
3 0.1609 424 
1 403 N/A 
2 390 0.0049 
3 396 0.0025 
4 0.1611 429 
1 395 0.0031 
2 374 0.0015 
3 405 N/A 
Average 397.08 0.0033 
Standard Deviation 10.33 0.002 
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3.4.2 Third BAEC & HUVEC Experiment 
3.4.2.1 Preparation and Application of Glycemic Cell Media Solutions 
 For the 400 mg/dL hyperglycemic solutions of the third BAEC and HUVEC experiments, 
an additional 0.020 g of glucose was added to the calculated amount of Sigma G6152 D-(+)-
Glucose to compensate for any lost glucose during syringe-filter sterilization.  Recall, Lonza 
EBM was used for the BAEC experiment and Gibco Medium 199 was used for the HUVEC 
experiment.  Table 16 summarizes the recipes of the hyperglycemic solutions for each 
experiment.     
Table 16 - Recipes to Create 400 mg/dL Hyperglycemic Solutions for Final BAEC & HUVEC 
Experiments 
Experiment Volume of Cell Media (mL) 
 
 
Amt Glucose  
Added (g) 
Mixing 
Parameters 
Recorded 
Glucose 
Concentration 
(mg/dL) 
BAECs 3 20  0.0813 12 hours 25˚C 461 
HUVECs 3 20  0.0807 12 hours 25˚C 519 
In addition, the amount of glycemic cell media solution added to each well was increased 
from 3 mL to 6 mL per well (Figure 45).  The results of these experiments are discussed in the 
following section. 
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Figure 45- Amount of glycemic cell media solution added to each well for the third BAEC & 
HUVEC experiments 
3.5 Results of Third BAEC & HUVEC Experiments 
3.5.1  100 mg/dL Normal Glycemic Environment 
3.5.1.2  Glucose Consumption 
Figure 46 shows the average glucose concentrations of all wells exposed to the 100 
mg/dL normal glycemic cell media solution at each time of evaluation.  Additionally, Table 17 
lists the average glucose concentrations for each experiment, as well as the calculated difference 
in glucose concentration between t = 0 and t = 72 hours.    
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Figure 46 – The BAECs and HUVECs exposed to the 100 mg/dL normal glycemic cell media 
solutions in the third experiment exhibited similar decrease in glucose concentration. 
Table 17 - Average Glucose Concentrations of the 100 mg/dL Normal Glycemic Cell Media 
Solutions Exposed to BAECs & HUVECs of Final Experiments 
Average Glucose Concentrations of 100 mg/dL Normal Glycemic Cell 
Media Solutions Exposed to BAECs & HUVECs of Third 
Experiments 
Time (Hours) 
Average Glucose Concentration of Three 100 mg/dL 
Wells 
BAEC 3 HUVEC 3 Average St. Dev. 
0 80.00 84.33 82.17 3.06 
24 76.00 78.67 77.33 1.88 
48 75.33 72.67 74 1.88 
72 75.67 70.67 73.17 3.53 
∆ (t0–t72) 4.33 13.67 9.00 6.599 
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As expected, Figure 46 shows the same decrease in glucose concentration that the 
previous experiments exhibited for the endothelial cells exposed to the 100 mg/dL normal 
glycemic cell media solutions.  In addition, Table 17 shows the little change in glucose 
concentration from t = 0 hours to t = 72 hours – 9.00 mg/dL.    
The series of two-tailed T-tests were conducted in order to analyze whether or not there 
was a statistically significant difference between the average glucose concentration of the wells 
at t = 0 and t  = 72 hours (Table 18). 
Table 18 - Two-Tailed T-Test Results for the Final BAEC & HUVEC Experiments Exposed to 
100 mg/dL Normal Glycemic Cell Media Solutions 
Two-Tailed T-Tests Results for the Third BAEC & HUVEC Experiments Exposed 
to 100 mg/dL Normal Glycemic Cell Media Solutions 
Ho: µ1=µ2; Ha: µ1≠µ2; α=0.05  
Array 1 (hours) Array 2 (hours) p-Value 
0 24 0.097796746 
0 48 0.010774561 
0 72 0.006721393 
24 48 0.255720974 
24 72 0.166718562 
48 72 0.769038752 
The statistical analysis shows a statistically significant difference between the average 
glucose concentration at t = 0 hours and t = 72 hours.  As before, this difference was compared to 
the statistical difference seen between the average glucose concentration at t = 0 and t = 72 hours 
for the endothelial cells exposed to the 400 mg/dL hyperglycemic cell media solutions.  
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3.5.1.3  Cell Confluency 
 For the third BAEC & HUVEC experiments, cell morphology was observed at each time 
of evaluation.  Studies have shown that hyperglycemia can induce cellular apoptosis in HUVECs 
and BAECs [145, 152]; thus, the BAECs and HUVECs were observed under a microscope to see 
if cell confluency had decreased over the 72 hour experimentation time.  Since the BAECs and 
HUVECs exposed to the 100 mg/dL normal glycemic cell media solutions were generally in a 
state of homeostasis, a significant decrease in cell confluency was not expected. 
 Figure 47 shows that the HUVEC (Figure 47a) and BAEC (Figure 47b) cell confluency 
did not decrease from t = 0 hours to t = 72 hours (HUVEC confluency was also initially much 
better than BAEC confluency). 
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(a)   
    t = 0     t = 72 
(b)   
t = 0     t = 72 
Figure 47 – (a) The cell confluency of the HUVECs exposed to the 100 mg/dL normal glycemic 
cell media solution did not change from t = 0 to t = 72 hours.  (b) Additionally, the cell 
confluency of the BAECs exposed to the 100 mg/dL normal glycemic cell media solution did not 
change from t = 0 to t = 72 hours either. 
 The evaluation of the endothelial cells under the microscope confirmed little change in 
cell morphology in the 100 mg/dL normal glycemic cell media solutions over the 72 hour time 
period.   
3.5.2  400 mg/dL Hyperglycemic Environment 
3.5.2.1  Glucose Consumption 
 Figure 48 shows the recorded glucose concentrations at each time of evaluation.  
Additionally,  
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Table 19 lists the average glucose concentrations of each experiment, as well as the calculated 
difference in glucosee concentration between t = 0 and t = 72 hours. 
 
Figure 48 - The BAECs and HUVECs exposed to the 400 mg/dL hyperglycemic cell media 
solutions for the third experiment exhibited a decrease in glucose concentration over the 72 hour 
test time; thus, exhibiting glucose consumption.   
 
Table 19 - Average Glucose Concentrations of the 400 mg/dL Hyperglycemic Cell Media 
Solutions Exposed to BAECs & HUVECs of Third Experiments 
Average Glucose Concentrations of the 400 mg/dL Hyperglycemic 
Cell Media Solutions Exposed to BAECs & HUVECs of Third 
Experiments 
Time (Hours) 
Average Glucose Concentration of Three 400 mg/dL 
Wells 
BAEC 3 HUVEC 3 Average St. Dev. 
0 362.67 352.67 357.67 7.07 
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24 303.67 306.67 305.17 2.12 
48 296.00 296.00 296.00 0.00 
72 283.67 283.67 283.67 0.00 
∆ (t0–t72) 79.00 69.00 74.00 7.07 
 
The data of Figure 48 shows greater decrease in glucose concentration over the 72 hour 
test period.  Additionally, the values recorded in  
Table 19 were calculated by taking the average of the recorded glucose concentrations for 
all three wells containing the 400 mg/dL hyperglycemic cell media solution at each evaluation 
period.  This table shows a significantly greater average change in glucose concentration from t = 
0 to t = 72 hours – 74.00 mg/dL.   
 Again, a series of two-tailed T-tests were conducted in order to analyze whether or not 
there was any statistical significant difference between the average glucose concentration of the 
wells at t = 0 and t  = 72 hours (Table 20). 
 
Table 20 - Two-Tailed T-Tests for Final BAEC & HUVEC Experiments Exposed to the 400 
mg/dL Hyperglycemic Cell Media Solutions 
Two-Tailed T-Tests for Final BAEC & HUVEC Experiments Exposed to the 400 
mg/dL Hyperglycemic Cell Media Solutions 
Ho: µ1=µ2; Ha: µ1≠µ2; α=0.05  
Array 1 (hours) Array 2 (hours) p-Value 
0 24 0.001406033 
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0 48 0.000591077 
0 72 4.39249E-05 
24 48 0.452472321 
24 72 0.054662491 
48 72 0.265310104 
The resulting p-values showed that there was statistical significant difference between the 
average glucose concentration of the well at t = 0 and t = 72 hours.   
3.5.2.2  Cell Confluency 
 The BAECs and HUVECs exposed to the 400 mg/dL hyperglycemic cell media solution 
were in a hoemstatic imbalanced environment with high glucose toxicity.  Thus, the evaluation 
of the cells under the microscope from t = 0 hours to t = 72 hours should have exhibited greater 
decrease in cell confluncy. 
 Figure 49 shows that the HUVECs (Figure 49a) and the BAECs (Figure 49b) both did not 
exhibit significant decrease in cell conflunecy from t = 0 hours to t = 72 hours. 
(a)   
    t = 0     t = 72 
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(b)   
t = 0     t = 72 
Figure 49 – The cell confluency of the HUVECs exposed to the 400 mg/dL hyperglycemic cell 
media solution did not significantly decrease from t = 0 to t = 72 hours.  (b) Additionally, the cell 
confluency of the BAECs exposed to the 400 mg/dL hyperglycemic cell media solution did not 
decrease from t = 0 to t = 72 hour. 
The evaluation of the endothelial cells under the microscope confirmed insignificant 
levels of cell death in the 400 mg/dL hyperglycemic cell media solutions over the 72 hour time 
period.    
 Above all, there was still cause for concern due to the continuous low glucose 
concentration of the 400 mg/dL hyperglycemic cell media solution at t = 0.  During this third 
experiment; however, it was realized that the decreased glucose concentration of the 400 mg/dL 
solutions in the second BAEC experiment, first two HUVEC experiments, and the third BAEC 
and HUVEC experiments was due to a missed step in the established procedure during the 
implementation of the glycemic cell media solutions to the wells containing the endothelial cells.  
This discovery and evaluation is discussed in Section 3.6.3 of the discussion section below. 
3.6 Discussion and Conclusion 
The purpose of the experiments in this chapter was to determine whether or not the 
developed 400 mg/dL hyperglycemic cell media solutions and 100 mg/dL normal glycemic cell 
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media solutions would evoke a cellular response similar to cells exposed to an actual 
hyperglycemic environment.  This was done in the attempt to confirm that a solution with an 
elevated glucose concentration resembles a hyperglycemic environment.  
The two glycemic cell media solutions were introduced to the endothelial cells in sterile 
6-well plates.  The hypothesis was tested by monitoring the glucose concentration, with the 
Aviva Accu-Chek blood glucose meter, over a 72 hour time period at 24-hour time intervals in 
order to observe any glucose consumption.  Additionally, the last experiment observed cell 
confluency of the cells under a microscope to observe any cell death.  
The 400 mg/dL hyperglycemic cell media solutions were developed with the protocol 
established in Chapter 2.  Sigma G6152 D-(+)-Glucose was added to either Lonza EBM (for 
experimentation with BAECs), or Gibco Medium 199 (for experimentation with HUVECs).  
Since the Sigma G6152 D-(+)-Glucose was an unsterile substance, the composed 400 mg/dL 
hyperglycemic cell media solutions had to be sterilized via syringe-filter sterilization before 
being introduced to the endothelial cells.  The sterilization was conducted in the laminar flow 
hood with 10 mL syringes and 0.22 µm syringe filters.  The 100 mg/dL normal glycemic cell 
media solutions were already sterile; thus, did not require sterilization before application to the 
endothelial cells.  The experiments began right when the glycemic cell media solutions were 
introduced to the endothelial cells and the initial evaluation at t = 0 was conducted. 
3.6.1 100 mg/dL Normal Glycemic Environment 
 According to the p-value calculated in Table 11, the endothelial cells exposed to the 100 
mg/dL normal glycemic cell media solutions exhibited a statistical significant difference in 
average glucose concentration from t = 0 to t = 72 hours.  Although these cells were in a 
125 
 
balanced glycemic environment, there was still a good amount of glucose consumption.  To see a 
lower glucose values at t = 72 hours compared with t = 0 was actually not completely surprising 
as the cells were alive; thus, they would be consuming glucose for up to at least 72 hours.  
Additionally, this is why it is standard procedure in cell culture to change out the media every 
three days. 
 Although statistical analysis did show a statistical significant difference in glucose 
concentrations, the evaluation of the cells under the microscope showed hardly any decrease in 
cell confluency – meaning the 100 mg/dL normal glycemic environment did not evoke any 
unexpected cell death.  While the initial cell morphology for the HUVECs was excellent (and 
remained excellent throughout the experiment), the initial cell morphology of the BAECs was 
poor, but was constant throughout the experiment.  
3.6.2 400 mg/dL Hyperglycemic Environment 
The accumulated results for the initial experiments with HUVECs and BAECs indicate a 
greater amount of glucose consumption in the 400 mg/dL hyperglycemic environment.  
Additionally, the average ∆ (t0–t72) of the glucose concentration in the cells was 38.75 mg/dL, 
which is greater than the glucose consumption of the cells in the 100 mg/dL normal glycemic 
cell media solutions that only had an average ∆ (t0–t72) of 11.58 mg/dL.  However, although there 
was a high number of consumption when comparing the two environments, relative to one 
another, the consumption was not drastically greater in the 400 mg/dL wells than the 100 mg/dL 
wells (12.14% vs. 12.64% for BAEC & HUVEC experiments 1 & 2).  The average change in 
glucose concentration would most likely have been even greater for the 400 mg/dL environment 
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had the error not occurred with the three experiments that had a substantially lower glucose 
concentration than planned at t = 0 hours.   
 However, statistical analysis confirmed no statistical significant difference in the average 
glucose concentrations between any of the evaluation periods.  Obviously, the analysis was 
biased due to the unexpected low glucose concentrations recorded at t = 0 hours for the second 
BAEC experiment and the first two HUVEC experiments.  Additionally, the analyzed sample 
size was small; therefore, the calculated p-values may not have given a fair evaluation of the 
endothelial cells exposed to the 400 mg/dL hyperglycemic cell media solutions.   
Since the first BAEC experiment ran as expected, the same two-tailed T-tests were 
conducted on only the data accumulated from the first BAEC experiment.  Table 21 shows the 
calculated p-values. 
 
 
 
Table 21 - Two-Tailed T-Test Results for First BAEC Experiment Exposed to 400 mg/dL 
Hyperglycemic Cell Media Solutions 
Two-Tailed T-Test Results for the First BAEC Experiment Exposed to the 400 
mg/dL Hyperglycemic Cell Media Solutions 
Ho: µ1=µ2; Ha: µ1=µ2; α=0.05  
Array 1 (hours) Array 2 (hours) p-Value 
0 24 0.004460281 
0 48 0.003424838 
0  72 0.001345804 
24 48 0.979821034 
24 72 0.423717128 
48 72 0.413348961 
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 The results of these t-tests confirmed a statistical significant difference between the 
average glucose concentrations at t = 0 and t = 72 hours.  In addition, the calculated p-value was 
less than the calculated p-value comparing the average glucose concentrations at t = 0 and 72 
hours for the 100 mg/dL wells; therefore, supporting the test’s original hypothesis that the 
endothelial cells exposed to the 400 mg/dL hyperglycemic cell media solutions would experience 
greater glucose consumption than the endothelial cells exposed to the 100 mg/dL cell media.  
Though this was the case for the first BAEC experiment, recall, the same outcome did not occur 
for all experiments. 
The final BAEC and HUVEC experiments accumulated increased results with an average 
∆ (t0–t72) of 74.00 mg/dL.   Thus, greater glucose consumption was observed in the third 
experiment by the BAECs and HUVECs exposed to the 400 mg/dL hyperglycemic cell media 
solutions compared to the cells exposed to the 100 mg/dL normal glycemic cell media solutions, 
which had an average ∆ (t0–t72) of 9.00 mg/dL.  Also, the ∆ (t0–t72) observed in the 400 mg/dL wells 
greater than the ∆ (t0–t72) of the initial BAEC & HUVEC experiments.    Additionally, the 
calculated p-value was smaller than the p-value recorded comparing the average glucose 
concentration of the wells exposed to the 100 mg/dL normal glycemic cell media solution 
between t = 0 hours and t = 72 hours.  The greater statistical difference confirms that there was 
greater glucose consumption by the endothelial cells exposed to the hyperglycemic environment 
in these particular experiments.   
There was little evidence of any cell death of the BAECs and HUVECs exposed to the 
400 mg/dL hyperglycemic cell media solutions.  At first this was discouraging; however, the 
unsubstantial amount of cell death in the 400 mg/dL environment is a preferable outcome as this 
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hyperglycemic environment can now be an adequate environment to evaluate endothelial cells in 
a hyperglycemic BVM.  
However, even though additional glucose was added to the original recipe for the 400 
mg/dL hyperglycemic solution, to compensate for any lost glucose during the sterilization, the 
results still showed slightly low glucose concentrations at t = 0 – roughly 357.67 mg/dL.  Thus, 
something other than the sterilization process was diluting the hyperglycemic solution.  The 
following section discusses the resolution.   
3.6.3 Removal Complete Cell Media during Application of Glycemic Cell 
Media Solutions 
 The initial part of the experiment required the BAECs and HUVECs to be cultured into 
6-well plates and routinely fed with approximately 2-3 mL of complete cell media (base media 
plus all the aliquots).  This media was also a “low glucose” cell media like the Gibco Medium 
199 and Lonza EBM; thus, it already contained 100 mg/dL of glucose.  In addition, the 
procedure for the first BAEC experiment was conducted by a trained lab technician; therefore, 
there was no error in the procedure and the results of this experiment came out as expected.  
Unfortunately, one significant step in the procedure was missed when observing and developing 
the protocol. Before introducing the glycemic cell media to the endothelial cells, it was necessary 
to remove the complete cell media feeding the cultured endothelial cells first.  It seems like an 
obvious step in the protocol; however, throughout the strict maintenance of a sterile environment 
during these experiments, it can be an obvious but easy step to miss. 
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 Recall, approximately 3 mL of glycemic cell media solution was added to each well 
during the second BAEC experiment and the first two HUVEC experiments.  This volume of 
was increased to 6 mL for the third BAEC and HUVEC experiments.  Assuming that the wells 
originally contained 2 mL of the homogenous cell media, the amount of glucose in the small 
volume of added glycemic cell media solution (3 mL or 6 mL) was calculated using the amount 
of glucose weighed and added to create the solutions, and then adjusted to compensate for the 
additional 2 mL of complete “low glucose” cell media.  Table 22 shows the results of these 
calculations. 
 
 
 
 
 
Table 22 - Calculated Glucose Concentrations Compensating for Additional 2 mL of Complete 
Cell Media that was mistakenly not removed 
Experiment Glucose Added (g) 
Cell Media 
Volume 
(mL) 
Assumed 
Volume of 
Complete 
“Low 
Glucose” Cell 
Media (mL) 
Volume of 
Applied 
Glycemic 
Cell Media 
Solution 
(mL) 
Average 
Glucose 
Concentration 
of Wells 
(mg/dL) 
Adjusted 
Glucose 
Concentration 
of Wells 
(mg/dL) 
BAEC 2 0.0613 20 2 3 287.67 223.90 
HUVEC 1 
HUVEC 2  0.1214 40 2 3 246.67 222.10 
BAEC 3 0.0813 20 2 6 362.67 328.75 
130 
 
HUVEC 3 0.0807 20 2 6 352.67 327.63 
For example, the adjusted glucose concentration of the BAECs from the second experiment was 
calculated as follows: 
1. Find the amount of glucose in the volume of applied glycemic cell media solution. 
0.0613 g / 20 mL = x g / 3 mL 
x = 0.009195 g / 3 mL 
2. Compensate the result by adding the addition 2 mL of “low glucose” media. 
0.009195 g / 3 mL + 0.002 g / 2 mL = 0.011195 g / 5 mL 
3. Convert g / mL to mg / dL. 
0.011195 g / 5 mL × 1000 mg / 1 g × 100 mL / 1 dL = 223.90 mg/dL 
 The calculated adjustments are slightly smaller than the recorded average glucose 
concentrations; however, this calculation was conducted assuming 2 mL of homogenous media 
was already in the wells.  Nonetheless, the adjustments confirmed that this incorrect step in the 
protocol was the most likely root cause for the decreased glucose concentration of the 400 mg/dL 
hyperglycemic cell media solutions at the t = 0 evaluation time.  In the future, similar studies 
should be contucted by removing all normoglycemic complete media before adding the 
hyperglycemic media, so that the composition of media exposed to the cells is well controlled. 
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3.6.4 Summary 
A total of six studies were conducted for this chapter – three studies with BAECs and 
three studies with HUVECs.  There were four key factors that differed among the experiments: 
1. Adding Glycemic Cell Media Solutions 
a. 10 mL of the glycemic cell media solution was added to each well for the first 
BAEC experiment.   
b. 3 mL of glycemic cell media solution was added to each well for the second 
BAEC experiment and first two HUVEC experiments.   
c. 6 mL of glycemic cell media solution was added each well for the third BAEC 
and HUVEC experiments. 
2. The first and second HUVEC experiments used the same 400 mg/dL 
hyperglycemic cell media solution. 
3. The third BAEC and HUVEC experiments had additional glucose added to 
compensate for any lost glucose during the sterilization process. 
4. Cell morphology was evaluated and recorded for only the third BAEC and 
HUVEC experiments. 
In addition, Table 23 summarizes the conclusions derived from the results of the experiments of 
this chapter. 
Table 23 – Summary of Conclusions from Experimentation with BAECs & HUVECs in 100 
mg/dL & 400 mg/dL Environments 
Summary of Conclusions from Experimentation with BAECs & HUVECs in 100 mg/dL & 400 mg/dL 
Environments 
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Glycemic 
Environment 
Hypothesis Results Conclusion 
Glucose 
Consumption 
Cell 
Morphology 
Glucose 
Consumption 
Cell 
Confluency 
Glucose 
Consumption 
Cell 
Confluency 
100 mg/dL 
Normal 
Glycemic Cell 
Media 
Solutions 
Minimal 
decrease in 
glucose 
concentration 
= minimal 
glucose 
consumption 
Minimal 
decrease in 
cell 
confluency = 
minimal cell 
death 
Statistically 
significant 
difference in 
average 
glucose 
concentration 
between t = 0 
& t = 72 
hours 
Little or no 
decrease in 
cell 
confluency 
Cells are 
active and 
consuming 
glucose; 
however, not 
as much as 
cells exposed 
to 
hyperglycemic 
environment. 
Cells are 
active and 
healthy in 100 
mg/dL normal 
glycemic 
environment.  
Cell death is 
not evoked. 
400 mg/dL 
Hyperglycemic 
Cell Media 
Solutions 
Significant 
decrease in 
glucose 
concentration 
= significant  
glucose 
consumption 
Significant 
decrease in 
cell 
confluency = 
significant 
cell death 
Statistically 
significant 
difference in 
average 
glucose 
concentration 
between t = 0 
& t = 72 
hours 
Little 
decrease in 
cell 
confluency 
Cells are more 
active and 
consuming 
higher 
amounts of 
glucose 
compared to 
normal 
glycemic 
environment. 
Cells are able 
to survive 400 
mg/dL 
hyperglycemic 
environment.  
Allows for 
adequate 
evaluation of 
cells within 
hyperglycemic 
BVM. 
Thus, pardoning the improper step conducted during the procedure of the experiments, in 
conclusion, the results of the BAEC and HUVEC experiments did in fact support the hypothesis 
that the developed 400 mg/dL hyperglycemic cell media evoked the expected glucose 
consumption, although cell morphology was not drastically affected.  Although the results did 
not accumulate as planned, the constant inquiries contributed to an excellent learning experience. 
 Finally, the high glucose concentrated solutions developed in Chapter 2 evoked one of 
the expected characteristics that endothelial cells would exhibit in an actual hyperglycemic 
environment: they increased glucose consumption.  Though this was not true for all the 
conducted experiments, the results did show that hyperglycemic solutions can be introduced to 
endothelial cells, the glucose concentration can be monitored over time (no matter what the 
initial concentration is), and endothelial cells are able to survive high glycemic environments, 
which would allow for adequate evaluation of BVMs introduced to various glycemic 
environments.  The conclusions from this chapter open the opportunity to further evaluate the 
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effects induced by various glycemic environments by analyzing the phenotype and expression of 
endothelial cells exposed to these environments. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Discussion & Conclusion 
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4.1 Overview of Thesis 
4.1.1 Diabetes Mellitus 
Diabetes Mellitus is a disease that affects the body’s ability to properly produce and use 
insulin in order to metabolize blood glucose and maintain an adequate blood glucose level.  At 
first, the disease was a slow and painful death.  While years of research were conducted on 
attempting to cure the disease, the first breakthrough didn’t occur until 1879 when Joseph Von 
Mering and Oscar Minkowski, of Germany, discovered that removing the pancreas of a dog 
caused the dog to develop diabetes as the dog excessively urinated and the urine contained high 
levels of glucose [1].  Thus, the anti-diabetic substance researchers were looking for was within 
the pancreas.  While many tried to extract a purified sample of the substance for human use, it 
was an extremely challenging procedure – to the point where many scientists were giving up and 
losing hope.  However, in 1921, Dr. Fredrick Banting, Dr. James M Macleod, and James B. 
Collip, from the University of Toronto, were able to obtain the first purified sample for human 
testing – insulin [3].   Insulin drastically improved the condition of diagnosed patients, and the 
discovery awarded Banting and Macleod the Nobel Prize in Medicine in 1923 [3].  Due to this 
discovery, what used to be a horrifying experience for physicians and patients became an open 
door for new research in quest of a cure for the disease.   
There are two common types of diabetes mellitus – type 1 diabetes mellitus, and type II 
diabetes mellitus.  Type I diabetes is an autoimmune that involves the degeneration of pancreatic 
β-cells – cells that produce and secrete insulin – thus, patients are unable to regulate blood 
glucose levels and require constant blood glucose monitoring and injections of insulin.  Type II 
diabetes mellitus is different from Type I in in that that the pancreatic β-cells are impaired and 
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cannot produce proper amount of insulin, and the body cells exhibit a resistance to the insulin. 
Thus, patients are unable to regulate blood glucose levels with only insulin injections and require 
an overall lifestyle adjustment with an improved diet and increased level of exercise, along with 
medications.   
4.1.2 Complications of Diabetes Mellitus 
Diabetes mellitus involves homeostatic imbalance in the body’s blood sugar; therefore, 
hyperglycemia is a chronic condition associated with diabetes – especially type II diabetics.  
Chronic hyperglycemia can lead to significant complications, such as hypertension, ketoacidosis, 
nephropathy, neuropathy, and cardiovascular disease – particularly, coronary artery disease 
(CAD) [88].  Since patients with type I diabetes are able to manage their blood glucose levels 
well with continuous insulin injections, most complications are frequently seen in patients with 
type II diabetes.  Out of all these major complications, this thesis focused on the condition of 
coronary artery disease, as it is the significant contributing factor to the high mortality rate seen 
with type II diabetics. 
Coronary artery disease results in the narrowing of the coronary arteries due to 
atherosclerosis – the build-up of plaques within the arteries.  The hyperglycemic environment in 
diabetics contributes to an increase of endothelial cell dysfunction in coronary blood vessels, 
making diabetics more susceptible to atherosclerotic build-up.  Revascularization treatments are 
necessary for patients with CAD, and the most common treatment is coronary stent implantation 
[69].  Numerous studies show that CAD patients with diabetes experience a greater need for 
coronary stent replacement procedures and have a lower overall survival rate following the 
coronary therapy procedure compared to non-diabetic patients [153].  CAD patients with 
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diabetes especially experience a high rate of restenosis and a need for repeat revascularization 
with coronary stent replacement.  In-stent restenosis is the reformation of atherosclerotic 
blockage due to the vascular injury caused by the implantation of the stent.  Studies show that 
hyperglycemia is correlated with high levels of expression of vascular adhesion molecules 
throughout coronary blood vessels, leading to the high rate of in-stent restenosis [154].  Even 
with the introduction of drug-eluting stents, the rate of restenosis is still high among the CAD 
population with diabetes.   
Due to this high failure rate of stents in diabetics, it would be beneficial to have a testing 
system that could be used to optimize stent configurations and coatings for diabetic patients.  
While in vivo animal models and clinical testing are vital for product evaluation, it would also be 
valuable to test and evaluate stent designs prior to in vivo environments with an in vitro test that 
resembles the physiologic environment of a native diabetic blood vessel – a diabetic blood vessel 
mimic (BVM) [155]. 
4.1.3 Purpose & Direction of Study 
The purpose of this thesis was to demonstrate the concept that a diabetic environment 
could be replicated by inducing a high glucose concentrated environment in the attempt to 
resemble a hyperglycemic environment. This thesis was driven by the notion that a high 
concentration of glucose would properly replicate the chronic state of hyperglycemia seen in a 
diabetic environment. Although the scope of this concept was beyond a single thesis, the goal of 
the present work was to take initial steps towards creating a hyperglycemic in vitro environment. 
In order to achieve this goal, the thesis was broken down into three major parts: 
1.    Establish a protocol to create high glucose solutions in standard cell culture media 
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2. Establish a protocol to accurately monitor the concentrations of the high glucose 
solutions 
3. Test this monitoring protocol in cell culture over time and determine how the high 
glucose solutions affect endothelial cells 
This was done to serve the single purpose of determining whether or not the 
hyperglycemic solutions could be induced into an in vitro BVM.   
4.1.4 Method of Creating & Monitoring Glycemic Cell Media Solutions 
The first stage of the thesis was to establish a protocol of creating glycemic cell media 
solutions at specific glucose concentrations.  Preliminary tests were conducted and a feasible 
method was established using Sigma G6152 D-(+)-Glucose and Gibco Medium 199.   
The next stage was to test and establish a method to accurately measure the glucose 
concentration of the glycemic solutions.  After studying the literature, the most feasible methods 
that were tested were the blood glucose meter (specifically the Aviva Accu-Chek blood glucose 
meter) and the Glucoflex-R visual blood glucose test strips.  The goal of these experiments was 
to determine whether or not the Aviva Accu-Chek blood glucose meter and Glucoflex-R visual 
blood glucose test strips could accurately and precisely record the glucose concentrations of 
developed 200 mg/dL, 350 mg/dL and 500 mg/dL glycemic cell media solutions.  The results 
confirmed two things:  
1. The Aviva Accu-Chek blood glucose meter was the best method of monitoring 
the developed glycemic solutions as it was the most accurate and precise method. 
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2. The base Gibco Medium 199 was a “low glucose” solution that already contained 
100 mg/dL of D-glucose.   
4.1.5 Monitoring Glucose Consumption of BAECs and HUVECs 
Once the method of creating and monitoring glycemic cell media solutions was 
established, the next stage was to assess whether the developed glycemic cell media solutions 
affected bovine aortic endothelial cells (BAECs) and human umbilical vein endothelial cells 
(HUVECs) in culture.  Base cell medium was used as the control at 100 mg/dL, and was 
compared to a developed 400 mg/dL hyperglycemic cell media solution.  Glucose consumption 
was evaluated by monitoring the glucose concentration of the glycemic cell media solutions, and 
the cell death was evaluated, for only the third set of experiments, by monitoring the cell 
confluency of each well under a microscope.   
The endothelial cells exposed to the 100 mg/dL normal glycemic cell media solution 
exhibited a statistically significant amount of glucose consumption.  Additionally, there was little 
or no cell death observed in the 100 mg/dL wells for the final experiments.  The endothelial cells 
exposed to the 400 mg/dL hyperglycemic cell media solution exhibited greater glucose 
consumption only during the final experiments; however, these cells did not exhibit significant 
cell death throughout the experiment.  The results of the initial experiments did not exhibit the 
expected glucose consumption of the endothelial cells within the 400 mg/dL environment, and 
further investigation uncovered the cause of the obscure results.  An important step in the 
protocol of these experiments was to first remove the complete cell media before adding the 
glycemic cell media.  By not conducting this step, the glycemic solutions were diluted and 
resulted in low glucose concentrations at t = 0. 
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Therefore, the results of the initial test showed no difference in glucose consumption 
between the cells exposed to the 100 mg/dL environment and the cells exposed to the 400 mg/dL 
environment.  However, the results of the final experiments did exhibit greater glucose by the 
endothelial cells, especially in comparison to the initial experiments.  Additionally, the 
endothelial cells in the 400 mg/dL environment did not exhibit significant cell death from t = 0 to 
t = 72 hours.  These results show that the composed glycemic solutions can be introduced to 
endothelial cells, the glucose concentration of the glycemic solutions can be monitored over time 
(no matter what the initial concentration) with an Aviva Accu-Chek blood glucose meter, and the 
endothelial cells are able to survive a high glucose concentrated solution up to 400 mg/dL.  All 
of these steps lead towards to development of a replicable hyperglycemic environment within a 
BVM. 
Table 24 summarizes the experiments, results, and conclusions derived from this entire 
thesis. 
 
 
 
 
 
 
Table 24 – Summary of Experimentation, Results, and Conclusions of Entire Thesis 
Summary of Conclusions from Experimentation of Thesis 
Test Hypothesis Results Conclusions 
Development of Glycemic 
Solution Recipes 
Adding x g of Sigma 
G6152 D-(+)-Glucose to y 
Initial readings were high 
by 100 mg/dL.  Aviva 
1. Base cell media is a 
“low glucose” 
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mL of base cell media will 
yield a solution with a 
glucose concentration of z 
mg/dL 
Accu-Chek blood glucose 
meter had precise 
measurements of all 
glucose concentration.  
The Glucoflex-R visual 
blood glucose strips 
recorded imprecise results 
with extremely high 
variability. 
solution that contains 
100 mg/dL of D-
glucose   
2. Established protocol 
to develop various 
glycemic solutions is 
a valid method. 
3. Aviva Accu-Chek 
blood glucose meter 
accurately and 
precisely measured 
glucose concentration 
of developed 
glycemic cell media 
solutions 
Method of Monitoring 
Glucose Concentration of 
100 mg/dL, 250 mg/dL, 
and 400 mg/dL 
The Aviva Accu-Chek 
blood glucose meter and 
Glucoflex-R visual blood 
glucose strips can 
accurately and precisely 
measure the glucose 
concentration of various 
glycemic solutions 
developed using the 
established protocol 
Evaluation of Endothelial 
Cells in 100 mg/dL and 
400 mg/dL Environments 
BAECs and HUVECs 
exposed to 400 mg/dL 
hyperglycemic cell media 
solution will exhibit 
greater glucose 
consumption and cell 
death than ECs exposed to 
100 mg/dL normal 
glycemic cell media 
solution  
1. Initial experiments 
showed statistically 
significant decrease in 
glucose concentration 
in100 mg/dL solutions, 
but insignificant 
decrease in glucose 
concentration in 400 
mg/dL solutions.  
Additionally, all 400 
mg/dL environments 
(except for BAEC1) 
had low glucose 
concentrations at t = 0. 
2. Final experiments 
showed significant 
decrease in glucose 
concentration in 100 
mg/dL solutions, and 
even greater decrease 
in glucose 
concentration in 400 
mg/dL solutions. 
3. Final experiments 
showed no significant 
decrease in cell 
confluency for neither 
the cells in the100 
mg/dL nor the 400 
mg/dL environments. 
1. Unexpected decrease 
in glucose 
concentration for 
initial experiments 
was caused by not 
removing “complete” 
cell media already in 
the wells.  This 
diluted the 400 mg/dL 
solutions. 
2. Cells in both the 100 
mg/dL and 400 
mg/dL solutions 
exhibited glucose 
consumption; 
however, final 
experiments showed 
400 mg/dL 
environment to 
promote greater 
consumption. 
3. The 400 mg/dL 
environment did not 
evoke greater cell 
death than the 100 
mg/dL environment. 
This is acceptable as 
now 400 mg/dL 
environment may be 
used to evaluate 
endothelial cells 
within a diabetic 
BVM. 
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4.2 Discussion of Thesis 
4.2.1 Improvements to Test Protocols 
The experiments conducted during this thesis made initial steps towards creating an 
environment that can resemble a hyperglycemic environment to potentially develop a diabetic 
blood vessel mimic for stent evaluation.  With the completion of this thesis, a protocol is 
established for the development of hyperglycemic cell media solutions for incorporation with 
BVMs.  In addition, the glucose concentration of these solutions can be accurately and precisely 
measured with an Accu-Chek blood glucose meter.   
As with any set of experiments, there were steps in the procedure that caused trouble and 
likely caused obscurities in the data.  For example, one significant observation was the 
inaccuracy of the balance used to weigh the initial amount of Sigma G6512 D-(+)-glucose.  
Although the balance read the desired mass, the reading frequently decreased as much as 0.02 
mg in one minute.  Although this seems to be an insignificant amount, remember that an 
extremely small amount of glucose can alter the glucose concentration of a glycemic cell media 
solution drastically.  Thus, it wasn’t uncommon for multiple measurements to ensure that the 
correct amount of glucose was used for a particular glycemic cell media solution.   
The potential for error when measuring the mass of glucose was a continuous problem for 
the accuracy of the experiments.  A small volume of cell media was used for many of the 
experiments (20-40 mL); thus, the amount of glucose added to each solution was extremely 
small as well.  Therefore, the established protocol, for the development of the glycemic cell 
media solutions, calls for Sigma G6152 D-(+)-Glucose to be added to at least 100 mL of cell 
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media.  For example, in order to make 20 mL of 400 mg/dL hyperglycemic cell media solution, 
approximately 0.060 g of glucose was added to 20 mL of cell media solution (this was done via 
calculations and compensation of the 100 mg/dL of glucose already in the base cell media)..  In 
order to make 20 mL of 200 mg/dL hyperglycemic cell media solution, approximately 0.030 g of 
glucose needs to be added to the 20 mL of cell media.  Thus, only a difference of 0.030 g of 
glucose differentiates 200 mg/dL from 400 mg/dL.  However, if the volume of media was 
increased to as much as 1000 mL, then a 400 mg/dL hyperglycemic solution would require 
approximately 3.0 g of glucose, while a 250 mg/dL hyperglycemic solution would require 
approximately 1.5 g of glucose – a difference of 1.5 g is a much more practical margin of error 
than a difference of 0.03 g. 
Another error that occurred was the use of the incorrect media during test with the 
BAECs and HUVECs.  For the initial measurements (tests conducted for Chapter 2), the Gibco 
Medium 199 was the correct media to use.  However, the normal complete BAEC media and the 
normal complete HUVEC media should have been used for the experiments of Chapter 3.  This 
is BAEC & HUVEC base media with all the necessary aliquots.  Using the Gibco Medium 199 
for the HUVECs and the Lonza EBM did not hamper the experiments, but it should be noted that 
any further experiments should be conducted using the cell type’s normal, complete media. 
Lastly, using the Aviva Accu-Chek blood glucose meter was a practical and extremely 
convenient method of measuring the glucose concentration of glycemic cell media solutions.  
However, it was crucial to maintain the sterility of the test strips.  The strips are sterile; thus, 
must be handled in a sterile environment only to avoid any contamination – especially when used 
with the endothelial cells.  One consistent problem was remembering to not expose the strips 
outside of the laminar hood, which was necessary since many glucose concentrations were 
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recorded outside of the sterile environment.  One solution for this is obtaining a second batch of 
test strips that is used for the sterile experiments only.  Therefore, one set of test strips may be 
used for preliminary glucose measurements, while the other may be used for glucose 
concentrations of solutions interacting with endothelial cells. 
4.2.2 Future Work in Support of this Thesis 
As pointed out by the literature researched for this thesis, there is a vast amount of 
research being conducted on the physiological mechanisms occurring within diabetic 
vasculature.   These studies are focusing on primarily the expression and aggravation of 
particular genes or molecules caused by endothelial cell exposure to a hyperglycemic 
environment.  As stated in a mentioned study, TUNEL staining can be conducted in order to 
evaluate apoptosis of endothelial cells exposed to a hyperglycemic environment for an extended 
period of time [145].  In addition to that, a study showed that exposure of HUVECs to high 
levels of glucose (which, according to this study, mimicked hyperglycemia), induced the 
expression of microRNA 221 (miR-221) – a short RNA structure that controls the expression of 
other genes [156].  This in turn, triggers the inhibition of the proto-oncogene c-Kit (or tyrosine-
protein kinase Kit) – a protein receptor that is expressed on the surface of hematopoietic stem 
cells, which plays a crucial role in endothelial cell proliferation, differentiation, and migration 
[157].  This study, along with others, support the development of high glucose concentrated 
solutions in attempt to replicate a hyperglycemic environment, as well as experimentation with 
BAECs and HUVECs as reliable methods of evaluating endothelial cells dysfunction in a 
hyperglycemic environment. 
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Additionally, researchers are evaluating the expression of intercellular adhesion molecule 
(ICAM) – 1, as well as the expression of vascular cellular adhesion molecule (VCAM) – 1 
within endothelial cells exposed to a hyperglycemic environment.  ICAM1 and VCAM 1 are 
both responsible for the adhesion of leukocytes to endothelial cells when they are activated [158, 
159].  Studies have concluded that the hyperglycemic environment induced by diabetes promotes 
the expression of ICAM-1 and VCAM-1 along endothelial cells [160, 161].  This high 
expression of these adhesion molecules is most likely the cause of the high rate of in-stent 
restenosis in diabetics with CAD.  Therefore, the next significant step of this thesis will be to 
evaluate whether the glycemic media solutions developed in this thesis affect cellular adhesion 
and proliferation within a BVM, and whether the solutions induce a similar expression of 
VCAM-1 and ICAM-1 on the endothelial cells within the BVM.  The BVM can be analyzed by 
the following: 
• Cellular morphology with a scanning electron microscope (SEM) 
• Endothelial cell confluency and density with bisbenzimide (BBI) nucleus staining 
• Blood vessel wall cellular thickness and cell confluency with hematoxylin and 
eosin (H&E) staining 
• Cellular apoptosis with TUNEL staining 
• VCAM-1 & ICAM-1 expression with VCAM-1 antibody and ICAM-1 antibody 
staining 
While this entire thesis revolved around the affects hyperglycemia has on the cellular 
level, it is worth noting that hyperglycemia is not the only significant contributor to the 
detrimental vascular complications associated with diabetes.  Recall, obesity is a pandemic 
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caused by a combination of genetics and a modern environment where calorie-dense foods are 
widely available and inexpensive [187].  Coinciding with the obesity epidemic, type II diabetes 
mellitus is a related disorder with insulin resistance playing a crucial part in the pathogenesis of 
the disorder [188].  The cellular mechanisms contributing to the progression are poorly 
understood; however, previous studies by Randle et al. have hypothesized that the high 
availability of lipids as a source of fuel generate metabolic signals that impair the use of glucose 
through inhibition of key glycolytic enzymes [189].  Testing of this hypothesis has shown that 
lipid infusion raised plasma muscle lipids [190], and impaired oral glucose tolerance [191] and 
insulin-stimulated glucose disposal in healthy individuals [192, 193].  Thus, in healthy 
individuals, exposure to high concentrations of plasma fatty acids caused insulin resistance 
associated with an induced defect in either glucose transport or phosphorylation activity, not 
impairment of glycolysis [188].  Along with parallel studies, the results suggest that 
accumulation of lipids within muscle might be the cause of insulin resistance [188].  In addition, 
it has also been hypothesized that insulin resistance develops with the accumulation of fatty-acid 
metabolites (diacylglycerols) within insulin-responsive tissues [194].  The model of 
diacylglycerol-induced insulin resistance accounts for the insulin resistance seen in obesity and 
type II diabetes; moreover, reductions in in intracellular diacylglycerol content account for the 
improvements in insulin sensitivity after weight loss [195].  This drastic effect that lipid 
infiltration has on the development of insulin sensitivity encourages further research in its effect 
in type II diabetes; thus, it would be additionally beneficial to test the development of a 
hyperlipidemic cell media solutions and see the effect on endothelial cells in culture.        
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If the endothelial cells within a hyperglycemic and hyperlipidemic environment exhibit 
characteristics similar to endothelial cells within a native diabetic blood vessel, then the goal of 
creating an in vitro diabetic blood vessel mimic for stent evaluation will be achieved.   
This thesis is only a small part of the larger amount of research supporting both the 
development of blood vessel mimics for in vitro medical device evaluation at Cal Poly, as well 
as the understanding of mechanisms inducing many of the complications within diabetic patients 
at hospitals and labs worldwide.  The lifestyle – and life expectancy – of diabetic patients has 
improved immensely since the significant discovery of insulin.  New technologies and 
medications are continuously being studied and evaluated to further improve current methods of 
treatment.  While this thesis was only able to study a minor part incorporating diseased blood 
vessel mimics with medical technologies treating diagnosed patients, this thesis was a new 
“gateway” to help improve not only the vascular devices used to treat CAD patients with 
diabetes, but hopefully to improve devices treating other diseases as well. 
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Appendix A: Results for Preliminary Testing to 
Establish Method of Developing Glycemic Cell Media 
Solutions 
 Preliminary testing was conducted in order to analyze the simple procedure of adding 
specified amounts of Sigma G6152 D-(+)-Glucose to distilled water, and eventually base cell 
media.  These experiments also helped determine the feasibility of certain methods of monitoring 
glucose concentrations, such as the blood glucose meter and visual blood glucose strips.  The 
following tables show the results of these experiments. 
Table 25 - Development of 100 mg/dL Solution Trial #1 
Development of Hyperglycemic Solution Trial #1  
Tube # 
Expected 
Glucose 
Concentration 
(mg/dL) 
Volume of 
Distilled H2O 
(mL) 
Amount of 
Sigma G6152  
D-(+)- Glucose 
(g) 
Aviva Accu-
Chek Blood 
Glucose Meter 
Measurement 
(mg/dL) 
1 
100 mg/dL 
20 0.2004 76 
2 20 0.2002 129 
3 20 0.2001 162 
4 20 0.206 35 
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Table 26 - Development of 100 mg/dL & 180 mg/dL Solutions Trial #2 
Development of 100 mg/dL & 180 mg/dL Solutions Trial #2 
Expected 
Glucose 
Concentration 
(mg/dL) 
Volume of 
Distilled 
H2O (mL) 
Amount of 
Sigma 
G6152  
D-(+)- 
Glucose 
(g) 
Time (min) 
Aviva Accu-
Chek Blood 
Glucose Meter 
Measurement 
(mg/dL) 
100 10 0.011 
5 17 
10 71 
15 83 
20 106 
25 117 
30 129 
180 10 0.0187 
5 136 
10 201 
15 x 
20 x 
25 x 
30 x 
x Ran out of glucose test strips 
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Table 27 - Development of 100 mg/dL Normal Glycemic & 400 mg/dL Hyperglycemic 
Solutions Trial #3 
Development of 100 mg/dL Normal Glycemic & 400 mg/dL Hyperglycemic Solutions Trial #3 
Expected Glucose 
Concentration (mg/dL) 
Amount of 
Sigma G6152  
D-(+)- Glucose 
(g) added to 10 
mL H2O 
Time (min) Blood Glucose Meter Measurement (mg/dL) 
100 0.0134 
5 74 
10 130 
20 152 
30 217 
40 251 
Average 164.8 
460 0.00165 
5 445 
10 467 
20 480 
30 515 
40 485 
40 496 
40 501 
45 479 
Average 483.5 
 
 
 
 
 
 
 
166 
 
Table 28 - Development of 100 mg/dL Normal Glycemic & 350 mg/dL Hyperglycemic 
Solutions Trial #4 
Development of 100 mg/dL Normal Glycemic & 350 mg/dL Hyperglycemic Solutions Trial #4 
Expected Glucose 
Concentration 
(mg/dL) 
Amount Glucose 
Added to Media 
(g) 
Volume of Gibco 
Medium 199 (mL) 
Time (min) 
Blood Glucose Meter 
Measurement 
(mg/dL) 
100 
0.0506 50 
30 156 
60 189 
120 198 
240 201 
720 215 
0.1061 100 
30 148 
60 165 
120 184 
240 209 
720 206 
350 
0.1758 50 
30 318 
60 397 
120 413 
240 481 
720 435 
0.3507 100 
30 388 
60 417 
120 451 
240 466 
720 458 
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Appendix B: Results for Experimentation to 
Determine Most Feasible Method of Measuring 
Glucose Concentration of Developed Glycemic Cell 
Media Solutions 
 A set of experiments was conducted to evaluate the precision and accuracy of the Aviva 
Accu-Chek blood glucose meter and the Glucoflex-R visual blood glucose strips among 
glycemic solutions of 200 mg/dL, 350 mg/dL, and 500 mg/dL glucose concentrations.  The 
following tables show the results of these experiments.  Notice the calculated percent error as 
well as the standard deviation between the Aviva Accu-Chek blood glucose meter and the 
Glucoflex-R visual blood glucose test strips. 
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Table 29 - Method of Monitoring 200 mg/dL Normal Glycemic Environment Test Results 
Method of Monitoring 200 mg/dL Normal Glycemic Environment Test Results 
Method of 
Measurement Time (hours) 
Calibration 
Value (mg/dL) 
Measured 
Glucose 
Concentration 
Solution 1 
(mg/dL) 
Measured 
Glucose 
Concentration 
Solution 2 
(mg/dL) 
Measured 
Glucose 
Concentration 
Solution 3 
(mg/dL) 
Aviva Accu-
Chek Blood 
Glucose Meter 
1 437 189 169 174 
2 444 200 200 196 
3 456 204 199 190 
4 446 209 195 188 
5 452 206 192 192 
6 443 200 200 197 
12 439 215 207 208 
24 447 209 215 212 
36 455 213 213 207 
48 441 202 195 189 
Average 446.56 204.7 198.5 195.3 
St. Dev. 6.55 7.54 12.89 11.38 
%Error -0.77 2.35 -0.75 -2.35 
Method of 
Measurement Time (hours) 
Calibration 
Value (mg/dL) 
Measured 
Glucose 
Concentration 
Solution 1 
(mg/dL) 
Measured 
Glucose 
Concentration 
Solution 2 
(mg/dL) 
Measured 
Glucose 
Concentration 
Solution 3 
(mg/dL) 
Glucoflex-R 
Visual Blood 
Glucose Test 
Strips 
1 400 150 160 500 
2 N/A 200 160 300 
3 N/A 200 120 200 
4 N/A 300 160 200 
5 N/A 200 160 200 
6 N/A 180 200 160 
12 N/A 200 160 300 
24 N/A 300 160 800 
36 N/A 160 500 300 
48 N/A 160 160 160 
Average N/A 205 194 312 
St. Dev. N/A 53.59 109.16 199.38 
% Error N/A 2.50 -3.00 56.00 
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Table 30 - Method of Monitoring 350 mg/dL Hyperglycemic Environment Test Results 
Method of Monitoring 350 mg/dL Hyperglycemic Environment Test Results 
Method of 
Measurement Time (hours) 
Calibration 
Value (mg/dL) 
Measured 
Glucose 
Concentration 
Solution 1 
(mg/dL) 
Measured 
Glucose 
Concentration 
Solution 2 
(mg/dL) 
Measured 
Glucose 
Concentration 
Solution 3 
(mg/dL) 
Aviva Accu-
Chek Blood 
Glucose Meter 
1 446 271 137 133 
2 467 276 226 257 
3 433 292 299 302 
4 441 310 337 342 
5 457 352 359 349 
6 425 355 350 359 
12 449 373 354 360 
24 458 363 341 356 
36 461 357 366 365 
48 453 387 371 372 
Average (t=4) 449.00 356.71 354.00 357.57 
St. Dev. (t=4) 13.06 23.91 11.54 9.91 
% Error -0.22 1.92 1.14 2.16 
Glucoflex-R 
Visual Blood 
Glucose Test 
Strips 
1 300 300 200 200 
2 N/A 300 300 250 
3 N/A 500 300 300 
4 N/A 300 500 300 
5 N/A 400 300 300 
6 N/A 250 300 250 
12 N/A 200 250 300 
24 N/A 800 500 300 
36 N/A 300 200 300 
48 N/A 300 200 300 
Average (t=4) N/A 364.29 321.43 292.86 
St. Dev. (t=4) N/A 201.48 128.64 18.90 
% Error N/A 4.08 -8.16 -16.33 
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Table 31 - Method of Monitoring 500 mg/dL Hyperglycemic Environment Test Results 
Method of Monitoring 500 mg/dL Hyperglycemic Environment Test Results 
Method of 
Measurement Time (hours) 
Calibration 
Value (mg/dL) 
Measured 
Glucose 
Concentration 
Solution 1 
(mg/dL) 
Measured 
Glucose 
Concentration 
Solution 2 
(mg/dL) 
Measured 
Glucose 
Concentration 
Solution 3 
(mg/dL) 
Aviva Accu-
Chek Blood 
Glucose Meter 
1 447 177 164 165 
2 451 247 253 251 
3 450 303 313 299 
4 439 289 395 392 
5 444 459 457 452 
6 453 469 466 460 
12 448 479 472 461 
24 437 511 483 468 
36 448 528 473 475 
48 454 514 485 483 
Average (t=5) 447.33 493.33 472.67 466.50 
St. Dev. (t=5) 6.250 27.990 10.482 11.221 
% Error N/A -1.333 -5.467 -6.700 
Glucoflex-R 
Visual Blood 
Glucose Test 
Strips 
1 400 400 400 400 
2 500 500 300 500 
3 N/A 500 500 500 
4 N/A 800 500 300 
5 N/A 500 500 500 
6 N/A 800 300 300 
12 N/A 200 400 300 
24 N/A 500 400 400 
36 N/A 500 300 500 
48 N/A 500 400 400 
Average (t=5) N/A 500.00 383.33 400.00 
St. Dev. (t=5) N/A 189.737 75.277 89.443 
% Error N/A 0.000 -23.333 -20.000 
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Appendix C: Results for Experimentation of BAECs & 
HUVECs Exposed to 100 mg/dL Normal Glycemic 
Cell Media Solutions & 400 mg/dL Hyperglycemic 
Cell Media Solutions 
 The following tables show the results of the six experiments conducted with BAECs and 
HUVECs.  The purpose of these tests was to evaluate the glucose consumption of the cells in the 
100 mg/dL and 400 mg/dL glycemic cell media solutions.  Additionally, the change in glucose 
concentrations was calculated in order to analyze the rate of glucose consumption between the 
different times of evaluation (0, 24, 48, and 72 hours). 
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Table 32 - BAEC Glucose Consumption Comparative Study Experiment #1 
BAEC Glucose Consumption Comparative Study Experiment #1 
Time 
Expected Glucose 
Concentration 
(mg/dL) 
Glucose Measurements via Accu-Check Glucose Meter (mg/dL) 
Well #1 Well #2 Well #3 
0 100 99 98 99 
400 416 398 414 
24 100 100 103 98 
400 335 365 341 
48 100 94 91 94 
400 355 355 330 
72 100 96 95 95 
400 347 340 323 
 
Table 33 - BAEC Glucose Consumption Comparative Study Experiment #1 - Well ∆ mg/dL per 
Time Chart 
BAEC Glucose Consumption Comparative Study Experiment #1 -                                                                                                                 
Well ∆ mg/dL per Time Chart 
100 mg/dL 
Well 
# 
∆ mg/dL  
(t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL        
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ 
mg/dL        
(t48 - t72) 
1 3 
3.333 
-1 
-1.667 
6 
7.333 
-2 
-2.333 2 3 -5 12 
-4 
3 4 1 4 
-1 
400 mg/dL 
Well 
# 
∆ mg/dL  
(t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL        
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ 
mg/dL        
(t48 - t72) 
1 69 
72.667 
81 
62.333 
-20 
0.333 
8 
10.000 2 58 33 10 15 
3 91 73 11 7 
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Table 34 - HUVEC Glucose Consumption Comparative Study Experiment #1 
HUVEC Glucose Consumption Comparative Study Experiment #1 
Time 
Expected Glucose 
Concentration 
(mg/dL) 
Glucose Measurements via Accu-Check Glucose Meter (mg/dL) 
Well #1 Well #2 Well #3 
0 100 103 106 100 
400 258 222 260 
24 100 90 96 96 
400 229 226 218 
48 100 89 88 90 
400 223 219 224 
72 100 90 91 90 
400 234 224 223 
 
Table 35 - HUVEC Glucose Consumption Comparative Experiment Trial #1 - Well ∆ mg/dL per 
Time Chart 
HUVEC Glucose Consumption Comparative Experiment Trial #1 -                                                                                                                 
Well ∆ mg/dL per Time Chart 
100 mg/dL 
Well # ∆ mg/dL  (t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL        
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ 
mg/dL        
(t48 - t72) 
1 13 
12.667 
13 
9.000 
1 
5.000 
-1 
-1.333 2 15 10 8 
-3 
3 10 4 6 0 
400 mg/dL 
Well # ∆ mg/dL  (t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL     
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ 
mg/dL        
(t48 - t72) 
1 24 
19.667 
29 
22.333 
6 
2.333 
-11 
-5.000 2 -2 -4 7 -5 
3 37 42 -6 1 
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Table 36 - BAEC Glucose Consumption Comparative Study Experiment #2 
BAEC Glucose Consumption Comparative Study Experiment #2 
Time 
Expected Glucose 
Concentration 
(mg/dL) 
Glucose Measurements via Accu-Check Glucose Meter (mg/dL) 
Well #1 Well #2 Well #3 
0 100 90 85 89 
400 289 277 297 
24 100 89 88 90 
400 288 263 281 
48 100 83 82 82 
400 253 253 266 
72 100 75 70 70 
400 252 241 252 
 
Table 37 - BAEC Glucose Consumption Comparative Study Experiment #2 - Well ∆ mg/dL per 
Time Chart 
BAEC Glucose Consumption Comparative Study Experiment #2 -                                                                                                                 
Well ∆ mg/dL per Time Chart 
100 mg/dL 
Well # ∆ mg/dL  (t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL        
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ 
mg/dL        
(t48 - t72) 
1 15 
16.333 
1 
-1.000 
6 
6.667 
8 
10.667 2 15 -3 6 12 
3 19 -1 8 12 
400 mg/dL 
Well # ∆ mg/dL  (t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL     
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ 
mg/dL        
(t48 - t72) 
1 37 
39.333 
1 
10.333 
35 
20.000 
1 
9.000 2 36 14 10 12 
3 45 16 15 14 
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Table 38 - HUVEC Glucose Consumption Comparative Study Experiment #2 
HUVEC Glucose Consumption Comparative Study Experiment #2 
Time 
Expected Glucose 
Concentration 
(mg/dL) 
Glucose Measurements via Accu-Check Glucose Meter (mg/dL) 
Well #1 Well #2 Well #3 
0 100 94 91 90 
400 263 288 296 
24 100 85 79 81 
400 277 246 288 
48 100 86 79 78 
400 274 267 266 
72 100 79 80 74 
400 261 259 257 
 
Table 39 - HUVEC Glucose Consumption Comparative Study Experiment #2 - Well ∆ mg/dL 
per Time Chart 
HUVEC Glucose Consumption Comparative Study Experiment #2 -                                                                                                                 
Well ∆ mg/dL per Time Chart 
100 mg/dL 
Well # ∆ mg/dL  (t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL        
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ 
mg/dL        
(t48 - t72) 
1 15 
14.000 
9 
10.000 
-1 
0.667 
7 
3.333 2 11 12 0 
-1 
3 16 9 3 4 
400 mg/dL 
Well # ∆ mg/dL  (t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL     
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ 
mg/dL        
(t48 - t72) 
1 2 
23.333 
-14 
12.000 
3 
1.333 
13 
10.000 2 29 42 -21 8 
3 39 8 22 9 
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Table 40 - BAEC Glucose Consumption Comparative Study Experiment #3 
BAEC Glucose Consumption Comparative Study Experiment #3 
Time 
Expected Glucose 
Concentration 
(mg/dL) 
Glucose Measurements via Accu-Check Glucose Meter (mg/dL) 
Well #1 Well #2 Well #3 
0 100 74 82 84 
400 367 364 357 
24 100 77 79 72 
400 311 324 276 
48 100 76 70 80 
400 306 313 269 
72 100 75 71 81 
400 292 293 266 
 
Table 41 - BAEC Glucose Consumption Comparative Study Experiment #3 - Well ∆ mg/dL per 
Time Chart 
BAEC Glucose Consumption Comparative Study Experiment #3 -                                                                                                                 
Well ∆ mg/dL per Time Chart 
100 mg/dL 
Well # ∆ mg/dL  (t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL        
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ 
mg/dL        
(t48 - t72) 
1 -1 
4.333 
-3 
4.000 
1 
0.667 
1 
-0.333 2 11 3 9 
-1 
3 3 12 -8 
-1 
400 mg/dL 
Well # ∆ mg/dL  (t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL     
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ 
mg/dL        
(t48 - t72) 
1 75 
79.000 
56 
48.000 
5 
7.667 
14 
12.333 2 71 40 11 20 
3 91 81 7 3 
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Table 42 - HUVEC Glucose Consumption Comparative Study Experiment #3 
HUVEC Glucose Consumption Comparative Study Experiment #3 
Time 
Expected Glucose 
Concentration 
(mg/dL) 
Glucose Measurements via Accu-Check Glucose Meter (mg/dL) 
Well #1 Well #2 Well #3 
0 100 85 86 82 
400 386 353 319 
24 100 75 86 75 
400 316 318 286 
48 100 68 72 78 
400 313 306 269 
72 100 69 68 75 
400 288 298 265 
 
Table 43 - HUVEC Glucose Consumption Comparative Study Experiment #3 - Well ∆ mg/dL 
per Time Chart 
HUVEC Glucose Consumption Comparative Study Experiment #3 -                                                                                                                 
Well ∆ mg/dL per Time Chart 
100 mg/dL 
Well # ∆ mg/dL  (t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL        
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ mg/dL        
(t48 - t72) 
1 16 
13.667 
10 
5.667 
7 
6.000 
-1 
2.000 2 18 0 14 4 
3 7 7 -3 3 
400 mg/dL 
Well # ∆ mg/dL  (t0 - t72) 
Avg ∆ 
mg/dL        
(t0 - t72) 
∆ mg/dL  
(t0 - t24) 
Avg ∆ 
mg/dL        
(t0 - t24) 
∆ mg/dL  
(t24 - t48) 
Avg ∆ 
mg/dL     
(t24 - t48) 
∆ mg/dL  
(t48 - t72) 
Avg ∆ mg/dL        
(t48 - t72) 
1 98 
69.000 
70 
46.000 
3 
10.667 
25 
12.333 2 55 35 12 8 
3 54 33 17 4 
 
 
 
178 
 
Appendix D: Protocol for the Development of Sterile 
400 mg/dL Hyperglycemic Cell Media Solution 
• Materials 
o 100 mL complete cell media 
o 0.30 g Sigma G6152 D-(+)-Glucose 
o Aviva Accu-Chek Blood Glucose Meter & Test Strips 
Note: Use two different sets of blood glucose test strips – one for use in a non-
sterile environment and one for use within a sterile environment. 
o 50 mL graduate cylinder 
o 250 mL beaker 
o Magnetic stir bar & stir plate 
o Balance 
o Four 50 mL conicals 
o Two 10mL syringes 
o Four 0.22µm syringe filters 
• Procedure 
o Development of 400 mg/dL Hyperglycemic Cell Media Solution 
1. Weigh 0.3g of Sigma G6152 D-(+)-Glucose 
2. Using a 50 mL graduated cylinder, measure 100 mL of cell media into a 
250 mL beaker. 
3. Add all 0.3g of Sigma G6152 D-(+)-Glucose to the 100 mL of cell media. 
4. Place magnetic stir bar into beaker and stir solution on stir plate for at 
least six hours at 25ºC to allow uniform mixing. 
5. Using Aviva Accu-Chek blood glucose meter, record the glucose 
concentration of the glycemic cell media solution. 
6. Transfer solution from 250 mL beaker to two 50 mL conicals. 
o Sterilization of 400 mg/dL Hyperglycemic Cell Media Solution 
1. Ensure hands are washed with gloves on.  Spray gloves with 70% IPA. 
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2. Spray inside of laminar flow hood with 70% IPA. 
3. Keep sterile packaged syringes and syringe filters inside packaging and place 
inside hood.  
4. Sterilize two brand new 50 mL conicals and place inside hood. 
5. Sterilize 50 mL conical with 400 mg/dL hyperglycemic cell media solution 
(cap closed) with 70% IPA. 
6. Open syringes and syringe filters inside hood.  Do not allow the tips to touch 
the outside of the packing.  Discard of packaging. 
7. Uptake 10 mL of 400 mg/dL hyperglycemic cell media solution into 10mL 
syringe. 
8. Place 22µm syringe filter on end of syringe. 
9. Slowly transfer 10 mL of solution through filter into a brand new conical.  
This solution is now sterile. 
10. Repeat steps 8-10 for all 100 mL of unsterile 400 mg/dL hyperglycemic 
solution.  Use second conical when necessary. 
11. Once all media has been sterilized into sterile conicals, tightly cap the conicals 
inside laminar flow hood and store sterilized 400 mg/dL solution at 5-10 ºC. 
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Appendix E: Protocol Using Aviva Accu-Chek Blood 
Glucose Meter 
*All images provided from Aviva Accu-Chek Owner’s Booklet 
1. Overview of the blood glucose meter 
 
 
Display 
Test Strip Slot 
Power Button 
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Code Key Slot 
Battery Door 
Code Key  
(example of code on front) 
Test Strip Container 
(example of code on bottle) 
Golden end inserted 
into meter  
Capillary mouth 
(touch solution here) 
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2. Coding the Meter 
 Ensure that the meter is off 
 Turn meter over 
 Remove old code key (if there is one in the meter) and discard it 
 Insert new code key for test strip container (ensure that the code is 
facing away from you).  Push in the code key until it stops.  Leave 
code key in meter until a new container of test strips (with a 
different code key) is being used. 
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3. Running a Glucose Concentration Test 
 Insert a test strip into the test strip slot of the blood glucose meter.  
The meter will automatically turn on. 
 Ensure that the code on the display shows the same code that is 
on the container.  If missed, remove the test strip and reinsert it 
to observe the code on the display screen. 
 When blood/solution drop image flashes on display, dip test strip 
into solution.  Ensure solution goes into capillary mouth. 
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 The result will appear on the display. 
 
 
 
 
